id	sid	tid	token	lemma	pos
dpc-3647	1	1	dermatology	dermatology	NOUN
dpc-3647	1	2	:	:	PUNCT
dpc-3647	1	3	practical	practical	ADJ
dpc-3647	1	4	and	and	CCONJ
dpc-3647	1	5	conceptual	conceptual	ADJ
dpc-3647	1	6	original	original	ADJ
dpc-3647	1	7	article	article	NOUN
dpc-3647	1	8	|	|	ADV
dpc-3647	1	9	dermatol	dermatol	ADJ
dpc-3647	1	10	pract	pract	NOUN
dpc-3647	1	11	concept	concept	NOUN
dpc-3647	1	12	.	.	PUNCT
dpc-3647	2	1	2024;14(1):e2024065	2024;14(1):e2024065	NUM
dpc-3647	2	2	1	1	NUM
dpc-3647	2	3	effect	effect	NOUN
dpc-3647	2	4	of	of	ADP
dpc-3647	2	5	treatment	treatment	NOUN
dpc-3647	2	6	with	with	ADP
dpc-3647	2	7	biologic	biologic	ADJ
dpc-3647	2	8	agents	agent	NOUN
dpc-3647	2	9	on	on	ADP
dpc-3647	2	10	 	 	SPACE
dpc-3647	2	11	the	the	DET
dpc-3647	2	12	 	 	SPACE
dpc-3647	2	13	novel	novel	ADJ
dpc-3647	2	14	inflammatory	inflammatory	ADJ
dpc-3647	2	15	biomarkers	biomarker	NOUN
dpc-3647	2	16	systemic	systemic	ADJ
dpc-3647	2	17	immune	immune	ADJ
dpc-3647	2	18	inflammation	inflammation	NOUN
dpc-3647	2	19	index	index	NOUN
dpc-3647	2	20	and	and	CCONJ
dpc-3647	2	21	systemic	systemic	ADJ
dpc-3647	2	22	inflammation	inflammation	ADJ
dpc-3647	2	23	response	response	NOUN
dpc-3647	2	24	index	index	NOUN
dpc-3647	2	25	for	for	ADP
dpc-3647	2	26	psoriasis	psoriasis	NOUN
dpc-3647	2	27	funda	funda	NOUN
dpc-3647	2	28	tamer1	tamer1	NOUN
dpc-3647	2	29	,	,	PUNCT
dpc-3647	2	30	yusuf	yusuf	PROPN
dpc-3647	2	31	can	can	AUX
dpc-3647	2	32	edek1	edek1	PROPN
dpc-3647	2	33	,	,	PUNCT
dpc-3647	2	34	ahmet	ahmet	PROPN
dpc-3647	2	35	burhan	burhan	PROPN
dpc-3647	2	36	aksakal1	aksakal1	PROPN
dpc-3647	3	1	1	1	NUM
dpc-3647	3	2	department	department	NOUN
dpc-3647	3	3	of	of	ADP
dpc-3647	3	4	dermatology	dermatology	NOUN
dpc-3647	3	5	,	,	PUNCT
dpc-3647	3	6	gazi	gazi	PROPN
dpc-3647	3	7	university	university	PROPN
dpc-3647	3	8	school	school	NOUN
dpc-3647	3	9	of	of	ADP
dpc-3647	3	10	medicine	medicine	NOUN
dpc-3647	3	11	,	,	PUNCT
dpc-3647	3	12	ankara	ankara	PROPN
dpc-3647	3	13	,	,	PUNCT
dpc-3647	3	14	turkey	turkey	PROPN
dpc-3647	3	15	key	key	ADJ
dpc-3647	3	16	words	word	NOUN
dpc-3647	3	17	:	:	PUNCT
dpc-3647	3	18	biological	biological	ADJ
dpc-3647	3	19	agents	agent	NOUN
dpc-3647	3	20	,	,	PUNCT
dpc-3647	3	21	psoriasis	psoriasis	NOUN
dpc-3647	3	22	,	,	PUNCT
dpc-3647	3	23	systemic	systemic	ADJ
dpc-3647	3	24	immune	immune	ADJ
dpc-3647	3	25	inflammation	inflammation	NOUN
dpc-3647	3	26	index	index	NOUN
dpc-3647	3	27	,	,	PUNCT
dpc-3647	3	28	systemic	systemic	ADJ
dpc-3647	3	29	inflammation	inflammation	ADJ
dpc-3647	3	30	response	response	NOUN
dpc-3647	3	31	index	index	NOUN
dpc-3647	3	32	,	,	PUNCT
dpc-3647	3	33	treatment	treatment	NOUN
dpc-3647	3	34	citation	citation	NOUN
dpc-3647	3	35	:	:	PUNCT
dpc-3647	3	36	tamer	tame	ADJ
dpc-3647	3	37	f	f	NOUN
dpc-3647	3	38	,	,	PUNCT
dpc-3647	3	39	edek	edek	NOUN
dpc-3647	3	40	yc	yc	NOUN
dpc-3647	3	41	,	,	PUNCT
dpc-3647	3	42	aksakal	aksakal	PROPN
dpc-3647	3	43	ab	ab	PROPN
dpc-3647	3	44	.	.	PROPN
dpc-3647	3	45	effect	effect	NOUN
dpc-3647	3	46	of	of	ADP
dpc-3647	3	47	treatment	treatment	NOUN
dpc-3647	3	48	with	with	ADP
dpc-3647	3	49	biologic	biologic	NOUN
dpc-3647	3	50	agents	agent	NOUN
dpc-3647	3	51	on	on	ADP
dpc-3647	3	52	the	the	DET
dpc-3647	3	53	novel	novel	ADJ
dpc-3647	3	54	inflammatory	inflammatory	ADJ
dpc-3647	3	55	biomarkers	biomarker	NOUN
dpc-3647	3	56	systemic	systemic	ADJ
dpc-3647	3	57	immune	immune	ADJ
dpc-3647	3	58	inflammation	inflammation	NOUN
dpc-3647	3	59	index	index	NOUN
dpc-3647	3	60	and	and	CCONJ
dpc-3647	3	61	systemic	systemic	ADJ
dpc-3647	3	62	inflammation	inflammation	ADJ
dpc-3647	3	63	response	response	NOUN
dpc-3647	3	64	index	index	NOUN
dpc-3647	3	65	for	for	ADP
dpc-3647	3	66	psoriasis	psoriasis	NOUN
dpc-3647	3	67	.	.	PUNCT
dpc-3647	4	1	dermatol	dermatol	NOUN
dpc-3647	4	2	pract	pract	PROPN
dpc-3647	4	3	concept	concept	NOUN
dpc-3647	4	4	.	.	PUNCT
dpc-3647	5	1	2024;14(1):e2024065	2024;14(1):e2024065	X
dpc-3647	5	2	.	.	PUNCT
dpc-3647	6	1	doi	doi	NOUN
dpc-3647	6	2	:	:	PUNCT
dpc-3647	6	3	https://doi.org/10.5826/dpc.1401a65	https://doi.org/10.5826/dpc.1401a65	ADJ
dpc-3647	6	4	accepted	accept	VERB
dpc-3647	6	5	:	:	PUNCT
dpc-3647	6	6	april	april	PROPN
dpc-3647	6	7	9	9	NUM
dpc-3647	6	8	,	,	PUNCT
dpc-3647	6	9	2023	2023	NUM
dpc-3647	6	10	;	;	PUNCT
dpc-3647	6	11	published	publish	VERB
dpc-3647	6	12	:	:	PUNCT
dpc-3647	6	13	january	january	PROPN
dpc-3647	6	14	2024	2024	NUM
dpc-3647	7	1	copyright	copyright	NOUN
dpc-3647	7	2	:	:	PUNCT
dpc-3647	7	3	©	©	PROPN
dpc-3647	7	4	2024	2024	NUM
dpc-3647	7	5	tamer	tamer	X
dpc-3647	7	6	et	et	PROPN
dpc-3647	7	7	al	al	PROPN
dpc-3647	7	8	.	.	PUNCT
dpc-3647	8	1	this	this	PRON
dpc-3647	8	2	is	be	AUX
dpc-3647	8	3	an	an	DET
dpc-3647	8	4	open	open	ADJ
dpc-3647	8	5	-	-	PUNCT
dpc-3647	8	6	access	access	NOUN
dpc-3647	8	7	article	article	NOUN
dpc-3647	8	8	distributed	distribute	VERB
dpc-3647	8	9	under	under	ADP
dpc-3647	8	10	the	the	DET
dpc-3647	8	11	terms	term	NOUN
dpc-3647	8	12	of	of	ADP
dpc-3647	8	13	the	the	DET
dpc-3647	8	14	creative	creative	ADJ
dpc-3647	8	15	commons	common	NOUN
dpc-3647	8	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-3647	8	17	license	license	NOUN
dpc-3647	8	18	(	(	PUNCT
dpc-3647	8	19	by	by	ADP
dpc-3647	8	20	-	-	PUNCT
dpc-3647	8	21	nc-4.0	nc-4.0	NOUN
dpc-3647	8	22	)	)	PUNCT
dpc-3647	8	23	,	,	PUNCT
dpc-3647	8	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-3647	8	25	,	,	PUNCT
dpc-3647	8	26	which	which	PRON
dpc-3647	8	27	permits	permit	VERB
dpc-3647	8	28	unrestricted	unrestricted	ADJ
dpc-3647	8	29	noncommercial	noncommercial	ADJ
dpc-3647	8	30	use	use	NOUN
dpc-3647	8	31	,	,	PUNCT
dpc-3647	8	32	distribution	distribution	NOUN
dpc-3647	8	33	,	,	PUNCT
dpc-3647	8	34	and	and	CCONJ
dpc-3647	8	35	reproduction	reproduction	NOUN
dpc-3647	8	36	in	in	ADP
dpc-3647	8	37	any	any	DET
dpc-3647	8	38	medium	medium	NOUN
dpc-3647	8	39	,	,	PUNCT
dpc-3647	8	40	provided	provide	VERB
dpc-3647	8	41	the	the	DET
dpc-3647	8	42	original	original	ADJ
dpc-3647	8	43	authors	author	NOUN
dpc-3647	8	44	and	and	CCONJ
dpc-3647	8	45	source	source	NOUN
dpc-3647	8	46	are	be	AUX
dpc-3647	8	47	credited	credit	VERB
dpc-3647	8	48	.	.	PUNCT
dpc-3647	9	1	funding	funding	NOUN
dpc-3647	9	2	:	:	PUNCT
dpc-3647	9	3	none	none	NOUN
dpc-3647	9	4	.	.	PUNCT
dpc-3647	10	1	competing	compete	VERB
dpc-3647	10	2	interests	interest	NOUN
dpc-3647	10	3	:	:	PUNCT
dpc-3647	10	4	none	none	NOUN
dpc-3647	10	5	.	.	PUNCT
dpc-3647	11	1	authorship	authorship	NOUN
dpc-3647	11	2	:	:	PUNCT
dpc-3647	11	3	all	all	DET
dpc-3647	11	4	authors	author	NOUN
dpc-3647	11	5	have	have	AUX
dpc-3647	11	6	contributed	contribute	VERB
dpc-3647	11	7	significantly	significantly	ADV
dpc-3647	11	8	to	to	ADP
dpc-3647	11	9	this	this	DET
dpc-3647	11	10	publication	publication	NOUN
dpc-3647	11	11	.	.	PUNCT
dpc-3647	12	1	corresponding	correspond	VERB
dpc-3647	12	2	author	author	NOUN
dpc-3647	12	3	:	:	PUNCT
dpc-3647	12	4	funda	funda	PROPN
dpc-3647	12	5	tamer	tamer	NOUN
dpc-3647	12	6	,	,	PUNCT
dpc-3647	12	7	gazi	gazi	PROPN
dpc-3647	12	8	universitesi	universitesi	NOUN
dpc-3647	12	9	hastanesi	hastanesi	NOUN
dpc-3647	12	10	,	,	PUNCT
dpc-3647	12	11	emniyet	emniyet	NOUN
dpc-3647	12	12	mahallesi	mahallesi	NOUN
dpc-3647	12	13	,	,	PUNCT
dpc-3647	12	14	29	29	NUM
dpc-3647	12	15	,	,	PUNCT
dpc-3647	12	16	06560	06560	NUM
dpc-3647	12	17	,	,	PUNCT
dpc-3647	12	18	ankara/	ankara/	NUM
dpc-3647	12	19	turkey	turkey	NOUN
dpc-3647	12	20	.	.	PUNCT
dpc-3647	13	1	tel	tel	ADP
dpc-3647	13	2	:	:	PUNCT
dpc-3647	13	3	+903122026129	+903122026129	NUM
dpc-3647	13	4	.	.	PUNCT
dpc-3647	14	1	e	e	X
dpc-3647	14	2	-	-	NOUN
dpc-3647	14	3	mail	mail	NOUN
dpc-3647	14	4	:	:	PUNCT
dpc-3647	15	1	fundatmr@yahoo.com	fundatmr@yahoo.com	X
dpc-3647	15	2	.	.	PUNCT
dpc-3647	15	3	introduction	introduction	NOUN
dpc-3647	15	4	:	:	PUNCT
dpc-3647	15	5	psoriasis	psoriasis	NOUN
dpc-3647	15	6	is	be	AUX
dpc-3647	15	7	a	a	DET
dpc-3647	15	8	chronic	chronic	ADJ
dpc-3647	15	9	cutaneous	cutaneous	ADJ
dpc-3647	15	10	disorder	disorder	NOUN
dpc-3647	15	11	with	with	ADP
dpc-3647	15	12	underlying	underlie	VERB
dpc-3647	15	13	systemic	systemic	ADJ
dpc-3647	15	14	inflammation	inflammation	NOUN
dpc-3647	15	15	.	.	PUNCT
dpc-3647	16	1	the	the	DET
dpc-3647	16	2	systemic	systemic	ADJ
dpc-3647	16	3	immune	immune	ADJ
dpc-3647	16	4	inflammation	inflammation	NOUN
dpc-3647	16	5	(	(	PUNCT
dpc-3647	16	6	sii	sii	PROPN
dpc-3647	16	7	)	)	PUNCT
dpc-3647	16	8	and	and	CCONJ
dpc-3647	16	9	systemic	systemic	ADJ
dpc-3647	16	10	inflammation	inflammation	ADJ
dpc-3647	16	11	response	response	NOUN
dpc-3647	16	12	indexes	index	NOUN
dpc-3647	16	13	(	(	PUNCT
dpc-3647	16	14	siri	siri	NOUN
dpc-3647	16	15	)	)	PUNCT
dpc-3647	16	16	are	be	AUX
dpc-3647	16	17	novel	novel	ADJ
dpc-3647	16	18	biomarkers	biomarker	NOUN
dpc-3647	16	19	that	that	PRON
dpc-3647	16	20	indicate	indicate	VERB
dpc-3647	16	21	systemic	systemic	ADJ
dpc-3647	16	22	inflammation	inflammation	NOUN
dpc-3647	16	23	.	.	PUNCT
dpc-3647	17	1	objectives	objective	NOUN
dpc-3647	17	2	:	:	PUNCT
dpc-3647	17	3	we	we	PRON
dpc-3647	17	4	aimed	aim	VERB
dpc-3647	17	5	to	to	PART
dpc-3647	17	6	evaluate	evaluate	VERB
dpc-3647	17	7	the	the	DET
dpc-3647	17	8	effect	effect	NOUN
dpc-3647	17	9	of	of	ADP
dpc-3647	17	10	biological	biological	ADJ
dpc-3647	17	11	agent	agent	NOUN
dpc-3647	17	12	treatment	treatment	NOUN
dpc-3647	17	13	on	on	ADP
dpc-3647	17	14	sii	sii	ADJ
dpc-3647	17	15	and	and	CCONJ
dpc-3647	17	16	siri	siri	NOUN
dpc-3647	17	17	in	in	ADP
dpc-3647	17	18	psoriasis	psoriasis	NOUN
dpc-3647	17	19	patients	patient	NOUN
dpc-3647	17	20	.	.	PUNCT
dpc-3647	18	1	methods	method	NOUN
dpc-3647	18	2	:	:	PUNCT
dpc-3647	18	3	between	between	ADP
dpc-3647	18	4	april	april	PROPN
dpc-3647	18	5	2019	2019	NUM
dpc-3647	18	6	and	and	CCONJ
dpc-3647	18	7	october	october	PROPN
dpc-3647	18	8	2022	2022	NUM
dpc-3647	18	9	,	,	PUNCT
dpc-3647	18	10	sii	sii	PROPN
dpc-3647	18	11	and	and	CCONJ
dpc-3647	18	12	siri	siri	NOUN
dpc-3647	18	13	were	be	AUX
dpc-3647	18	14	retrospectively	retrospectively	ADV
dpc-3647	18	15	evaluated	evaluate	VERB
dpc-3647	18	16	in	in	ADP
dpc-3647	18	17	patients	patient	NOUN
dpc-3647	18	18	with	with	ADP
dpc-3647	18	19	psoriasis	psoriasis	NOUN
dpc-3647	18	20	before	before	ADV
dpc-3647	18	21	and	and	CCONJ
dpc-3647	18	22	three	three	NUM
dpc-3647	18	23	months	month	NOUN
dpc-3647	18	24	after	after	ADP
dpc-3647	18	25	the	the	DET
dpc-3647	18	26	initiation	initiation	NOUN
dpc-3647	18	27	of	of	ADP
dpc-3647	18	28	biological	biological	ADJ
dpc-3647	18	29	agents	agent	NOUN
dpc-3647	18	30	.	.	PUNCT
dpc-3647	19	1	results	result	NOUN
dpc-3647	19	2	:	:	PUNCT
dpc-3647	19	3	this	this	DET
dpc-3647	19	4	study	study	NOUN
dpc-3647	19	5	included	include	VERB
dpc-3647	19	6	220	220	NUM
dpc-3647	19	7	patients	patient	NOUN
dpc-3647	19	8	,	,	PUNCT
dpc-3647	19	9	101	101	NUM
dpc-3647	19	10	females	female	NOUN
dpc-3647	19	11	and	and	CCONJ
dpc-3647	19	12	119	119	NUM
dpc-3647	19	13	males	male	NOUN
dpc-3647	19	14	.	.	PUNCT
dpc-3647	20	1	siri	siri	NOUN
dpc-3647	20	2	was	be	AUX
dpc-3647	20	3	significantly	significantly	ADV
dpc-3647	20	4	higher	high	ADJ
dpc-3647	20	5	in	in	ADP
dpc-3647	20	6	male	male	ADJ
dpc-3647	20	7	patients	patient	NOUN
dpc-3647	20	8	compared	compare	VERB
dpc-3647	20	9	to	to	ADP
dpc-3647	20	10	females	female	NOUN
dpc-3647	20	11	(	(	PUNCT
dpc-3647	20	12	p	p	X
dpc-3647	20	13	<	<	X
dpc-3647	20	14	0.001	0.001	NUM
dpc-3647	20	15	)	)	PUNCT
dpc-3647	20	16	.	.	PUNCT
dpc-3647	21	1	although	although	SCONJ
dpc-3647	21	2	not	not	PART
dpc-3647	21	3	statistically	statistically	ADV
dpc-3647	21	4	significant	significant	ADJ
dpc-3647	21	5	,	,	PUNCT
dpc-3647	21	6	sii	sii	ADJ
dpc-3647	21	7	and	and	CCONJ
dpc-3647	21	8	siri	siri	NOUN
dpc-3647	21	9	were	be	AUX
dpc-3647	21	10	higher	high	ADJ
dpc-3647	21	11	in	in	ADP
dpc-3647	21	12	obese	obese	ADJ
dpc-3647	21	13	patients	patient	NOUN
dpc-3647	21	14	,	,	PUNCT
dpc-3647	21	15	patients	patient	NOUN
dpc-3647	21	16	with	with	ADP
dpc-3647	21	17	severe	severe	ADJ
dpc-3647	21	18	psoriasis	psoriasis	NOUN
dpc-3647	21	19	,	,	PUNCT
dpc-3647	21	20	longer	long	ADJ
dpc-3647	21	21	disease	disease	NOUN
dpc-3647	21	22	duration	duration	NOUN
dpc-3647	21	23	,	,	PUNCT
dpc-3647	21	24	nail	nail	NOUN
dpc-3647	21	25	involvement	involvement	NOUN
dpc-3647	21	26	and	and	CCONJ
dpc-3647	21	27	patients	patient	NOUN
dpc-3647	21	28	who	who	PRON
dpc-3647	21	29	received	receive	VERB
dpc-3647	21	30	previous	previous	ADJ
dpc-3647	21	31	biological	biological	ADJ
dpc-3647	21	32	agent	agent	NOUN
dpc-3647	21	33	treatment	treatment	NOUN
dpc-3647	21	34	.	.	PUNCT
dpc-3647	22	1	sii	sii	PROPN
dpc-3647	22	2	was	be	AUX
dpc-3647	22	3	also	also	ADV
dpc-3647	22	4	higher	high	ADJ
dpc-3647	22	5	in	in	ADP
dpc-3647	22	6	patients	patient	NOUN
dpc-3647	22	7	with	with	ADP
dpc-3647	22	8	hypertension	hypertension	NOUN
dpc-3647	22	9	,	,	PUNCT
dpc-3647	22	10	diabetes	diabetes	NOUN
dpc-3647	22	11	,	,	PUNCT
dpc-3647	22	12	hepatic	hepatic	ADJ
dpc-3647	22	13	steatosis	steatosis	NOUN
dpc-3647	22	14	,	,	PUNCT
dpc-3647	22	15	depression	depression	NOUN
dpc-3647	22	16	and	and	CCONJ
dpc-3647	22	17	coronary	coronary	ADJ
dpc-3647	22	18	artery	artery	NOUN
dpc-3647	22	19	disease	disease	NOUN
dpc-3647	22	20	(	(	PUNCT
dpc-3647	22	21	p	p	X
dpc-3647	22	22	=	=	NOUN
dpc-3647	22	23	0.801	0.801	NUM
dpc-3647	22	24	,	,	PUNCT
dpc-3647	22	25	p	p	X
dpc-3647	22	26	=	=	NOUN
dpc-3647	22	27	0.752	0.752	NUM
dpc-3647	22	28	,	,	PUNCT
dpc-3647	22	29	p	p	X
dpc-3647	22	30	 	 	SPACE
dpc-3647	22	31	=	=	NOUN
dpc-3647	22	32	 	 	SPACE
dpc-3647	22	33	0.706	0.706	NUM
dpc-3647	22	34	,	,	PUNCT
dpc-3647	22	35	p	p	X
dpc-3647	22	36	=	=	PROPN
dpc-3647	22	37	0.079	0.079	NUM
dpc-3647	22	38	,	,	PUNCT
dpc-3647	22	39	p	p	X
dpc-3647	22	40	=	=	PROPN
dpc-3647	22	41	0.861	0.861	NUM
dpc-3647	22	42	,	,	PUNCT
dpc-3647	22	43	respectively	respectively	ADV
dpc-3647	22	44	)	)	PUNCT
dpc-3647	22	45	,	,	PUNCT
dpc-3647	22	46	whereas	whereas	SCONJ
dpc-3647	22	47	siri	siri	NOUN
dpc-3647	22	48	was	be	AUX
dpc-3647	22	49	higher	high	ADJ
dpc-3647	22	50	in	in	ADP
dpc-3647	22	51	patients	patient	NOUN
dpc-3647	22	52	with	with	ADP
dpc-3647	22	53	diabetes	diabetes	NOUN
dpc-3647	22	54	and	and	CCONJ
dpc-3647	22	55	depression	depression	NOUN
dpc-3647	22	56	(	(	PUNCT
dpc-3647	22	57	p	p	X
dpc-3647	22	58	=	=	PUNCT
dpc-3647	22	59	0.263	0.263	NUM
dpc-3647	22	60	,	,	PUNCT
dpc-3647	22	61	p	p	X
dpc-3647	22	62	=	=	NOUN
dpc-3647	22	63	0.777	0.777	NUM
dpc-3647	22	64	,	,	PUNCT
dpc-3647	22	65	respectively	respectively	ADV
dpc-3647	22	66	)	)	PUNCT
dpc-3647	22	67	.	.	PUNCT
dpc-3647	23	1	both	both	PRON
dpc-3647	23	2	sii	sii	ADJ
dpc-3647	23	3	and	and	CCONJ
dpc-3647	23	4	siri	siri	NOUN
dpc-3647	23	5	statistically	statistically	ADV
dpc-3647	23	6	significantly	significantly	ADV
dpc-3647	23	7	decreased	decrease	VERB
dpc-3647	23	8	after	after	ADP
dpc-3647	23	9	treatment	treatment	NOUN
dpc-3647	23	10	with	with	ADP
dpc-3647	23	11	adalimumab	adalimumab	NOUN
dpc-3647	23	12	,	,	PUNCT
dpc-3647	23	13	infliximab	infliximab	NOUN
dpc-3647	23	14	,	,	PUNCT
dpc-3647	23	15	ixekizumab	ixekizumab	NOUN
dpc-3647	23	16	,	,	PUNCT
dpc-3647	23	17	secukinumab	secukinumab	NOUN
dpc-3647	23	18	,	,	PUNCT
dpc-3647	23	19	ustekinumab	ustekinumab	NOUN
dpc-3647	23	20	and	and	CCONJ
dpc-3647	23	21	risankizumab	risankizumab	NOUN
dpc-3647	23	22	.	.	PUNCT
dpc-3647	24	1	abstract	abstract	ADJ
dpc-3647	24	2	2	2	NUM
dpc-3647	24	3	original	original	ADJ
dpc-3647	24	4	article	article	NOUN
dpc-3647	24	5	|	|	ADV
dpc-3647	24	6	dermatol	dermatol	ADJ
dpc-3647	24	7	pract	pract	NOUN
dpc-3647	24	8	concept	concept	NOUN
dpc-3647	24	9	.	.	PUNCT
dpc-3647	25	1	2024;14(1):e2024065	2024;14(1):e2024065	NUM
dpc-3647	25	2	introduction	introduction	NOUN
dpc-3647	25	3	psoriasis	psoriasis	NOUN
dpc-3647	25	4	is	be	AUX
dpc-3647	25	5	a	a	DET
dpc-3647	25	6	chronic	chronic	ADJ
dpc-3647	25	7	inflammatory	inflammatory	ADJ
dpc-3647	25	8	cutaneous	cutaneous	ADJ
dpc-3647	25	9	disorder	disorder	NOUN
dpc-3647	25	10	which	which	PRON
dpc-3647	25	11	has	have	AUX
dpc-3647	25	12	been	be	AUX
dpc-3647	25	13	related	relate	VERB
dpc-3647	25	14	to	to	ADP
dpc-3647	25	15	comorbidities	comorbiditie	NOUN
dpc-3647	25	16	such	such	ADJ
dpc-3647	25	17	as	as	ADP
dpc-3647	25	18	psoriatic	psoriatic	ADJ
dpc-3647	25	19	arthritis	arthritis	NOUN
dpc-3647	25	20	,	,	PUNCT
dpc-3647	25	21	diabetes	diabetes	NOUN
dpc-3647	25	22	,	,	PUNCT
dpc-3647	25	23	obesity	obesity	NOUN
dpc-3647	25	24	,	,	PUNCT
dpc-3647	25	25	cardiovascular	cardiovascular	ADJ
dpc-3647	25	26	diseases	disease	NOUN
dpc-3647	25	27	and	and	CCONJ
dpc-3647	25	28	depression	depression	NOUN
dpc-3647	25	29	due	due	ADP
dpc-3647	25	30	to	to	ADP
dpc-3647	25	31	underlying	underlie	VERB
dpc-3647	25	32	systemic	systemic	ADJ
dpc-3647	25	33	inflammation	inflammation	NOUN
dpc-3647	25	34	[	[	X
dpc-3647	25	35	1	1	NUM
dpc-3647	25	36	]	]	PUNCT
dpc-3647	25	37	.	.	PUNCT
dpc-3647	26	1	it	it	PRON
dpc-3647	26	2	has	have	AUX
dpc-3647	26	3	been	be	AUX
dpc-3647	26	4	suggested	suggest	VERB
dpc-3647	26	5	that	that	SCONJ
dpc-3647	26	6	proinflammatory	proinflammatory	ADJ
dpc-3647	26	7	cytokines	cytokine	NOUN
dpc-3647	26	8	,	,	PUNCT
dpc-3647	26	9	which	which	PRON
dpc-3647	26	10	have	have	AUX
dpc-3647	26	11	been	be	AUX
dpc-3647	26	12	implicated	implicate	VERB
dpc-3647	26	13	in	in	ADP
dpc-3647	26	14	the	the	DET
dpc-3647	26	15	development	development	NOUN
dpc-3647	26	16	of	of	ADP
dpc-3647	26	17	cutaneous	cutaneous	ADJ
dpc-3647	26	18	findings	finding	NOUN
dpc-3647	26	19	such	such	ADJ
dpc-3647	26	20	as	as	ADP
dpc-3647	26	21	tumor	tumor	NOUN
dpc-3647	26	22	necrosis	necrosis	NOUN
dpc-3647	26	23	factor	factor	NOUN
dpc-3647	26	24	(	(	PUNCT
dpc-3647	26	25	tnf)-α	tnf)-α	PROPN
dpc-3647	26	26	,	,	PUNCT
dpc-3647	26	27	interleukin	interleukin	NOUN
dpc-3647	26	28	(	(	PUNCT
dpc-3647	26	29	il)-17	il)-17	PROPN
dpc-3647	26	30	,	,	PUNCT
dpc-3647	26	31	il-23	il-23	NOUN
dpc-3647	26	32	,	,	PUNCT
dpc-3647	26	33	were	be	AUX
dpc-3647	26	34	increased	increase	VERB
dpc-3647	26	35	in	in	ADP
dpc-3647	26	36	both	both	DET
dpc-3647	26	37	skin	skin	NOUN
dpc-3647	26	38	and	and	CCONJ
dpc-3647	26	39	the	the	DET
dpc-3647	26	40	circulation	circulation	NOUN
dpc-3647	27	1	[	[	X
dpc-3647	27	2	2	2	NUM
dpc-3647	27	3	]	]	PUNCT
dpc-3647	27	4	.	.	PUNCT
dpc-3647	28	1	although	although	SCONJ
dpc-3647	28	2	the	the	DET
dpc-3647	28	3	systemic	systemic	ADJ
dpc-3647	28	4	inflammatory	inflammatory	ADJ
dpc-3647	28	5	response	response	NOUN
dpc-3647	28	6	,	,	PUNCT
dpc-3647	28	7	which	which	PRON
dpc-3647	28	8	is	be	AUX
dpc-3647	28	9	not	not	PART
dpc-3647	28	10	limited	limit	VERB
dpc-3647	28	11	to	to	ADP
dpc-3647	28	12	the	the	DET
dpc-3647	28	13	skin	skin	NOUN
dpc-3647	28	14	,	,	PUNCT
dpc-3647	28	15	may	may	AUX
dpc-3647	28	16	lead	lead	VERB
dpc-3647	28	17	to	to	ADP
dpc-3647	28	18	tissue	tissue	NOUN
dpc-3647	28	19	and	and	CCONJ
dpc-3647	28	20	organ	organ	NOUN
dpc-3647	28	21	dysfunction	dysfunction	NOUN
dpc-3647	28	22	,	,	PUNCT
dpc-3647	28	23	the	the	DET
dpc-3647	28	24	risk	risk	NOUN
dpc-3647	28	25	for	for	ADP
dpc-3647	28	26	the	the	DET
dpc-3647	28	27	development	development	NOUN
dpc-3647	28	28	of	of	ADP
dpc-3647	28	29	the	the	DET
dpc-3647	28	30	disease	disease	NOUN
dpc-3647	28	31	and	and	CCONJ
dpc-3647	28	32	pathogenesis	pathogenesis	NOUN
dpc-3647	28	33	of	of	ADP
dpc-3647	28	34	the	the	DET
dpc-3647	28	35	systemic	systemic	ADJ
dpc-3647	28	36	involvement	involvement	NOUN
dpc-3647	28	37	have	have	AUX
dpc-3647	28	38	not	not	PART
dpc-3647	28	39	been	be	AUX
dpc-3647	28	40	fully	fully	ADV
dpc-3647	28	41	understood	understand	VERB
dpc-3647	28	42	[	[	X
dpc-3647	28	43	3	3	NUM
dpc-3647	28	44	]	]	PUNCT
dpc-3647	28	45	.	.	PUNCT
dpc-3647	29	1	it	it	PRON
dpc-3647	29	2	has	have	AUX
dpc-3647	29	3	been	be	AUX
dpc-3647	29	4	suggested	suggest	VERB
dpc-3647	29	5	that	that	SCONJ
dpc-3647	29	6	biological	biological	ADJ
dpc-3647	29	7	agents	agent	NOUN
dpc-3647	29	8	used	use	VERB
dpc-3647	29	9	in	in	ADP
dpc-3647	29	10	the	the	DET
dpc-3647	29	11	treatment	treatment	NOUN
dpc-3647	29	12	of	of	ADP
dpc-3647	29	13	psoriasis	psoriasis	NOUN
dpc-3647	29	14	might	might	AUX
dpc-3647	29	15	reduce	reduce	VERB
dpc-3647	29	16	the	the	DET
dpc-3647	29	17	risk	risk	NOUN
dpc-3647	29	18	of	of	ADP
dpc-3647	29	19	the	the	DET
dpc-3647	29	20	development	development	NOUN
dpc-3647	29	21	of	of	ADP
dpc-3647	29	22	systemic	systemic	ADJ
dpc-3647	29	23	comorbidities	comorbiditie	NOUN
dpc-3647	29	24	and	and	CCONJ
dpc-3647	29	25	prevent	prevent	VERB
dpc-3647	29	26	the	the	DET
dpc-3647	29	27	progression	progression	NOUN
dpc-3647	29	28	of	of	ADP
dpc-3647	29	29	existing	exist	VERB
dpc-3647	29	30	comorbidities	comorbiditie	NOUN
dpc-3647	29	31	due	due	ADP
dpc-3647	29	32	to	to	ADP
dpc-3647	29	33	their	their	PRON
dpc-3647	29	34	anti	anti	ADJ
dpc-3647	29	35	-	-	ADJ
dpc-3647	29	36	inflammatory	inflammatory	ADJ
dpc-3647	29	37	effects	effect	NOUN
dpc-3647	29	38	[	[	X
dpc-3647	29	39	4	4	NUM
dpc-3647	29	40	]	]	PUNCT
dpc-3647	29	41	.	.	PUNCT
dpc-3647	30	1	it	it	PRON
dpc-3647	30	2	is	be	AUX
dpc-3647	30	3	important	important	ADJ
dpc-3647	30	4	to	to	PART
dpc-3647	30	5	identify	identify	VERB
dpc-3647	30	6	biomarkers	biomarker	NOUN
dpc-3647	30	7	that	that	PRON
dpc-3647	30	8	can	can	AUX
dpc-3647	30	9	indicate	indicate	VERB
dpc-3647	30	10	disease	disease	NOUN
dpc-3647	30	11	activity	activity	NOUN
dpc-3647	30	12	and	and	CCONJ
dpc-3647	30	13	remission	remission	NOUN
dpc-3647	30	14	in	in	ADP
dpc-3647	30	15	psoriasis	psoriasis	NOUN
dpc-3647	30	16	.	.	PUNCT
dpc-3647	31	1	inflammatory	inflammatory	ADJ
dpc-3647	31	2	biomarkers	biomarker	NOUN
dpc-3647	31	3	,	,	PUNCT
dpc-3647	31	4	especially	especially	ADV
dpc-3647	31	5	obtained	obtain	VERB
dpc-3647	31	6	from	from	ADP
dpc-3647	31	7	blood	blood	NOUN
dpc-3647	31	8	samples	sample	NOUN
dpc-3647	31	9	,	,	PUNCT
dpc-3647	31	10	may	may	AUX
dpc-3647	31	11	be	be	AUX
dpc-3647	31	12	easily	easily	ADV
dpc-3647	31	13	performed	perform	VERB
dpc-3647	31	14	and	and	CCONJ
dpc-3647	31	15	used	use	VERB
dpc-3647	31	16	in	in	ADP
dpc-3647	31	17	the	the	DET
dpc-3647	31	18	follow	follow	NOUN
dpc-3647	31	19	-	-	PUNCT
dpc-3647	31	20	up	up	NOUN
dpc-3647	31	21	of	of	ADP
dpc-3647	31	22	patients	patient	NOUN
dpc-3647	31	23	with	with	ADP
dpc-3647	31	24	psoriasis	psoriasis	NOUN
dpc-3647	31	25	[	[	X
dpc-3647	31	26	5	5	NUM
dpc-3647	31	27	]	]	PUNCT
dpc-3647	31	28	.	.	PUNCT
dpc-3647	32	1	various	various	ADJ
dpc-3647	32	2	biomarkers	biomarker	NOUN
dpc-3647	32	3	such	such	ADJ
dpc-3647	32	4	as	as	ADP
dpc-3647	32	5	neutrophil/	neutrophil/	NUM
dpc-3647	32	6	lymphocytes	lymphocyte	NOUN
dpc-3647	32	7	ratio	ratio	NOUN
dpc-3647	32	8	,	,	PUNCT
dpc-3647	32	9	platelet	platelet	NOUN
dpc-3647	32	10	/	/	SYM
dpc-3647	32	11	lymphocytes	lymphocyte	VERB
dpc-3647	32	12	ratio	ratio	NOUN
dpc-3647	32	13	and	and	CCONJ
dpc-3647	32	14	systemic	systemic	ADJ
dpc-3647	32	15	immune	immune	ADJ
dpc-3647	32	16	inflammation	inflammation	NOUN
dpc-3647	32	17	index	index	NOUN
dpc-3647	32	18	have	have	AUX
dpc-3647	32	19	been	be	AUX
dpc-3647	32	20	proposed	propose	VERB
dpc-3647	32	21	to	to	PART
dpc-3647	32	22	be	be	AUX
dpc-3647	32	23	used	use	VERB
dpc-3647	32	24	to	to	PART
dpc-3647	32	25	detect	detect	VERB
dpc-3647	32	26	systemic	systemic	ADJ
dpc-3647	32	27	inflammation	inflammation	NOUN
dpc-3647	32	28	in	in	ADP
dpc-3647	32	29	patients	patient	NOUN
dpc-3647	32	30	with	with	ADP
dpc-3647	32	31	psoriasis	psoriasis	NOUN
dpc-3647	32	32	 	 	SPACE
dpc-3647	33	1	[	[	X
dpc-3647	33	2	1,5	1,5	NUM
dpc-3647	33	3	]	]	PUNCT
dpc-3647	33	4	.	.	PUNCT
dpc-3647	34	1	however	however	ADV
dpc-3647	34	2	,	,	PUNCT
dpc-3647	34	3	there	there	PRON
dpc-3647	34	4	is	be	VERB
dpc-3647	34	5	no	no	DET
dpc-3647	34	6	consensus	consensus	NOUN
dpc-3647	34	7	on	on	ADP
dpc-3647	34	8	the	the	DET
dpc-3647	34	9	biomarkers	biomarker	NOUN
dpc-3647	34	10	that	that	PRON
dpc-3647	34	11	can	can	AUX
dpc-3647	34	12	be	be	AUX
dpc-3647	34	13	used	use	VERB
dpc-3647	34	14	to	to	PART
dpc-3647	34	15	create	create	VERB
dpc-3647	34	16	an	an	DET
dpc-3647	34	17	optimized	optimize	VERB
dpc-3647	34	18	treatment	treatment	NOUN
dpc-3647	34	19	strategy	strategy	NOUN
dpc-3647	34	20	in	in	ADP
dpc-3647	34	21	the	the	DET
dpc-3647	34	22	management	management	NOUN
dpc-3647	34	23	of	of	ADP
dpc-3647	34	24	psoriasis	psoriasis	NOUN
dpc-3647	34	25	[	[	X
dpc-3647	34	26	5	5	NUM
dpc-3647	34	27	]	]	PUNCT
dpc-3647	34	28	.	.	PUNCT
dpc-3647	35	1	systemic	systemic	ADJ
dpc-3647	35	2	immune	immune	ADJ
dpc-3647	35	3	inflammation	inflammation	NOUN
dpc-3647	35	4	index	index	NOUN
dpc-3647	35	5	(	(	PUNCT
dpc-3647	35	6	sii	sii	PROPN
dpc-3647	35	7	)	)	PUNCT
dpc-3647	35	8	and	and	CCONJ
dpc-3647	35	9	systemic	systemic	ADJ
dpc-3647	35	10	inflammation	inflammation	ADJ
dpc-3647	35	11	response	response	NOUN
dpc-3647	35	12	index	index	NOUN
dpc-3647	35	13	(	(	PUNCT
dpc-3647	35	14	siri	siri	NOUN
dpc-3647	35	15	)	)	PUNCT
dpc-3647	35	16	are	be	AUX
dpc-3647	35	17	new	new	ADJ
dpc-3647	35	18	biomarkers	biomarker	NOUN
dpc-3647	35	19	that	that	PRON
dpc-3647	35	20	have	have	AUX
dpc-3647	35	21	been	be	AUX
dpc-3647	35	22	reported	report	VERB
dpc-3647	35	23	to	to	PART
dpc-3647	35	24	indicate	indicate	VERB
dpc-3647	35	25	systemic	systemic	ADJ
dpc-3647	35	26	inflammation	inflammation	NOUN
dpc-3647	35	27	[	[	X
dpc-3647	35	28	6	6	NUM
dpc-3647	35	29	]	]	PUNCT
dpc-3647	35	30	.	.	PUNCT
dpc-3647	36	1	sii	sii	PROPN
dpc-3647	36	2	and	and	CCONJ
dpc-3647	36	3	siri	siri	NOUN
dpc-3647	36	4	have	have	AUX
dpc-3647	36	5	been	be	AUX
dpc-3647	36	6	associated	associate	VERB
dpc-3647	36	7	with	with	ADP
dpc-3647	36	8	various	various	ADJ
dpc-3647	36	9	disorders	disorder	NOUN
dpc-3647	36	10	such	such	ADJ
dpc-3647	36	11	as	as	ADP
dpc-3647	36	12	hepatic	hepatic	ADJ
dpc-3647	36	13	steatosis	steatosis	NOUN
dpc-3647	36	14	,	,	PUNCT
dpc-3647	36	15	cardiovascular	cardiovascular	ADJ
dpc-3647	36	16	diseases	disease	NOUN
dpc-3647	36	17	,	,	PUNCT
dpc-3647	36	18	risk	risk	NOUN
dpc-3647	36	19	of	of	ADP
dpc-3647	36	20	cancer	cancer	NOUN
dpc-3647	36	21	development	development	NOUN
dpc-3647	36	22	and	and	CCONJ
dpc-3647	36	23	depression	depression	NOUN
dpc-3647	36	24	[	[	X
dpc-3647	36	25	6	6	NUM
dpc-3647	36	26	-	-	SYM
dpc-3647	36	27	9	9	NUM
dpc-3647	36	28	]	]	PUNCT
dpc-3647	36	29	.	.	PUNCT
dpc-3647	37	1	in	in	ADP
dpc-3647	37	2	a	a	DET
dpc-3647	37	3	few	few	ADJ
dpc-3647	37	4	studies	study	NOUN
dpc-3647	37	5	,	,	PUNCT
dpc-3647	37	6	high	high	ADJ
dpc-3647	37	7	sii	sii	PROPN
dpc-3647	37	8	levels	level	NOUN
dpc-3647	37	9	have	have	AUX
dpc-3647	37	10	been	be	AUX
dpc-3647	37	11	reported	report	VERB
dpc-3647	37	12	in	in	ADP
dpc-3647	37	13	patients	patient	NOUN
dpc-3647	37	14	with	with	ADP
dpc-3647	37	15	psoriasis	psoriasis	NOUN
dpc-3647	37	16	[	[	X
dpc-3647	37	17	10,11	10,11	NOUN
dpc-3647	37	18	]	]	PUNCT
dpc-3647	37	19	.	.	PUNCT
dpc-3647	38	1	recently	recently	ADV
dpc-3647	38	2	,	,	PUNCT
dpc-3647	38	3	sugimoto	sugimoto	PROPN
dpc-3647	38	4	et	et	PROPN
dpc-3647	38	5	al	al	PROPN
dpc-3647	38	6	reported	report	VERB
dpc-3647	38	7	that	that	SCONJ
dpc-3647	38	8	patients	patient	NOUN
dpc-3647	38	9	with	with	ADP
dpc-3647	38	10	psoriatic	psoriatic	ADJ
dpc-3647	38	11	arthritis	arthritis	NOUN
dpc-3647	38	12	were	be	AUX
dpc-3647	38	13	likely	likely	ADJ
dpc-3647	38	14	to	to	PART
dpc-3647	38	15	have	have	VERB
dpc-3647	38	16	high	high	ADJ
dpc-3647	38	17	siri	siri	NOUN
dpc-3647	38	18	levels	level	NOUN
dpc-3647	38	19	[	[	X
dpc-3647	38	20	1	1	NUM
dpc-3647	38	21	]	]	PUNCT
dpc-3647	38	22	.	.	PUNCT
dpc-3647	39	1	however	however	ADV
dpc-3647	39	2	,	,	PUNCT
dpc-3647	39	3	sii	sii	PROPN
dpc-3647	39	4	and	and	CCONJ
dpc-3647	39	5	siri	siri	NOUN
dpc-3647	39	6	have	have	AUX
dpc-3647	39	7	not	not	PART
dpc-3647	39	8	been	be	AUX
dpc-3647	39	9	adequately	adequately	ADV
dpc-3647	39	10	studied	study	VERB
dpc-3647	39	11	in	in	ADP
dpc-3647	39	12	patients	patient	NOUN
dpc-3647	39	13	with	with	ADP
dpc-3647	39	14	psoriasis	psoriasis	NOUN
dpc-3647	39	15	.	.	PUNCT
dpc-3647	40	1	objectives	objective	VERB
dpc-3647	40	2	the	the	DET
dpc-3647	40	3	aim	aim	NOUN
dpc-3647	40	4	of	of	ADP
dpc-3647	40	5	this	this	DET
dpc-3647	40	6	study	study	NOUN
dpc-3647	40	7	was	be	AUX
dpc-3647	40	8	to	to	PART
dpc-3647	40	9	evaluate	evaluate	VERB
dpc-3647	40	10	the	the	DET
dpc-3647	40	11	sii	sii	ADJ
dpc-3647	40	12	and	and	CCONJ
dpc-3647	40	13	siri	siri	NOUN
dpc-3647	40	14	in	in	ADP
dpc-3647	40	15	patients	patient	NOUN
dpc-3647	40	16	with	with	ADP
dpc-3647	40	17	psoriasis	psoriasis	NOUN
dpc-3647	40	18	treated	treat	VERB
dpc-3647	40	19	with	with	ADP
dpc-3647	40	20	biological	biological	ADJ
dpc-3647	40	21	agents	agent	NOUN
dpc-3647	40	22	.	.	PUNCT
dpc-3647	41	1	methods	method	NOUN
dpc-3647	41	2	gazi	gazi	PROPN
dpc-3647	41	3	university	university	PROPN
dpc-3647	41	4	ethics	ethic	NOUN
dpc-3647	41	5	committee	committee	PROPN
dpc-3647	41	6	approved	approve	VERB
dpc-3647	41	7	this	this	DET
dpc-3647	41	8	study	study	NOUN
dpc-3647	41	9	(	(	PUNCT
dpc-3647	41	10	approval	approval	NOUN
dpc-3647	41	11	number	number	NOUN
dpc-3647	41	12	:	:	PUNCT
dpc-3647	41	13	2022	2022	NUM
dpc-3647	41	14	-	-	SYM
dpc-3647	41	15	1108	1108	NUM
dpc-3647	41	16	)	)	PUNCT
dpc-3647	41	17	.	.	PUNCT
dpc-3647	42	1	medical	medical	ADJ
dpc-3647	42	2	records	record	NOUN
dpc-3647	42	3	of	of	ADP
dpc-3647	42	4	patients	patient	NOUN
dpc-3647	42	5	who	who	PRON
dpc-3647	42	6	were	be	AUX
dpc-3647	42	7	admitted	admit	VERB
dpc-3647	42	8	for	for	ADP
dpc-3647	42	9	the	the	DET
dpc-3647	42	10	treatment	treatment	NOUN
dpc-3647	42	11	of	of	ADP
dpc-3647	42	12	psoriasis	psoriasis	NOUN
dpc-3647	42	13	between	between	ADP
dpc-3647	42	14	april	april	PROPN
dpc-3647	42	15	2019	2019	NUM
dpc-3647	42	16	and	and	CCONJ
dpc-3647	42	17	october	october	PROPN
dpc-3647	42	18	2022	2022	NUM
dpc-3647	42	19	were	be	AUX
dpc-3647	42	20	retrospectively	retrospectively	ADV
dpc-3647	42	21	reviewed	review	VERB
dpc-3647	42	22	.	.	PUNCT
dpc-3647	43	1	patients	patient	NOUN
dpc-3647	43	2	with	with	ADP
dpc-3647	43	3	psoriasis	psoriasis	NOUN
dpc-3647	43	4	aged	age	VERB
dpc-3647	43	5	18	18	NUM
dpc-3647	43	6	years	year	NOUN
dpc-3647	43	7	and	and	CCONJ
dpc-3647	43	8	over	over	ADV
dpc-3647	43	9	and	and	CCONJ
dpc-3647	43	10	who	who	PRON
dpc-3647	43	11	were	be	AUX
dpc-3647	43	12	treated	treat	VERB
dpc-3647	43	13	with	with	ADP
dpc-3647	43	14	biological	biological	ADJ
dpc-3647	43	15	agents	agent	NOUN
dpc-3647	43	16	were	be	AUX
dpc-3647	43	17	included	include	VERB
dpc-3647	43	18	in	in	ADP
dpc-3647	43	19	this	this	DET
dpc-3647	43	20	study	study	NOUN
dpc-3647	43	21	.	.	PUNCT
dpc-3647	44	1	psoriasis	psoriasis	NOUN
dpc-3647	44	2	type	type	NOUN
dpc-3647	44	3	,	,	PUNCT
dpc-3647	44	4	psoriasis	psoriasis	NOUN
dpc-3647	44	5	duration	duration	NOUN
dpc-3647	44	6	,	,	PUNCT
dpc-3647	44	7	accompanying	accompany	VERB
dpc-3647	44	8	psoriatic	psoriatic	ADJ
dpc-3647	44	9	arthritis	arthritis	NOUN
dpc-3647	44	10	and	and	CCONJ
dpc-3647	44	11	systemic	systemic	ADJ
dpc-3647	44	12	diseases	disease	NOUN
dpc-3647	44	13	,	,	PUNCT
dpc-3647	44	14	psoriasis	psoriasis	NOUN
dpc-3647	44	15	treatment	treatment	NOUN
dpc-3647	44	16	,	,	PUNCT
dpc-3647	44	17	psoriasis	psoriasis	NOUN
dpc-3647	44	18	area	area	NOUN
dpc-3647	44	19	and	and	CCONJ
dpc-3647	44	20	severity	severity	NOUN
dpc-3647	44	21	index	index	NOUN
dpc-3647	44	22	(	(	PUNCT
dpc-3647	44	23	pasi	pasi	NOUN
dpc-3647	44	24	)	)	PUNCT
dpc-3647	44	25	and	and	CCONJ
dpc-3647	44	26	body	body	NOUN
dpc-3647	44	27	mass	mass	NOUN
dpc-3647	44	28	index	index	NOUN
dpc-3647	44	29	(	(	PUNCT
dpc-3647	44	30	bmi	bmi	PROPN
dpc-3647	44	31	)	)	PUNCT
dpc-3647	44	32	were	be	AUX
dpc-3647	44	33	noted	note	VERB
dpc-3647	44	34	.	.	PUNCT
dpc-3647	45	1	pasi	pasi	PROPN
dpc-3647	45	2	less	less	ADJ
dpc-3647	45	3	than	than	ADP
dpc-3647	45	4	10	10	NUM
dpc-3647	45	5	was	be	AUX
dpc-3647	45	6	regarded	regard	VERB
dpc-3647	45	7	as	as	ADV
dpc-3647	45	8	mild	mild	ADJ
dpc-3647	45	9	to	to	ADP
dpc-3647	45	10	moderate	moderate	ADJ
dpc-3647	45	11	psoriasis	psoriasis	NOUN
dpc-3647	45	12	,	,	PUNCT
dpc-3647	45	13	whereas	whereas	SCONJ
dpc-3647	45	14	pasi	pasi	NOUN
dpc-3647	45	15	greater	great	ADJ
dpc-3647	45	16	than	than	ADP
dpc-3647	45	17	10	10	NUM
dpc-3647	45	18	was	be	AUX
dpc-3647	45	19	severe	severe	ADJ
dpc-3647	45	20	disease	disease	NOUN
dpc-3647	45	21	  	  	SPACE
dpc-3647	46	1	[	[	X
dpc-3647	46	2	12	12	NUM
dpc-3647	46	3	]	]	PUNCT
dpc-3647	46	4	.	.	PUNCT
dpc-3647	47	1	obesity	obesity	NOUN
dpc-3647	47	2	was	be	AUX
dpc-3647	47	3	defined	define	VERB
dpc-3647	47	4	as	as	ADP
dpc-3647	47	5	body	body	NOUN
dpc-3647	47	6	mass	mass	NOUN
dpc-3647	47	7	index	index	NOUN
dpc-3647	47	8	(	(	PUNCT
dpc-3647	47	9	bmi	bmi	PROPN
dpc-3647	47	10	)	)	PUNCT
dpc-3647	47	11	≥	≥	NOUN
dpc-3647	47	12	30	30	NUM
dpc-3647	47	13	kg	kg	NOUN
dpc-3647	47	14	/	/	SYM
dpc-3647	47	15	m2	m2	PROPN
dpc-3647	47	16	  	  	SPACE
dpc-3647	48	1	[	[	X
dpc-3647	48	2	13	13	NUM
dpc-3647	48	3	]	]	PUNCT
dpc-3647	48	4	.	.	PUNCT
dpc-3647	49	1	in	in	ADP
dpc-3647	49	2	addition	addition	NOUN
dpc-3647	49	3	,	,	PUNCT
dpc-3647	49	4	sii	sii	PROPN
dpc-3647	49	5	and	and	CCONJ
dpc-3647	49	6	siri	siri	NOUN
dpc-3647	49	7	were	be	AUX
dpc-3647	49	8	evaluated	evaluate	VERB
dpc-3647	49	9	before	before	ADP
dpc-3647	49	10	and	and	CCONJ
dpc-3647	49	11	three	three	NUM
dpc-3647	49	12	months	month	NOUN
dpc-3647	49	13	after	after	ADP
dpc-3647	49	14	treatment	treatment	NOUN
dpc-3647	49	15	with	with	ADP
dpc-3647	49	16	biological	biological	ADJ
dpc-3647	49	17	agents	agent	NOUN
dpc-3647	49	18	.	.	PUNCT
dpc-3647	50	1	sii	sii	PROPN
dpc-3647	50	2	and	and	CCONJ
dpc-3647	50	3	siri	siri	NOUN
dpc-3647	50	4	were	be	AUX
dpc-3647	50	5	calculated	calculate	VERB
dpc-3647	50	6	using	use	VERB
dpc-3647	50	7	the	the	DET
dpc-3647	50	8	data	datum	NOUN
dpc-3647	50	9	obtained	obtain	VERB
dpc-3647	50	10	from	from	ADP
dpc-3647	50	11	complete	complete	ADJ
dpc-3647	50	12	blood	blood	NOUN
dpc-3647	50	13	count	count	NOUN
dpc-3647	50	14	;	;	PUNCT
dpc-3647	50	15	sii=	sii=	NUM
dpc-3647	50	16	platelet	platelet	NOUN
dpc-3647	50	17	count	count	NOUN
dpc-3647	50	18	(	(	PUNCT
dpc-3647	50	19	x103/µl	x103/µl	PROPN
dpc-3647	50	20	)	)	PUNCT
dpc-3647	50	21	x	x	SYM
dpc-3647	50	22	neutrophil	neutrophil	ADJ
dpc-3647	50	23	count	count	NOUN
dpc-3647	50	24	(	(	PUNCT
dpc-3647	50	25	x103/µl	x103/µl	PROPN
dpc-3647	50	26	)	)	PUNCT
dpc-3647	50	27	/	/	SYM
dpc-3647	50	28	lymphocyte	lymphocyte	ADJ
dpc-3647	50	29	count	count	NOUN
dpc-3647	50	30	(	(	PUNCT
dpc-3647	50	31	x103/µl	x103/µl	PROPN
dpc-3647	50	32	)	)	PUNCT
dpc-3647	50	33	and	and	CCONJ
dpc-3647	50	34	siri=	siri=	NUM
dpc-3647	50	35	neutrophil	neutrophil	ADJ
dpc-3647	50	36	count	count	NOUN
dpc-3647	50	37	(	(	PUNCT
dpc-3647	50	38	x103/µl	x103/µl	PROPN
dpc-3647	50	39	)	)	PUNCT
dpc-3647	50	40	x	x	SYM
dpc-3647	50	41	monocyte	monocyte	NOUN
dpc-3647	50	42	count	count	NOUN
dpc-3647	50	43	(	(	PUNCT
dpc-3647	50	44	x103/µl	x103/µl	PROPN
dpc-3647	50	45	)	)	PUNCT
dpc-3647	50	46	/	/	SYM
dpc-3647	50	47	lymphocyte	lymphocyte	ADJ
dpc-3647	50	48	count	count	NOUN
dpc-3647	50	49	(	(	PUNCT
dpc-3647	50	50	x103/µl	x103/µl	X
dpc-3647	50	51	)	)	PUNCT
dpc-3647	51	1	[	[	X
dpc-3647	51	2	14,15	14,15	NUM
dpc-3647	51	3	]	]	PUNCT
dpc-3647	51	4	.	.	PUNCT
dpc-3647	52	1	statistical	statistical	ADJ
dpc-3647	52	2	analysis	analysis	NOUN
dpc-3647	52	3	was	be	AUX
dpc-3647	52	4	performed	perform	VERB
dpc-3647	52	5	using	use	VERB
dpc-3647	52	6	spss	spss	PROPN
dpc-3647	52	7	version	version	NOUN
dpc-3647	52	8	25.0	25.0	NUM
dpc-3647	52	9	.	.	PUNCT
dpc-3647	53	1	continuous	continuous	ADJ
dpc-3647	53	2	variables	variable	NOUN
dpc-3647	53	3	were	be	AUX
dpc-3647	53	4	presented	present	VERB
dpc-3647	53	5	as	as	ADP
dpc-3647	53	6	mean	mean	NOUN
dpc-3647	53	7	±	±	NUM
dpc-3647	53	8	standard	standard	ADJ
dpc-3647	53	9	deviation	deviation	NOUN
dpc-3647	53	10	or	or	CCONJ
dpc-3647	53	11	median	median	NOUN
dpc-3647	53	12	(	(	PUNCT
dpc-3647	53	13	interquartile	interquartile	NOUN
dpc-3647	53	14	range	range	NOUN
dpc-3647	53	15	)	)	PUNCT
dpc-3647	53	16	,	,	PUNCT
dpc-3647	53	17	whereas	whereas	SCONJ
dpc-3647	53	18	categorical	categorical	ADJ
dpc-3647	53	19	variables	variable	NOUN
dpc-3647	53	20	were	be	AUX
dpc-3647	53	21	presented	present	VERB
dpc-3647	53	22	as	as	ADP
dpc-3647	53	23	counts	count	NOUN
dpc-3647	53	24	and	and	CCONJ
dpc-3647	53	25	percentages	percentage	NOUN
dpc-3647	53	26	.	.	PUNCT
dpc-3647	54	1	kolmogorov	kolmogorov	ADJ
dpc-3647	54	2	-	-	PUNCT
dpc-3647	54	3	smirnov	smirnov	PROPN
dpc-3647	54	4	test	test	NOUN
dpc-3647	54	5	was	be	AUX
dpc-3647	54	6	used	use	VERB
dpc-3647	54	7	to	to	PART
dpc-3647	54	8	detect	detect	VERB
dpc-3647	54	9	the	the	DET
dpc-3647	54	10	normality	normality	NOUN
dpc-3647	54	11	of	of	ADP
dpc-3647	54	12	the	the	DET
dpc-3647	54	13	distribution	distribution	NOUN
dpc-3647	54	14	of	of	ADP
dpc-3647	54	15	the	the	DET
dpc-3647	54	16	variables	variable	NOUN
dpc-3647	54	17	.	.	PUNCT
dpc-3647	55	1	the	the	DET
dpc-3647	55	2	differences	difference	NOUN
dpc-3647	55	3	between	between	ADP
dpc-3647	55	4	the	the	DET
dpc-3647	55	5	groups	group	NOUN
dpc-3647	55	6	were	be	AUX
dpc-3647	55	7	evaluated	evaluate	VERB
dpc-3647	55	8	by	by	ADP
dpc-3647	55	9	mann	mann	PROPN
dpc-3647	55	10	-	-	PUNCT
dpc-3647	55	11	whitney	whitney	PROPN
dpc-3647	55	12	u	u	PROPN
dpc-3647	55	13	test	test	NOUN
dpc-3647	55	14	and	and	CCONJ
dpc-3647	55	15	wilcoxon	wilcoxon	PROPN
dpc-3647	55	16	signed	sign	VERB
dpc-3647	55	17	ranks	rank	NOUN
dpc-3647	55	18	test	test	NOUN
dpc-3647	55	19	.	.	PUNCT
dpc-3647	56	1	p	p	X
dpc-3647	56	2	<	<	X
dpc-3647	56	3	0.05	0.05	NUM
dpc-3647	56	4	was	be	AUX
dpc-3647	56	5	considered	consider	VERB
dpc-3647	56	6	statistically	statistically	ADV
dpc-3647	56	7	significant	significant	ADJ
dpc-3647	56	8	.	.	PUNCT
dpc-3647	57	1	results	result	VERB
dpc-3647	57	2	this	this	DET
dpc-3647	57	3	study	study	NOUN
dpc-3647	57	4	included	include	VERB
dpc-3647	57	5	220	220	NUM
dpc-3647	57	6	patients	patient	NOUN
dpc-3647	57	7	,	,	PUNCT
dpc-3647	57	8	101	101	NUM
dpc-3647	57	9	(	(	PUNCT
dpc-3647	57	10	45.9	45.9	NUM
dpc-3647	57	11	%	%	NOUN
dpc-3647	57	12	)	)	PUNCT
dpc-3647	57	13	females	female	NOUN
dpc-3647	57	14	and	and	CCONJ
dpc-3647	57	15	119	119	NUM
dpc-3647	57	16	(	(	PUNCT
dpc-3647	57	17	54.1	54.1	NUM
dpc-3647	57	18	%	%	NOUN
dpc-3647	57	19	)	)	PUNCT
dpc-3647	57	20	males	male	NOUN
dpc-3647	57	21	with	with	ADP
dpc-3647	57	22	a	a	DET
dpc-3647	57	23	mean	mean	ADJ
dpc-3647	57	24	age	age	NOUN
dpc-3647	57	25	of	of	ADP
dpc-3647	57	26	49.61±13.29	49.61±13.29	NOUN
dpc-3647	57	27	years	year	NOUN
dpc-3647	57	28	(	(	PUNCT
dpc-3647	57	29	range	range	NOUN
dpc-3647	57	30	:	:	PUNCT
dpc-3647	57	31	20	20	NUM
dpc-3647	57	32	-	-	SYM
dpc-3647	57	33	77	77	NUM
dpc-3647	57	34	years	year	NOUN
dpc-3647	57	35	)	)	PUNCT
dpc-3647	57	36	(	(	PUNCT
dpc-3647	57	37	table	table	NOUN
dpc-3647	57	38	1	1	NUM
dpc-3647	57	39	)	)	PUNCT
dpc-3647	57	40	.	.	PUNCT
dpc-3647	58	1	the	the	DET
dpc-3647	58	2	median	median	ADJ
dpc-3647	58	3	psoriasis	psoriasis	NOUN
dpc-3647	58	4	duration	duration	NOUN
dpc-3647	58	5	was	be	AUX
dpc-3647	58	6	20	20	NUM
dpc-3647	58	7	(	(	PUNCT
dpc-3647	58	8	16	16	NUM
dpc-3647	58	9	)	)	PUNCT
dpc-3647	58	10	years	year	NOUN
dpc-3647	58	11	in	in	ADP
dpc-3647	58	12	male	male	ADJ
dpc-3647	58	13	patients	patient	NOUN
dpc-3647	58	14	and	and	CCONJ
dpc-3647	58	15	15	15	NUM
dpc-3647	58	16	(	(	PUNCT
dpc-3647	58	17	18	18	NUM
dpc-3647	58	18	)	)	PUNCT
dpc-3647	58	19	years	year	NOUN
dpc-3647	58	20	in	in	ADP
dpc-3647	58	21	females	female	NOUN
dpc-3647	58	22	(	(	PUNCT
dpc-3647	58	23	p=0.006	p=0.006	NOUN
dpc-3647	58	24	)	)	PUNCT
dpc-3647	58	25	.	.	PUNCT
dpc-3647	59	1	the	the	DET
dpc-3647	59	2	median	median	ADJ
dpc-3647	59	3	pasi	pasi	NOUN
dpc-3647	59	4	and	and	CCONJ
dpc-3647	59	5	bmi	bmi	NOUN
dpc-3647	59	6	was	be	AUX
dpc-3647	59	7	14	14	NUM
dpc-3647	59	8	  	  	SPACE
dpc-3647	59	9	(	(	PUNCT
dpc-3647	59	10	8.5	8.5	NUM
dpc-3647	59	11	)	)	PUNCT
dpc-3647	59	12	and	and	CCONJ
dpc-3647	59	13	28.6	28.6	NUM
dpc-3647	59	14	(	(	PUNCT
dpc-3647	59	15	8)	8)	NUM
dpc-3647	59	16	kg	kg	NOUN
dpc-3647	59	17	/	/	SYM
dpc-3647	59	18	m2	m2	PROPN
dpc-3647	59	19	,	,	PUNCT
dpc-3647	59	20	respectively	respectively	ADV
dpc-3647	59	21	.	.	PUNCT
dpc-3647	60	1	sixty	sixty	NUM
dpc-3647	60	2	-	-	PUNCT
dpc-3647	60	3	six	six	NUM
dpc-3647	60	4	(	(	PUNCT
dpc-3647	60	5	30	30	NUM
dpc-3647	60	6	%	%	NOUN
dpc-3647	60	7	)	)	PUNCT
dpc-3647	60	8	patients	patient	NOUN
dpc-3647	60	9	were	be	AUX
dpc-3647	60	10	treated	treat	VERB
dpc-3647	60	11	with	with	ADP
dpc-3647	60	12	ustekinumab	ustekinumab	NOUN
dpc-3647	60	13	,	,	PUNCT
dpc-3647	60	14	56	56	NUM
dpc-3647	60	15	(	(	PUNCT
dpc-3647	60	16	25.5	25.5	NUM
dpc-3647	60	17	%	%	NOUN
dpc-3647	60	18	)	)	PUNCT
dpc-3647	60	19	with	with	ADP
dpc-3647	60	20	ixekizumab	ixekizumab	NOUN
dpc-3647	60	21	,	,	PUNCT
dpc-3647	60	22	43	43	NUM
dpc-3647	60	23	(	(	PUNCT
dpc-3647	60	24	19.5	19.5	NUM
dpc-3647	60	25	%	%	NOUN
dpc-3647	60	26	)	)	PUNCT
dpc-3647	60	27	with	with	ADP
dpc-3647	60	28	adalimumab	adalimumab	NOUN
dpc-3647	60	29	,	,	PUNCT
dpc-3647	60	30	24	24	NUM
dpc-3647	60	31	(	(	PUNCT
dpc-3647	60	32	10.9	10.9	NUM
dpc-3647	60	33	%	%	NOUN
dpc-3647	60	34	)	)	PUNCT
dpc-3647	60	35	with	with	ADP
dpc-3647	60	36	secukinumab	secukinumab	NOUN
dpc-3647	60	37	,	,	PUNCT
dpc-3647	60	38	15	15	NUM
dpc-3647	60	39	(	(	PUNCT
dpc-3647	60	40	6.8	6.8	NUM
dpc-3647	60	41	%	%	NOUN
dpc-3647	60	42	)	)	PUNCT
dpc-3647	60	43	with	with	ADP
dpc-3647	60	44	infliximab	infliximab	NOUN
dpc-3647	60	45	,	,	PUNCT
dpc-3647	60	46	11	11	NUM
dpc-3647	60	47	(	(	PUNCT
dpc-3647	60	48	5	5	NUM
dpc-3647	60	49	%	%	NOUN
dpc-3647	60	50	)	)	PUNCT
dpc-3647	60	51	with	with	ADP
dpc-3647	60	52	risankizumab	risankizumab	NOUN
dpc-3647	60	53	and	and	CCONJ
dpc-3647	60	54	5	5	NUM
dpc-3647	60	55	(	(	PUNCT
dpc-3647	60	56	2.3	2.3	NUM
dpc-3647	60	57	%	%	NOUN
dpc-3647	60	58	)	)	PUNCT
dpc-3647	60	59	with	with	ADP
dpc-3647	60	60	guselkumab	guselkumab	NOUN
dpc-3647	60	61	.	.	PUNCT
dpc-3647	61	1	conclusions	conclusion	NOUN
dpc-3647	61	2	:	:	PUNCT
dpc-3647	61	3	sii	sii	ADJ
dpc-3647	61	4	and	and	CCONJ
dpc-3647	61	5	siri	siri	NOUN
dpc-3647	61	6	may	may	AUX
dpc-3647	61	7	indicate	indicate	VERB
dpc-3647	61	8	the	the	DET
dpc-3647	61	9	severity	severity	NOUN
dpc-3647	61	10	of	of	ADP
dpc-3647	61	11	psoriasis	psoriasis	NOUN
dpc-3647	61	12	as	as	ADV
dpc-3647	61	13	well	well	ADV
dpc-3647	61	14	as	as	ADP
dpc-3647	61	15	sii	sii	PROPN
dpc-3647	61	16	may	may	AUX
dpc-3647	61	17	be	be	AUX
dpc-3647	61	18	associated	associate	VERB
dpc-3647	61	19	with	with	ADP
dpc-3647	61	20	psoriatic	psoriatic	ADJ
dpc-3647	61	21	arthritis	arthritis	NOUN
dpc-3647	61	22	,	,	PUNCT
dpc-3647	61	23	hypertension	hypertension	NOUN
dpc-3647	61	24	,	,	PUNCT
dpc-3647	61	25	hepatic	hepatic	ADJ
dpc-3647	61	26	steatosis	steatosis	NOUN
dpc-3647	61	27	and	and	CCONJ
dpc-3647	61	28	coronary	coronary	ADJ
dpc-3647	61	29	artery	artery	NOUN
dpc-3647	61	30	disease	disease	NOUN
dpc-3647	61	31	in	in	ADP
dpc-3647	61	32	patients	patient	NOUN
dpc-3647	61	33	with	with	ADP
dpc-3647	61	34	psoriasis	psoriasis	NOUN
dpc-3647	61	35	.	.	PUNCT
dpc-3647	62	1	there	there	PRON
dpc-3647	62	2	is	be	VERB
dpc-3647	62	3	no	no	DET
dpc-3647	62	4	consensus	consensus	NOUN
dpc-3647	62	5	on	on	ADP
dpc-3647	62	6	the	the	DET
dpc-3647	62	7	biomarkers	biomarker	NOUN
dpc-3647	62	8	that	that	PRON
dpc-3647	62	9	can	can	AUX
dpc-3647	62	10	be	be	AUX
dpc-3647	62	11	used	use	VERB
dpc-3647	62	12	to	to	PART
dpc-3647	62	13	create	create	VERB
dpc-3647	62	14	an	an	DET
dpc-3647	62	15	optimized	optimize	VERB
dpc-3647	62	16	treatment	treatment	NOUN
dpc-3647	62	17	strategy	strategy	NOUN
dpc-3647	62	18	in	in	ADP
dpc-3647	62	19	psoriasis	psoriasis	NOUN
dpc-3647	62	20	.	.	PUNCT
dpc-3647	63	1	therefore	therefore	ADV
dpc-3647	63	2	,	,	PUNCT
dpc-3647	63	3	sii	sii	PROPN
dpc-3647	63	4	and	and	CCONJ
dpc-3647	63	5	siri	siri	NOUN
dpc-3647	63	6	may	may	AUX
dpc-3647	63	7	be	be	AUX
dpc-3647	63	8	helpful	helpful	ADJ
dpc-3647	63	9	in	in	ADP
dpc-3647	63	10	making	make	VERB
dpc-3647	63	11	the	the	DET
dpc-3647	63	12	choice	choice	NOUN
dpc-3647	63	13	of	of	ADP
dpc-3647	63	14	treatment	treatment	NOUN
dpc-3647	63	15	and	and	CCONJ
dpc-3647	63	16	in	in	ADP
dpc-3647	63	17	the	the	DET
dpc-3647	63	18	follow	follow	NOUN
dpc-3647	63	19	-	-	PUNCT
dpc-3647	63	20	up	up	NOUN
dpc-3647	63	21	of	of	ADP
dpc-3647	63	22	patients	patient	NOUN
dpc-3647	63	23	with	with	ADP
dpc-3647	63	24	psoriasis	psoriasis	NOUN
dpc-3647	63	25	treated	treat	VERB
dpc-3647	63	26	with	with	ADP
dpc-3647	63	27	biological	biological	ADJ
dpc-3647	63	28	agents	agent	NOUN
dpc-3647	63	29	.	.	PUNCT
dpc-3647	64	1	original	original	ADJ
dpc-3647	64	2	article	article	NOUN
dpc-3647	64	3	|	|	ADV
dpc-3647	64	4	dermatol	dermatol	ADJ
dpc-3647	64	5	pract	pract	NOUN
dpc-3647	64	6	concept	concept	NOUN
dpc-3647	64	7	.	.	PUNCT
dpc-3647	65	1	2024;14(1):e2024065	2024;14(1):e2024065	NUM
dpc-3647	65	2	3	3	NUM
dpc-3647	65	3	although	although	SCONJ
dpc-3647	65	4	not	not	PART
dpc-3647	65	5	statistically	statistically	ADV
dpc-3647	65	6	significant	significant	ADJ
dpc-3647	65	7	,	,	PUNCT
dpc-3647	65	8	higher	high	ADJ
dpc-3647	65	9	sii	sii	PROPN
dpc-3647	65	10	levels	level	NOUN
dpc-3647	65	11	were	be	AUX
dpc-3647	65	12	detected	detect	VERB
dpc-3647	65	13	in	in	ADP
dpc-3647	65	14	male	male	ADJ
dpc-3647	65	15	patients	patient	NOUN
dpc-3647	65	16	,	,	PUNCT
dpc-3647	65	17	patients	patient	NOUN
dpc-3647	65	18	with	with	ADP
dpc-3647	65	19	severe	severe	ADJ
dpc-3647	65	20	psoriasis	psoriasis	NOUN
dpc-3647	65	21	,	,	PUNCT
dpc-3647	65	22	psoriasis	psoriasis	NOUN
dpc-3647	65	23	duration	duration	NOUN
dpc-3647	65	24	longer	long	ADV
dpc-3647	65	25	than	than	ADP
dpc-3647	65	26	20	20	NUM
dpc-3647	65	27	years	year	NOUN
dpc-3647	65	28	,	,	PUNCT
dpc-3647	65	29	patients	patient	NOUN
dpc-3647	65	30	with	with	ADP
dpc-3647	65	31	psoriatic	psoriatic	ADJ
dpc-3647	65	32	arthritis	arthritis	NOUN
dpc-3647	65	33	,	,	PUNCT
dpc-3647	65	34	nail	nail	NOUN
dpc-3647	65	35	involvement	involvement	NOUN
dpc-3647	65	36	,	,	PUNCT
dpc-3647	65	37	obese	obese	ADJ
dpc-3647	65	38	patients	patient	NOUN
dpc-3647	65	39	and	and	CCONJ
dpc-3647	65	40	patients	patient	NOUN
dpc-3647	65	41	previously	previously	ADV
dpc-3647	65	42	treated	treat	VERB
dpc-3647	65	43	with	with	ADP
dpc-3647	65	44	biological	biological	ADJ
dpc-3647	65	45	agents	agent	NOUN
dpc-3647	65	46	(	(	PUNCT
dpc-3647	65	47	p	p	X
dpc-3647	65	48	=	=	NOUN
dpc-3647	65	49	0.855	0.855	NUM
dpc-3647	65	50	,	,	PUNCT
dpc-3647	65	51	p	p	X
dpc-3647	66	1	=	=	NOUN
dpc-3647	66	2	  	  	SPACE
dpc-3647	66	3	0.267	0.267	NUM
dpc-3647	66	4	,	,	PUNCT
dpc-3647	66	5	p	p	X
dpc-3647	66	6	=	=	NOUN
dpc-3647	66	7	0.466	0.466	NUM
dpc-3647	66	8	,	,	PUNCT
dpc-3647	66	9	p	p	X
dpc-3647	66	10	=	=	NOUN
dpc-3647	66	11	0.968	0.968	NUM
dpc-3647	66	12	,	,	PUNCT
dpc-3647	66	13	p	p	X
dpc-3647	66	14	=	=	NOUN
dpc-3647	66	15	0.210	0.210	NUM
dpc-3647	66	16	,	,	PUNCT
dpc-3647	66	17	p	p	X
dpc-3647	66	18	=	=	PROPN
dpc-3647	66	19	0.071	0.071	NUM
dpc-3647	66	20	,	,	PUNCT
dpc-3647	66	21	p	p	X
dpc-3647	66	22	 	 	SPACE
dpc-3647	66	23	=	=	NOUN
dpc-3647	66	24	0.921	0.921	NUM
dpc-3647	66	25	,	,	PUNCT
dpc-3647	66	26	respectively	respectively	ADV
dpc-3647	66	27	)	)	PUNCT
dpc-3647	66	28	.	.	PUNCT
dpc-3647	67	1	sii	sii	PROPN
dpc-3647	67	2	was	be	AUX
dpc-3647	67	3	also	also	ADV
dpc-3647	67	4	higher	high	ADJ
dpc-3647	67	5	in	in	ADP
dpc-3647	67	6	patients	patient	NOUN
dpc-3647	67	7	with	with	ADP
dpc-3647	67	8	hypertension	hypertension	NOUN
dpc-3647	67	9	,	,	PUNCT
dpc-3647	67	10	diabetes	diabetes	NOUN
dpc-3647	67	11	,	,	PUNCT
dpc-3647	67	12	hepatic	hepatic	ADJ
dpc-3647	67	13	steatosis	steatosis	NOUN
dpc-3647	67	14	,	,	PUNCT
dpc-3647	67	15	depression	depression	NOUN
dpc-3647	67	16	and	and	CCONJ
dpc-3647	67	17	coronary	coronary	ADJ
dpc-3647	67	18	artery	artery	NOUN
dpc-3647	67	19	disease	disease	NOUN
dpc-3647	67	20	(	(	PUNCT
dpc-3647	67	21	p	p	X
dpc-3647	67	22	=	=	NOUN
dpc-3647	67	23	0.801	0.801	NUM
dpc-3647	67	24	,	,	PUNCT
dpc-3647	67	25	p	p	X
dpc-3647	67	26	=	=	NOUN
dpc-3647	67	27	0.752	0.752	NUM
dpc-3647	67	28	,	,	PUNCT
dpc-3647	67	29	p	p	X
dpc-3647	67	30	=	=	NOUN
dpc-3647	67	31	0.706	0.706	NUM
dpc-3647	67	32	,	,	PUNCT
dpc-3647	67	33	p	p	X
dpc-3647	67	34	=	=	PROPN
dpc-3647	67	35	0.079	0.079	NUM
dpc-3647	67	36	,	,	PUNCT
dpc-3647	67	37	p	p	X
dpc-3647	67	38	=	=	PROPN
dpc-3647	67	39	0.861	0.861	NUM
dpc-3647	67	40	,	,	PUNCT
dpc-3647	67	41	respectively	respectively	ADV
dpc-3647	67	42	)	)	PUNCT
dpc-3647	67	43	(	(	PUNCT
dpc-3647	67	44	table	table	NOUN
dpc-3647	67	45	2	2	NUM
dpc-3647	67	46	)	)	PUNCT
dpc-3647	67	47	.	.	PUNCT
dpc-3647	68	1	siri	siri	NOUN
dpc-3647	68	2	was	be	AUX
dpc-3647	68	3	statistically	statistically	ADV
dpc-3647	68	4	significantly	significantly	ADV
dpc-3647	68	5	higher	high	ADJ
dpc-3647	68	6	in	in	ADP
dpc-3647	68	7	male	male	ADJ
dpc-3647	68	8	patients	patient	NOUN
dpc-3647	68	9	compared	compare	VERB
dpc-3647	68	10	to	to	ADP
dpc-3647	68	11	females	female	NOUN
dpc-3647	68	12	(	(	PUNCT
dpc-3647	68	13	p	p	X
dpc-3647	68	14	<	<	X
dpc-3647	68	15	0.001	0.001	NUM
dpc-3647	68	16	)	)	PUNCT
dpc-3647	68	17	.	.	PUNCT
dpc-3647	69	1	although	although	SCONJ
dpc-3647	69	2	not	not	PART
dpc-3647	69	3	statistically	statistically	ADV
dpc-3647	69	4	significant	significant	ADJ
dpc-3647	69	5	,	,	PUNCT
dpc-3647	69	6	higher	high	ADJ
dpc-3647	69	7	siri	siri	NOUN
dpc-3647	69	8	levels	level	NOUN
dpc-3647	69	9	were	be	AUX
dpc-3647	69	10	detected	detect	VERB
dpc-3647	69	11	in	in	ADP
dpc-3647	69	12	patients	patient	NOUN
dpc-3647	69	13	with	with	ADP
dpc-3647	69	14	severe	severe	ADJ
dpc-3647	69	15	psoriasis	psoriasis	NOUN
dpc-3647	69	16	,	,	PUNCT
dpc-3647	69	17	nail	nail	NOUN
dpc-3647	69	18	findings	finding	NOUN
dpc-3647	69	19	,	,	PUNCT
dpc-3647	69	20	psoriasis	psoriasis	NOUN
dpc-3647	69	21	duration	duration	NOUN
dpc-3647	69	22	longer	long	ADV
dpc-3647	69	23	than	than	ADP
dpc-3647	69	24	20	20	NUM
dpc-3647	69	25	years	year	NOUN
dpc-3647	69	26	,	,	PUNCT
dpc-3647	69	27	obese	obese	ADJ
dpc-3647	69	28	patients	patient	NOUN
dpc-3647	69	29	and	and	CCONJ
dpc-3647	69	30	patients	patient	NOUN
dpc-3647	69	31	previously	previously	ADV
dpc-3647	69	32	treated	treat	VERB
dpc-3647	69	33	with	with	ADP
dpc-3647	69	34	biological	biological	ADJ
dpc-3647	69	35	agents	agent	NOUN
dpc-3647	69	36	(	(	PUNCT
dpc-3647	69	37	p	p	X
dpc-3647	69	38	=	=	NOUN
dpc-3647	69	39	0.295	0.295	NUM
dpc-3647	69	40	,	,	PUNCT
dpc-3647	69	41	p	p	X
dpc-3647	69	42	=	=	PROPN
dpc-3647	69	43	0.904	0.904	NUM
dpc-3647	69	44	,	,	PUNCT
dpc-3647	69	45	p	p	X
dpc-3647	69	46	=	=	NOUN
dpc-3647	69	47	0.381	0.381	NUM
dpc-3647	69	48	,	,	PUNCT
dpc-3647	69	49	p	p	X
dpc-3647	69	50	=	=	NOUN
dpc-3647	69	51	0.185	0.185	NUM
dpc-3647	69	52	,	,	PUNCT
dpc-3647	69	53	p	p	X
dpc-3647	69	54	=	=	NOUN
dpc-3647	69	55	0.921	0.921	NUM
dpc-3647	69	56	,	,	PUNCT
dpc-3647	69	57	respectively	respectively	ADV
dpc-3647	69	58	)	)	PUNCT
dpc-3647	69	59	.	.	PUNCT
dpc-3647	70	1	siri	siri	NOUN
dpc-3647	70	2	was	be	AUX
dpc-3647	70	3	also	also	ADV
dpc-3647	70	4	higher	high	ADJ
dpc-3647	70	5	in	in	ADP
dpc-3647	70	6	patients	patient	NOUN
dpc-3647	70	7	with	with	ADP
dpc-3647	70	8	diabetes	diabetes	NOUN
dpc-3647	70	9	and	and	CCONJ
dpc-3647	70	10	depression	depression	NOUN
dpc-3647	70	11	(	(	PUNCT
dpc-3647	70	12	p	p	X
dpc-3647	70	13	=	=	PUNCT
dpc-3647	70	14	0.263	0.263	NUM
dpc-3647	70	15	,	,	PUNCT
dpc-3647	70	16	p	p	X
dpc-3647	70	17	=	=	NOUN
dpc-3647	70	18	0.777	0.777	NUM
dpc-3647	70	19	,	,	PUNCT
dpc-3647	70	20	respectively	respectively	ADV
dpc-3647	70	21	)	)	PUNCT
dpc-3647	70	22	(	(	PUNCT
dpc-3647	70	23	table	table	NOUN
dpc-3647	70	24	3	3	NUM
dpc-3647	70	25	)	)	PUNCT
dpc-3647	70	26	.	.	PUNCT
dpc-3647	71	1	sii	sii	PROPN
dpc-3647	71	2	statistically	statistically	ADV
dpc-3647	71	3	significantly	significantly	ADV
dpc-3647	71	4	decreased	decrease	VERB
dpc-3647	71	5	in	in	ADP
dpc-3647	71	6	all	all	DET
dpc-3647	71	7	patients	patient	NOUN
dpc-3647	71	8	with	with	ADP
dpc-3647	71	9	psoriasis	psoriasis	NOUN
dpc-3647	71	10	three	three	NUM
dpc-3647	71	11	months	month	NOUN
dpc-3647	71	12	after	after	ADP
dpc-3647	71	13	biological	biological	ADJ
dpc-3647	71	14	agent	agent	NOUN
dpc-3647	71	15	treatment	treatment	NOUN
dpc-3647	71	16	(	(	PUNCT
dpc-3647	71	17	p	p	X
dpc-3647	71	18	<	<	X
dpc-3647	71	19	0.001	0.001	NUM
dpc-3647	71	20	)	)	PUNCT
dpc-3647	71	21	.	.	PUNCT
dpc-3647	72	1	in	in	ADP
dpc-3647	72	2	addition	addition	NOUN
dpc-3647	72	3	,	,	PUNCT
dpc-3647	72	4	sii	sii	PROPN
dpc-3647	72	5	significantly	significantly	ADV
dpc-3647	72	6	decreased	decrease	VERB
dpc-3647	72	7	in	in	ADP
dpc-3647	72	8	treatment	treatment	NOUN
dpc-3647	72	9	groups	group	NOUN
dpc-3647	72	10	such	such	ADJ
dpc-3647	72	11	as	as	ADP
dpc-3647	72	12	tnf	tnf	PROPN
dpc-3647	72	13	-	-	PUNCT
dpc-3647	72	14	α	α	PROPN
dpc-3647	72	15	inhibitors	inhibitor	NOUN
dpc-3647	72	16	,	,	PUNCT
dpc-3647	72	17	il-17	il-17	ADV
dpc-3647	72	18	inhibitors	inhibitor	NOUN
dpc-3647	72	19	and	and	CCONJ
dpc-3647	72	20	il-12/23	il-12/23	ADJ
dpc-3647	72	21	inhibitor	inhibitor	NOUN
dpc-3647	72	22	(	(	PUNCT
dpc-3647	72	23	p	p	X
dpc-3647	72	24	<	<	X
dpc-3647	72	25	0.001	0.001	NUM
dpc-3647	72	26	,	,	PUNCT
dpc-3647	72	27	p	p	X
dpc-3647	72	28	<	<	X
dpc-3647	72	29	0.001	0.001	NUM
dpc-3647	72	30	,	,	PUNCT
dpc-3647	72	31	p	p	X
dpc-3647	72	32	<	<	X
dpc-3647	72	33	0.001	0.001	NUM
dpc-3647	72	34	,	,	PUNCT
dpc-3647	72	35	respectively	respectively	ADV
dpc-3647	72	36	)	)	PUNCT
dpc-3647	72	37	.	.	PUNCT
dpc-3647	73	1	sii	sii	PROPN
dpc-3647	73	2	also	also	ADV
dpc-3647	73	3	statistically	statistically	ADV
dpc-3647	73	4	significantly	significantly	ADV
dpc-3647	73	5	decreased	decrease	VERB
dpc-3647	73	6	in	in	ADP
dpc-3647	73	7	patients	patient	NOUN
dpc-3647	73	8	treated	treat	VERB
dpc-3647	73	9	with	with	ADP
dpc-3647	73	10	adalimumab	adalimumab	NOUN
dpc-3647	73	11	,	,	PUNCT
dpc-3647	73	12	infliximab	infliximab	NOUN
dpc-3647	73	13	,	,	PUNCT
dpc-3647	73	14	ixekizumab	ixekizumab	NOUN
dpc-3647	73	15	,	,	PUNCT
dpc-3647	73	16	secukinumab	secukinumab	NOUN
dpc-3647	73	17	,	,	PUNCT
dpc-3647	73	18	ustekinumab	ustekinumab	NOUN
dpc-3647	73	19	and	and	CCONJ
dpc-3647	73	20	risankizumab	risankizumab	PROPN
dpc-3647	73	21	(	(	PUNCT
dpc-3647	73	22	p	p	X
dpc-3647	73	23	<	<	X
dpc-3647	73	24	0.001	0.001	NUM
dpc-3647	73	25	,	,	PUNCT
dpc-3647	73	26	p	p	X
dpc-3647	73	27	 	 	SPACE
dpc-3647	73	28	=	=	SYM
dpc-3647	73	29	0.002	0.002	NUM
dpc-3647	73	30	,	,	PUNCT
dpc-3647	73	31	p	p	X
dpc-3647	73	32	<	<	X
dpc-3647	73	33	0.001	0.001	NUM
dpc-3647	73	34	,	,	PUNCT
dpc-3647	73	35	p	p	NOUN
dpc-3647	73	36	=	=	NOUN
dpc-3647	73	37	0.004	0.004	NUM
dpc-3647	73	38	,	,	PUNCT
dpc-3647	73	39	p	p	X
dpc-3647	73	40	<	<	X
dpc-3647	73	41	0.001	0.001	NUM
dpc-3647	73	42	,	,	PUNCT
dpc-3647	73	43	p	p	X
dpc-3647	73	44	=	=	NOUN
dpc-3647	73	45	0.013	0.013	NUM
dpc-3647	73	46	,	,	PUNCT
dpc-3647	73	47	respectively	respectively	ADV
dpc-3647	73	48	)	)	PUNCT
dpc-3647	73	49	(	(	PUNCT
dpc-3647	73	50	table	table	NOUN
dpc-3647	73	51	4	4	NUM
dpc-3647	73	52	)	)	PUNCT
dpc-3647	73	53	(	(	PUNCT
dpc-3647	73	54	figure	figure	NOUN
dpc-3647	73	55	1	1	NUM
dpc-3647	73	56	)	)	PUNCT
dpc-3647	73	57	.	.	PUNCT
dpc-3647	74	1	siri	siri	NOUN
dpc-3647	74	2	statistically	statistically	ADV
dpc-3647	74	3	significantly	significantly	ADV
dpc-3647	74	4	decreased	decrease	VERB
dpc-3647	74	5	in	in	ADP
dpc-3647	74	6	all	all	DET
dpc-3647	74	7	patients	patient	NOUN
dpc-3647	74	8	with	with	ADP
dpc-3647	74	9	psoriasis	psoriasis	NOUN
dpc-3647	74	10	three	three	NUM
dpc-3647	74	11	months	month	NOUN
dpc-3647	74	12	after	after	ADP
dpc-3647	74	13	biological	biological	ADJ
dpc-3647	74	14	agent	agent	NOUN
dpc-3647	74	15	treatment	treatment	NOUN
dpc-3647	74	16	(	(	PUNCT
dpc-3647	74	17	p	p	X
dpc-3647	74	18	<	<	X
dpc-3647	74	19	0.001	0.001	NUM
dpc-3647	74	20	)	)	PUNCT
dpc-3647	74	21	.	.	PUNCT
dpc-3647	75	1	siri	siri	NOUN
dpc-3647	75	2	also	also	ADV
dpc-3647	75	3	significantly	significantly	ADV
dpc-3647	75	4	decreased	decrease	VERB
dpc-3647	75	5	in	in	ADP
dpc-3647	75	6	patients	patient	NOUN
dpc-3647	75	7	treated	treat	VERB
dpc-3647	75	8	with	with	ADP
dpc-3647	75	9	adalimumab	adalimumab	NOUN
dpc-3647	75	10	,	,	PUNCT
dpc-3647	75	11	infliximab	infliximab	NOUN
dpc-3647	75	12	,	,	PUNCT
dpc-3647	75	13	ixekizumab	ixekizumab	NOUN
dpc-3647	75	14	,	,	PUNCT
dpc-3647	75	15	secukinumab	secukinumab	NOUN
dpc-3647	75	16	,	,	PUNCT
dpc-3647	75	17	ustekinumab	ustekinumab	NOUN
dpc-3647	75	18	and	and	CCONJ
dpc-3647	75	19	risankizumab	risankizumab	PROPN
dpc-3647	75	20	(	(	PUNCT
dpc-3647	75	21	p	p	X
dpc-3647	75	22	<	<	X
dpc-3647	75	23	0.001	0.001	NUM
dpc-3647	75	24	,	,	PUNCT
dpc-3647	75	25	p	p	NOUN
dpc-3647	75	26	=	=	NOUN
dpc-3647	75	27	0.001	0.001	NUM
dpc-3647	75	28	,	,	PUNCT
dpc-3647	75	29	p	p	X
dpc-3647	75	30	=	=	NOUN
dpc-3647	75	31	0.002	0.002	NUM
dpc-3647	75	32	,	,	PUNCT
dpc-3647	75	33	p	p	NOUN
dpc-3647	75	34	=	=	NOUN
dpc-3647	75	35	0.018	0.018	NUM
dpc-3647	75	36	,	,	PUNCT
dpc-3647	75	37	p	p	X
dpc-3647	75	38	<	<	X
dpc-3647	75	39	0.001	0.001	NUM
dpc-3647	75	40	,	,	PUNCT
dpc-3647	75	41	p	p	NOUN
dpc-3647	75	42	=	=	NOUN
dpc-3647	75	43	0.041	0.041	NUM
dpc-3647	75	44	,	,	PUNCT
dpc-3647	75	45	respectively	respectively	ADV
dpc-3647	75	46	)	)	PUNCT
dpc-3647	75	47	(	(	PUNCT
dpc-3647	75	48	table	table	NOUN
dpc-3647	75	49	5	5	NUM
dpc-3647	75	50	and	and	CCONJ
dpc-3647	75	51	figure	figure	NOUN
dpc-3647	75	52	2	2	NUM
dpc-3647	75	53	)	)	PUNCT
dpc-3647	75	54	.	.	PUNCT
dpc-3647	76	1	conclusions	conclusion	NOUN
dpc-3647	76	2	sii	sii	ADJ
dpc-3647	76	3	and	and	CCONJ
dpc-3647	76	4	siri	siri	NOUN
dpc-3647	76	5	have	have	AUX
dpc-3647	76	6	been	be	AUX
dpc-3647	76	7	proposed	propose	VERB
dpc-3647	76	8	as	as	ADP
dpc-3647	76	9	novel	novel	ADJ
dpc-3647	76	10	biomarkers	biomarker	NOUN
dpc-3647	76	11	which	which	PRON
dpc-3647	76	12	might	might	AUX
dpc-3647	76	13	indicate	indicate	VERB
dpc-3647	76	14	systemic	systemic	ADJ
dpc-3647	76	15	inflammation	inflammation	NOUN
dpc-3647	76	16	,	,	PUNCT
dpc-3647	76	17	however	however	ADV
dpc-3647	76	18	,	,	PUNCT
dpc-3647	76	19	the	the	DET
dpc-3647	76	20	use	use	NOUN
dpc-3647	76	21	of	of	ADP
dpc-3647	76	22	sii	sii	ADJ
dpc-3647	76	23	and	and	CCONJ
dpc-3647	76	24	siri	siri	NOUN
dpc-3647	76	25	in	in	ADP
dpc-3647	76	26	patients	patient	NOUN
dpc-3647	76	27	with	with	ADP
dpc-3647	76	28	psoriasis	psoriasis	NOUN
dpc-3647	76	29	was	be	AUX
dpc-3647	76	30	evaluated	evaluate	VERB
dpc-3647	76	31	in	in	ADP
dpc-3647	76	32	limited	limited	ADJ
dpc-3647	76	33	studies	study	NOUN
dpc-3647	76	34	[	[	X
dpc-3647	76	35	1	1	NUM
dpc-3647	76	36	]	]	PUNCT
dpc-3647	76	37	.	.	PUNCT
dpc-3647	77	1	for	for	ADP
dpc-3647	77	2	instance	instance	NOUN
dpc-3647	77	3	,	,	PUNCT
dpc-3647	77	4	yorulmaz	yorulmaz	PRON
dpc-3647	77	5	et	et	PROPN
dpc-3647	77	6	al	al	PROPN
dpc-3647	77	7	reported	report	VERB
dpc-3647	77	8	higher	high	ADJ
dpc-3647	77	9	sii	sii	PROPN
dpc-3647	77	10	levels	level	NOUN
dpc-3647	77	11	in	in	ADP
dpc-3647	77	12	patients	patient	NOUN
dpc-3647	77	13	with	with	ADP
dpc-3647	77	14	psoriasis	psoriasis	NOUN
dpc-3647	77	15	compared	compare	VERB
dpc-3647	77	16	to	to	ADP
dpc-3647	77	17	healthy	healthy	ADJ
dpc-3647	77	18	individuals	individual	NOUN
dpc-3647	77	19	as	as	ADV
dpc-3647	77	20	well	well	ADV
dpc-3647	77	21	as	as	ADP
dpc-3647	77	22	sii	sii	PROPN
dpc-3647	77	23	was	be	AUX
dpc-3647	77	24	positively	positively	ADV
dpc-3647	77	25	correlated	correlate	VERB
dpc-3647	77	26	with	with	ADP
dpc-3647	77	27	pasi	pasi	NOUN
dpc-3647	77	28	and	and	CCONJ
dpc-3647	77	29	presence	presence	NOUN
dpc-3647	77	30	of	of	ADP
dpc-3647	77	31	psoriatic	psoriatic	ADJ
dpc-3647	77	32	arthritis	arthritis	NOUN
dpc-3647	77	33	[	[	X
dpc-3647	77	34	10	10	NUM
dpc-3647	77	35	]	]	PUNCT
dpc-3647	77	36	.	.	PUNCT
dpc-3647	78	1	similarly	similarly	ADV
dpc-3647	78	2	,	,	PUNCT
dpc-3647	78	3	melikoglu	melikoglu	PROPN
dpc-3647	78	4	et	et	PROPN
dpc-3647	78	5	al	al	PROPN
dpc-3647	78	6	reported	report	VERB
dpc-3647	78	7	an	an	DET
dpc-3647	78	8	association	association	NOUN
dpc-3647	78	9	between	between	ADP
dpc-3647	78	10	disease	disease	NOUN
dpc-3647	78	11	severity	severity	NOUN
dpc-3647	78	12	and	and	CCONJ
dpc-3647	78	13	sii	sii	ADJ
dpc-3647	78	14	levels	level	NOUN
dpc-3647	78	15	in	in	ADP
dpc-3647	78	16	patients	patient	NOUN
dpc-3647	78	17	with	with	ADP
dpc-3647	78	18	psoriasis	psoriasis	NOUN
dpc-3647	78	19	.	.	PUNCT
dpc-3647	79	1	in	in	ADP
dpc-3647	79	2	addition	addition	NOUN
dpc-3647	79	3	,	,	PUNCT
dpc-3647	79	4	melikoglu	melikoglu	NOUN
dpc-3647	79	5	et	et	PROPN
dpc-3647	79	6	al	al	PROPN
dpc-3647	79	7	reported	report	VERB
dpc-3647	79	8	no	no	DET
dpc-3647	79	9	difference	difference	NOUN
dpc-3647	79	10	in	in	ADP
dpc-3647	79	11	sii	sii	PROPN
dpc-3647	79	12	levels	level	NOUN
dpc-3647	79	13	in	in	ADP
dpc-3647	79	14	patients	patient	NOUN
dpc-3647	79	15	with	with	ADP
dpc-3647	79	16	different	different	ADJ
dpc-3647	79	17	table	table	NOUN
dpc-3647	79	18	1	1	NUM
dpc-3647	79	19	.	.	PUNCT
dpc-3647	80	1	the	the	DET
dpc-3647	80	2	characteristics	characteristic	NOUN
dpc-3647	80	3	of	of	ADP
dpc-3647	80	4	the	the	DET
dpc-3647	80	5	patients	patient	NOUN
dpc-3647	80	6	with	with	ADP
dpc-3647	80	7	psoriasis	psoriasis	NOUN
dpc-3647	80	8	.	.	PUNCT
dpc-3647	81	1	characteristics	characteristic	NOUN
dpc-3647	81	2	gender	gender	NOUN
dpc-3647	81	3	,	,	PUNCT
dpc-3647	81	4	n	n	CCONJ
dpc-3647	81	5	(	(	PUNCT
dpc-3647	81	6	%	%	INTJ
dpc-3647	81	7	)	)	PUNCT
dpc-3647	81	8	female	female	NOUN
dpc-3647	81	9	,	,	PUNCT
dpc-3647	81	10	101	101	NUM
dpc-3647	81	11	(	(	PUNCT
dpc-3647	81	12	45.9	45.9	NUM
dpc-3647	81	13	%	%	NOUN
dpc-3647	81	14	)	)	PUNCT
dpc-3647	81	15	male	male	NOUN
dpc-3647	81	16	,	,	PUNCT
dpc-3647	81	17	119	119	NUM
dpc-3647	81	18	(	(	PUNCT
dpc-3647	81	19	54.1	54.1	NUM
dpc-3647	81	20	%	%	NOUN
dpc-3647	81	21	)	)	PUNCT
dpc-3647	82	1	mean	mean	VERB
dpc-3647	82	2	age±sd	age±sd	NUM
dpc-3647	82	3	(	(	PUNCT
dpc-3647	82	4	years	year	NOUN
dpc-3647	82	5	)	)	PUNCT
dpc-3647	82	6	49.61±13.29	49.61±13.29	NOUN
dpc-3647	82	7	psoriasis	psoriasis	NOUN
dpc-3647	82	8	type	type	NOUN
dpc-3647	82	9	,	,	PUNCT
dpc-3647	82	10	n	n	CCONJ
dpc-3647	82	11	(	(	PUNCT
dpc-3647	82	12	%	%	INTJ
dpc-3647	82	13	)	)	PUNCT
dpc-3647	82	14	psoriasis	psoriasis	NOUN
dpc-3647	82	15	vulgaris	vulgaris	NOUN
dpc-3647	82	16	,	,	PUNCT
dpc-3647	82	17	195	195	NUM
dpc-3647	82	18	(	(	PUNCT
dpc-3647	82	19	88.6	88.6	NUM
dpc-3647	82	20	%	%	NOUN
dpc-3647	82	21	)	)	PUNCT
dpc-3647	82	22	palmoplantar	palmoplantar	NOUN
dpc-3647	82	23	psoriasis	psoriasis	NOUN
dpc-3647	82	24	,	,	PUNCT
dpc-3647	82	25	13	13	NUM
dpc-3647	82	26	(	(	PUNCT
dpc-3647	82	27	5.9	5.9	NUM
dpc-3647	82	28	%	%	NOUN
dpc-3647	82	29	)	)	PUNCT
dpc-3647	82	30	generalized	generalize	VERB
dpc-3647	82	31	pustular	pustular	ADJ
dpc-3647	82	32	,	,	PUNCT
dpc-3647	82	33	12	12	NUM
dpc-3647	82	34	(	(	PUNCT
dpc-3647	82	35	5.5	5.5	NUM
dpc-3647	82	36	%	%	NOUN
dpc-3647	82	37	)	)	PUNCT
dpc-3647	82	38	psoriasis	psoriasis	NOUN
dpc-3647	82	39	duration	duration	NOUN
dpc-3647	82	40	,	,	PUNCT
dpc-3647	82	41	median	median	PROPN
dpc-3647	82	42	(	(	PUNCT
dpc-3647	82	43	iqr	iqr	NOUN
dpc-3647	82	44	)	)	PUNCT
dpc-3647	82	45	(	(	PUNCT
dpc-3647	82	46	years	year	NOUN
dpc-3647	82	47	)	)	PUNCT
dpc-3647	82	48	18	18	NUM
dpc-3647	82	49	(	(	PUNCT
dpc-3647	82	50	16	16	NUM
dpc-3647	82	51	)	)	PUNCT
dpc-3647	82	52	psoriatic	psoriatic	ADJ
dpc-3647	82	53	arthritis	arthritis	NOUN
dpc-3647	82	54	,	,	PUNCT
dpc-3647	82	55	n	n	PROPN
dpc-3647	82	56	(	(	PUNCT
dpc-3647	82	57	%	%	INTJ
dpc-3647	82	58	)	)	PUNCT
dpc-3647	82	59	present	present	ADJ
dpc-3647	82	60	,	,	PUNCT
dpc-3647	82	61	66	66	NUM
dpc-3647	82	62	(	(	PUNCT
dpc-3647	82	63	30	30	NUM
dpc-3647	82	64	%	%	NOUN
dpc-3647	82	65	)	)	PUNCT
dpc-3647	82	66	none	none	NOUN
dpc-3647	82	67	,	,	PUNCT
dpc-3647	82	68	154	154	NUM
dpc-3647	82	69	(	(	PUNCT
dpc-3647	82	70	70	70	NUM
dpc-3647	82	71	%	%	NOUN
dpc-3647	82	72	)	)	PUNCT
dpc-3647	82	73	nail	nail	NOUN
dpc-3647	82	74	findings	finding	NOUN
dpc-3647	82	75	,	,	PUNCT
dpc-3647	82	76	n	n	PROPN
dpc-3647	82	77	(	(	PUNCT
dpc-3647	82	78	%	%	INTJ
dpc-3647	82	79	)	)	PUNCT
dpc-3647	82	80	present	present	ADJ
dpc-3647	82	81	,	,	PUNCT
dpc-3647	82	82	104	104	NUM
dpc-3647	82	83	(	(	PUNCT
dpc-3647	82	84	47.3	47.3	NUM
dpc-3647	82	85	%	%	NOUN
dpc-3647	82	86	)	)	PUNCT
dpc-3647	82	87	none	none	NOUN
dpc-3647	82	88	,	,	PUNCT
dpc-3647	82	89	116	116	NUM
dpc-3647	82	90	(	(	PUNCT
dpc-3647	82	91	52.7	52.7	NUM
dpc-3647	82	92	%	%	NOUN
dpc-3647	82	93	)	)	PUNCT
dpc-3647	83	1	past	past	ADP
dpc-3647	83	2	medical	medical	ADJ
dpc-3647	83	3	history	history	NOUN
dpc-3647	83	4	,	,	PUNCT
dpc-3647	83	5	n	n	CCONJ
dpc-3647	83	6	(	(	PUNCT
dpc-3647	83	7	%	%	INTJ
dpc-3647	83	8	)	)	PUNCT
dpc-3647	83	9	unremarkable	unremarkable	ADJ
dpc-3647	83	10	,	,	PUNCT
dpc-3647	83	11	100	100	NUM
dpc-3647	83	12	(	(	PUNCT
dpc-3647	83	13	45.5	45.5	NUM
dpc-3647	83	14	%	%	NOUN
dpc-3647	83	15	)	)	PUNCT
dpc-3647	83	16	hypertension	hypertension	NOUN
dpc-3647	83	17	,	,	PUNCT
dpc-3647	83	18	59	59	NUM
dpc-3647	83	19	(	(	PUNCT
dpc-3647	83	20	26.8	26.8	NUM
dpc-3647	83	21	%	%	NOUN
dpc-3647	83	22	)	)	PUNCT
dpc-3647	83	23	hyperlipidemia	hyperlipidemia	NOUN
dpc-3647	83	24	,	,	PUNCT
dpc-3647	83	25	45	45	NUM
dpc-3647	83	26	(	(	PUNCT
dpc-3647	83	27	20.5	20.5	NUM
dpc-3647	83	28	%	%	NOUN
dpc-3647	83	29	)	)	PUNCT
dpc-3647	83	30	diabetes	diabetes	NOUN
dpc-3647	83	31	mellitus	mellitus	NOUN
dpc-3647	83	32	,	,	PUNCT
dpc-3647	83	33	32	32	NUM
dpc-3647	83	34	(	(	PUNCT
dpc-3647	83	35	14.5	14.5	NUM
dpc-3647	83	36	%	%	NOUN
dpc-3647	83	37	)	)	PUNCT
dpc-3647	83	38	hepatic	hepatic	ADJ
dpc-3647	83	39	steatosis	steatosis	NOUN
dpc-3647	83	40	,	,	PUNCT
dpc-3647	83	41	24	24	NUM
dpc-3647	83	42	(	(	PUNCT
dpc-3647	83	43	10.9	10.9	NUM
dpc-3647	83	44	%	%	NOUN
dpc-3647	83	45	)	)	PUNCT
dpc-3647	83	46	hepatitis	hepatitis	PROPN
dpc-3647	83	47	b	b	PROPN
dpc-3647	83	48	virus	virus	NOUN
dpc-3647	83	49	carriage	carriage	NOUN
dpc-3647	83	50	,	,	PUNCT
dpc-3647	83	51	20	20	NUM
dpc-3647	83	52	(	(	PUNCT
dpc-3647	83	53	9.1	9.1	NUM
dpc-3647	83	54	%	%	NOUN
dpc-3647	83	55	)	)	PUNCT
dpc-3647	83	56	depression	depression	NOUN
dpc-3647	83	57	,	,	PUNCT
dpc-3647	83	58	19	19	NUM
dpc-3647	83	59	(	(	PUNCT
dpc-3647	83	60	8.6	8.6	NUM
dpc-3647	83	61	%	%	NOUN
dpc-3647	83	62	)	)	PUNCT
dpc-3647	83	63	coronary	coronary	ADJ
dpc-3647	83	64	artery	artery	NOUN
dpc-3647	83	65	disease	disease	NOUN
dpc-3647	83	66	,	,	PUNCT
dpc-3647	83	67	16	16	NUM
dpc-3647	83	68	(	(	PUNCT
dpc-3647	83	69	7.3	7.3	NUM
dpc-3647	83	70	%	%	NOUN
dpc-3647	83	71	)	)	PUNCT
dpc-3647	83	72	thyroid	thyroid	NOUN
dpc-3647	83	73	disease	disease	NOUN
dpc-3647	83	74	,	,	PUNCT
dpc-3647	83	75	9	9	NUM
dpc-3647	83	76	(	(	PUNCT
dpc-3647	83	77	4.1	4.1	NUM
dpc-3647	83	78	%	%	NOUN
dpc-3647	83	79	)	)	PUNCT
dpc-3647	84	1	asthma	asthma	NOUN
dpc-3647	84	2	,	,	PUNCT
dpc-3647	84	3	6	6	NUM
dpc-3647	84	4	(	(	PUNCT
dpc-3647	84	5	2.7	2.7	NUM
dpc-3647	84	6	%	%	NOUN
dpc-3647	84	7	)	)	PUNCT
dpc-3647	84	8	previous	previous	ADJ
dpc-3647	84	9	treatment	treatment	NOUN
dpc-3647	84	10	,	,	PUNCT
dpc-3647	84	11	n	n	CCONJ
dpc-3647	84	12	(	(	PUNCT
dpc-3647	84	13	%	%	INTJ
dpc-3647	84	14	)	)	PUNCT
dpc-3647	84	15	conventional	conventional	ADJ
dpc-3647	84	16	treatment	treatment	NOUN
dpc-3647	84	17	,	,	PUNCT
dpc-3647	84	18	214	214	NUM
dpc-3647	84	19	(	(	PUNCT
dpc-3647	84	20	97.3	97.3	NUM
dpc-3647	84	21	%	%	NOUN
dpc-3647	84	22	)	)	PUNCT
dpc-3647	84	23	biological	biological	ADJ
dpc-3647	84	24	agents	agent	NOUN
dpc-3647	84	25	,	,	PUNCT
dpc-3647	84	26	93	93	NUM
dpc-3647	84	27	(	(	PUNCT
dpc-3647	84	28	42.3	42.3	NUM
dpc-3647	84	29	%	%	NOUN
dpc-3647	84	30	)	)	PUNCT
dpc-3647	84	31	phototherapy	phototherapy	NOUN
dpc-3647	84	32	,	,	PUNCT
dpc-3647	84	33	70	70	NUM
dpc-3647	84	34	(	(	PUNCT
dpc-3647	84	35	31.8	31.8	NUM
dpc-3647	84	36	%	%	NOUN
dpc-3647	84	37	)	)	PUNCT
dpc-3647	84	38	iqr	iqr	PROPN
dpc-3647	85	1	=	=	NOUN
dpc-3647	85	2	interquartile	interquartile	NOUN
dpc-3647	85	3	range	range	NOUN
dpc-3647	85	4	;	;	PUNCT
dpc-3647	85	5	sd	sd	NOUN
dpc-3647	85	6	=	=	SYM
dpc-3647	85	7	standard	standard	ADJ
dpc-3647	85	8	deviation	deviation	NOUN
dpc-3647	85	9	.	.	PUNCT
dpc-3647	86	1	this	this	DET
dpc-3647	86	2	study	study	NOUN
dpc-3647	86	3	included	include	VERB
dpc-3647	86	4	220	220	NUM
dpc-3647	86	5	patients	patient	NOUN
dpc-3647	86	6	with	with	ADP
dpc-3647	86	7	a	a	DET
dpc-3647	86	8	mean	mean	ADJ
dpc-3647	86	9	age	age	NOUN
dpc-3647	86	10	of	of	ADP
dpc-3647	86	11	49.61±13.29	49.61±13.29	NOUN
dpc-3647	86	12	years	year	NOUN
dpc-3647	86	13	.	.	PUNCT
dpc-3647	87	1	most	most	ADJ
dpc-3647	87	2	of	of	ADP
dpc-3647	87	3	the	the	DET
dpc-3647	87	4	patients	patient	NOUN
dpc-3647	87	5	(	(	PUNCT
dpc-3647	87	6	88.6	88.6	NUM
dpc-3647	87	7	%	%	NOUN
dpc-3647	87	8	)	)	PUNCT
dpc-3647	87	9	had	have	VERB
dpc-3647	87	10	psoriasis	psoriasis	NOUN
dpc-3647	87	11	vulgaris	vulgaris	NOUN
dpc-3647	87	12	.	.	PUNCT
dpc-3647	88	1	the	the	DET
dpc-3647	88	2	frequency	frequency	NOUN
dpc-3647	88	3	of	of	ADP
dpc-3647	88	4	psoriatic	psoriatic	ADJ
dpc-3647	88	5	arthritis	arthritis	NOUN
dpc-3647	88	6	was	be	AUX
dpc-3647	88	7	30	30	NUM
dpc-3647	88	8	%	%	NOUN
dpc-3647	88	9	.	.	PUNCT
dpc-3647	89	1	4	4	NUM
dpc-3647	89	2	original	original	ADJ
dpc-3647	89	3	article	article	NOUN
dpc-3647	89	4	|	|	ADV
dpc-3647	89	5	dermatol	dermatol	ADJ
dpc-3647	89	6	pract	pract	NOUN
dpc-3647	89	7	concept	concept	NOUN
dpc-3647	89	8	.	.	PUNCT
dpc-3647	90	1	2024;14(1):e2024065	2024;14(1):e2024065	NUM
dpc-3647	90	2	table	table	NOUN
dpc-3647	90	3	2	2	NUM
dpc-3647	90	4	.	.	PUNCT
dpc-3647	90	5	systemic	systemic	ADJ
dpc-3647	90	6	immune	immune	ADJ
dpc-3647	90	7	inflammation	inflammation	ADJ
dpc-3647	90	8	index	index	NOUN
dpc-3647	90	9	in	in	ADP
dpc-3647	90	10	patients	patient	NOUN
dpc-3647	90	11	with	with	ADP
dpc-3647	90	12	psoriasis	psoriasis	NOUN
dpc-3647	90	13	.	.	PUNCT
dpc-3647	91	1	systemic	systemic	ADJ
dpc-3647	91	2	immune	immune	ADJ
dpc-3647	91	3	inflammation	inflammation	NOUN
dpc-3647	91	4	index	index	NOUN
dpc-3647	91	5	median	median	NOUN
dpc-3647	91	6	(	(	PUNCT
dpc-3647	91	7	iqr	iqr	NOUN
dpc-3647	91	8	)	)	PUNCT
dpc-3647	91	9	p	p	NOUN
dpc-3647	91	10	value	value	NOUN
dpc-3647	91	11	female	female	NOUN
dpc-3647	91	12	618	618	NUM
dpc-3647	91	13	(	(	PUNCT
dpc-3647	91	14	513	513	NUM
dpc-3647	91	15	)	)	PUNCT
dpc-3647	91	16	male	male	NOUN
dpc-3647	91	17	655	655	NUM
dpc-3647	91	18	(	(	PUNCT
dpc-3647	91	19	400	400	NUM
dpc-3647	91	20	)	)	PUNCT
dpc-3647	91	21	0.855	0.855	NUM
dpc-3647	91	22	with	with	ADP
dpc-3647	91	23	arthritis	arthritis	NOUN
dpc-3647	91	24	656	656	NUM
dpc-3647	91	25	(	(	PUNCT
dpc-3647	91	26	430	430	NUM
dpc-3647	91	27	)	)	PUNCT
dpc-3647	91	28	without	without	ADP
dpc-3647	91	29	arthritis	arthritis	NOUN
dpc-3647	91	30	642	642	NUM
dpc-3647	91	31	(	(	PUNCT
dpc-3647	91	32	419	419	NUM
dpc-3647	91	33	)	)	PUNCT
dpc-3647	91	34	0.968	0.968	NUM
dpc-3647	91	35	psoriasis	psoriasis	NOUN
dpc-3647	91	36	vulgaris	vulgaris	NOUN
dpc-3647	91	37	644	644	NUM
dpc-3647	91	38	(	(	PUNCT
dpc-3647	91	39	426	426	NUM
dpc-3647	91	40	)	)	PUNCT
dpc-3647	91	41	other	other	ADJ
dpc-3647	91	42	types	type	NOUN
dpc-3647	91	43	705	705	NUM
dpc-3647	91	44	(	(	PUNCT
dpc-3647	91	45	363	363	NUM
dpc-3647	91	46	)	)	PUNCT
dpc-3647	91	47	0.456	0.456	NUM
dpc-3647	91	48	nail	nail	NOUN
dpc-3647	91	49	involvement	involvement	NOUN
dpc-3647	91	50	696	696	NUM
dpc-3647	91	51	(	(	PUNCT
dpc-3647	91	52	434	434	NUM
dpc-3647	91	53	)	)	PUNCT
dpc-3647	91	54	without	without	ADP
dpc-3647	91	55	nail	nail	NOUN
dpc-3647	91	56	involvement	involvement	NOUN
dpc-3647	91	57	600	600	NUM
dpc-3647	91	58	(	(	PUNCT
dpc-3647	91	59	401	401	NUM
dpc-3647	91	60	)	)	PUNCT
dpc-3647	91	61	0.210	0.210	NUM
dpc-3647	91	62	psoriasis	psoriasis	NOUN
dpc-3647	91	63	duration	duration	NOUN
dpc-3647	91	64	(	(	PUNCT
dpc-3647	91	65	≤20	≤20	PROPN
dpc-3647	91	66	years	year	NOUN
dpc-3647	91	67	)	)	PUNCT
dpc-3647	91	68	643	643	NUM
dpc-3647	91	69	(	(	PUNCT
dpc-3647	91	70	429	429	NUM
dpc-3647	91	71	)	)	PUNCT
dpc-3647	91	72	psoriasis	psoriasis	NOUN
dpc-3647	91	73	duration	duration	NOUN
dpc-3647	91	74	(	(	PUNCT
dpc-3647	91	75	>	>	SYM
dpc-3647	91	76	20	20	NUM
dpc-3647	91	77	years	year	NOUN
dpc-3647	91	78	)	)	PUNCT
dpc-3647	91	79	656	656	NUM
dpc-3647	91	80	(	(	PUNCT
dpc-3647	91	81	428	428	NUM
dpc-3647	91	82	)	)	PUNCT
dpc-3647	91	83	0.466	0.466	NUM
dpc-3647	91	84	mild/	mild/	NUM
dpc-3647	91	85	moderate	moderate	ADJ
dpc-3647	91	86	psoriasis	psoriasis	NOUN
dpc-3647	91	87	624	624	NUM
dpc-3647	91	88	(	(	PUNCT
dpc-3647	91	89	388	388	NUM
dpc-3647	91	90	)	)	PUNCT
dpc-3647	91	91	severe	severe	ADJ
dpc-3647	91	92	psoriasis	psoriasis	NOUN
dpc-3647	91	93	652	652	NUM
dpc-3647	91	94	(	(	PUNCT
dpc-3647	91	95	490	490	NUM
dpc-3647	91	96	)	)	PUNCT
dpc-3647	91	97	0.267	0.267	NUM
dpc-3647	91	98	non	non	ADJ
dpc-3647	91	99	-	-	ADJ
dpc-3647	91	100	obese	obese	ADJ
dpc-3647	91	101	642	642	NUM
dpc-3647	91	102	(	(	PUNCT
dpc-3647	91	103	428	428	NUM
dpc-3647	91	104	)	)	PUNCT
dpc-3647	91	105	obese	obese	NOUN
dpc-3647	91	106	718	718	NUM
dpc-3647	91	107	(	(	PUNCT
dpc-3647	91	108	619	619	NUM
dpc-3647	91	109	)	)	PUNCT
dpc-3647	91	110	0.071	0.071	NUM
dpc-3647	91	111	previous	previous	ADJ
dpc-3647	91	112	biological	biological	ADJ
dpc-3647	91	113	treatment	treatment	NOUN
dpc-3647	91	114	658	658	NUM
dpc-3647	91	115	(	(	PUNCT
dpc-3647	91	116	411	411	NUM
dpc-3647	91	117	)	)	PUNCT
dpc-3647	91	118	biologic	biologic	NOUN
dpc-3647	91	119	-	-	PUNCT
dpc-3647	91	120	naïve	naïve	ADJ
dpc-3647	91	121	642	642	NUM
dpc-3647	91	122	(	(	PUNCT
dpc-3647	91	123	436	436	NUM
dpc-3647	91	124	)	)	PUNCT
dpc-3647	91	125	0.921	0.921	NUM
dpc-3647	91	126	unremarkable	unremarkable	ADJ
dpc-3647	91	127	medical	medical	ADJ
dpc-3647	91	128	history	history	NOUN
dpc-3647	91	129	645	645	NUM
dpc-3647	91	130	(	(	PUNCT
dpc-3647	91	131	395	395	NUM
dpc-3647	91	132	)	)	PUNCT
dpc-3647	91	133	with	with	ADP
dpc-3647	91	134	a	a	DET
dpc-3647	91	135	chronic	chronic	ADJ
dpc-3647	91	136	disease	disease	NOUN
dpc-3647	91	137	648	648	NUM
dpc-3647	91	138	(	(	PUNCT
dpc-3647	91	139	461	461	NUM
dpc-3647	91	140	)	)	PUNCT
dpc-3647	91	141	0.763	0.763	NUM
dpc-3647	91	142	with	with	ADP
dpc-3647	91	143	hypertension	hypertension	NOUN
dpc-3647	91	144	687	687	NUM
dpc-3647	91	145	(	(	PUNCT
dpc-3647	91	146	566	566	NUM
dpc-3647	91	147	)	)	PUNCT
dpc-3647	91	148	without	without	ADP
dpc-3647	91	149	hypertension	hypertension	NOUN
dpc-3647	91	150	642	642	NUM
dpc-3647	91	151	(	(	PUNCT
dpc-3647	91	152	411	411	NUM
dpc-3647	91	153	)	)	PUNCT
dpc-3647	91	154	0.801	0.801	NUM
dpc-3647	91	155	with	with	ADP
dpc-3647	91	156	hyperlipidemia	hyperlipidemia	NOUN
dpc-3647	91	157	598	598	NUM
dpc-3647	91	158	(	(	PUNCT
dpc-3647	91	159	388	388	NUM
dpc-3647	91	160	)	)	PUNCT
dpc-3647	91	161	without	without	ADP
dpc-3647	91	162	hyperlipidemia	hyperlipidemia	NOUN
dpc-3647	91	163	658	658	NUM
dpc-3647	91	164	(	(	PUNCT
dpc-3647	91	165	436	436	NUM
dpc-3647	91	166	)	)	PUNCT
dpc-3647	91	167	0.113	0.113	NUM
dpc-3647	91	168	with	with	ADP
dpc-3647	91	169	diabetes	diabetes	NOUN
dpc-3647	91	170	mellitus	mellitus	NOUN
dpc-3647	91	171	651	651	NUM
dpc-3647	91	172	(	(	PUNCT
dpc-3647	91	173	611	611	NUM
dpc-3647	91	174	)	)	PUNCT
dpc-3647	91	175	without	without	ADP
dpc-3647	91	176	diabetes	diabetes	NOUN
dpc-3647	91	177	mellitus	mellitus	NOUN
dpc-3647	91	178	645	645	NUM
dpc-3647	91	179	(	(	PUNCT
dpc-3647	91	180	403	403	NUM
dpc-3647	91	181	)	)	PUNCT
dpc-3647	91	182	0.752	0.752	NUM
dpc-3647	91	183	with	with	ADP
dpc-3647	91	184	hepatic	hepatic	ADJ
dpc-3647	91	185	steatosis	steatosis	NOUN
dpc-3647	91	186	735	735	NUM
dpc-3647	91	187	(	(	PUNCT
dpc-3647	91	188	461	461	NUM
dpc-3647	91	189	)	)	PUNCT
dpc-3647	91	190	without	without	ADP
dpc-3647	91	191	hepatic	hepatic	ADJ
dpc-3647	91	192	steatosis	steatosis	NOUN
dpc-3647	91	193	643	643	NUM
dpc-3647	91	194	(	(	PUNCT
dpc-3647	91	195	418	418	NUM
dpc-3647	91	196	)	)	PUNCT
dpc-3647	91	197	0.706	0.706	NUM
dpc-3647	91	198	with	with	ADP
dpc-3647	91	199	hepatitis	hepatitis	PROPN
dpc-3647	91	200	b	b	PROPN
dpc-3647	91	201	virus	virus	NOUN
dpc-3647	91	202	carriage	carriage	NOUN
dpc-3647	91	203	608	608	NUM
dpc-3647	91	204	(	(	PUNCT
dpc-3647	91	205	431	431	NUM
dpc-3647	91	206	)	)	PUNCT
dpc-3647	91	207	without	without	ADP
dpc-3647	91	208	hepatitis	hepatitis	PROPN
dpc-3647	91	209	b	b	PROPN
dpc-3647	91	210	 	 	SPACE
dpc-3647	91	211	virus	virus	NOUN
dpc-3647	91	212	carriage	carriage	NOUN
dpc-3647	91	213	650	650	NUM
dpc-3647	91	214	(	(	PUNCT
dpc-3647	91	215	421	421	NUM
dpc-3647	91	216	)	)	PUNCT
dpc-3647	91	217	0.915	0.915	NUM
dpc-3647	91	218	with	with	ADP
dpc-3647	91	219	depression	depression	NOUN
dpc-3647	91	220	782	782	NUM
dpc-3647	91	221	(	(	PUNCT
dpc-3647	91	222	239	239	NUM
dpc-3647	91	223	)	)	PUNCT
dpc-3647	91	224	without	without	ADP
dpc-3647	91	225	depression	depression	NOUN
dpc-3647	91	226	608	608	NUM
dpc-3647	91	227	(	(	PUNCT
dpc-3647	91	228	418	418	NUM
dpc-3647	91	229	)	)	PUNCT
dpc-3647	91	230	0.079	0.079	NUM
dpc-3647	91	231	with	with	ADP
dpc-3647	91	232	coronary	coronary	ADJ
dpc-3647	91	233	artery	artery	NOUN
dpc-3647	91	234	disease	disease	NOUN
dpc-3647	91	235	692	692	NUM
dpc-3647	91	236	(	(	PUNCT
dpc-3647	91	237	521	521	NUM
dpc-3647	91	238	)	)	PUNCT
dpc-3647	91	239	without	without	ADP
dpc-3647	91	240	coronary	coronary	ADJ
dpc-3647	91	241	artery	artery	NOUN
dpc-3647	91	242	disease	disease	NOUN
dpc-3647	91	243	643	643	NUM
dpc-3647	91	244	(	(	PUNCT
dpc-3647	91	245	416	416	NUM
dpc-3647	91	246	)	)	PUNCT
dpc-3647	91	247	0.861	0.861	NUM
dpc-3647	91	248	iqr	iqr	NOUN
dpc-3647	91	249	=	=	NOUN
dpc-3647	91	250	interquartile	interquartile	NOUN
dpc-3647	91	251	range	range	NOUN
dpc-3647	91	252	.	.	PUNCT
dpc-3647	92	1	higher	high	ADJ
dpc-3647	92	2	sii	sii	PROPN
dpc-3647	92	3	levels	level	NOUN
dpc-3647	92	4	were	be	AUX
dpc-3647	92	5	detected	detect	VERB
dpc-3647	92	6	in	in	ADP
dpc-3647	92	7	male	male	ADJ
dpc-3647	92	8	patients	patient	NOUN
dpc-3647	92	9	,	,	PUNCT
dpc-3647	92	10	patients	patient	NOUN
dpc-3647	92	11	with	with	ADP
dpc-3647	92	12	severe	severe	ADJ
dpc-3647	92	13	psoriasis	psoriasis	NOUN
dpc-3647	92	14	,	,	PUNCT
dpc-3647	92	15	patients	patient	NOUN
dpc-3647	92	16	with	with	ADP
dpc-3647	92	17	psoriatic	psoriatic	ADJ
dpc-3647	92	18	arthritis	arthritis	NOUN
dpc-3647	92	19	,	,	PUNCT
dpc-3647	92	20	nail	nail	NOUN
dpc-3647	92	21	findings	finding	NOUN
dpc-3647	92	22	and	and	CCONJ
dpc-3647	92	23	obese	obese	ADJ
dpc-3647	92	24	patients	patient	NOUN
dpc-3647	92	25	.	.	PUNCT
dpc-3647	93	1	sii	sii	PROPN
dpc-3647	93	2	may	may	AUX
dpc-3647	93	3	indicate	indicate	VERB
dpc-3647	93	4	the	the	DET
dpc-3647	93	5	severity	severity	NOUN
dpc-3647	93	6	of	of	ADP
dpc-3647	93	7	psoriasis	psoriasis	NOUN
dpc-3647	93	8	.	.	PUNCT
dpc-3647	94	1	table	table	NOUN
dpc-3647	94	2	3	3	NUM
dpc-3647	94	3	.	.	PUNCT
dpc-3647	95	1	systemic	systemic	ADJ
dpc-3647	95	2	inflammation	inflammation	ADJ
dpc-3647	95	3	response	response	NOUN
dpc-3647	95	4	index	index	NOUN
dpc-3647	95	5	in	in	ADP
dpc-3647	95	6	patients	patient	NOUN
dpc-3647	95	7	with	with	ADP
dpc-3647	95	8	psoriasis	psoriasis	NOUN
dpc-3647	95	9	.	.	PUNCT
dpc-3647	96	1	systemic	systemic	ADJ
dpc-3647	96	2	inflammation	inflammation	ADJ
dpc-3647	96	3	response	response	NOUN
dpc-3647	96	4	index	index	NOUN
dpc-3647	96	5	median	median	NOUN
dpc-3647	96	6	(	(	PUNCT
dpc-3647	96	7	iqr	iqr	NOUN
dpc-3647	96	8	)	)	PUNCT
dpc-3647	96	9	p	p	NOUN
dpc-3647	96	10	value	value	NOUN
dpc-3647	96	11	female	female	ADJ
dpc-3647	96	12	1.02	1.02	NUM
dpc-3647	96	13	(	(	PUNCT
dpc-3647	96	14	0.83	0.83	NUM
dpc-3647	96	15	)	)	PUNCT
dpc-3647	96	16	male	male	NOUN
dpc-3647	96	17	1.28	1.28	NUM
dpc-3647	96	18	(	(	PUNCT
dpc-3647	96	19	1.10	1.10	NUM
dpc-3647	96	20	)	)	PUNCT
dpc-3647	96	21	<	<	X
dpc-3647	96	22	0.001	0.001	NUM
dpc-3647	96	23	with	with	ADP
dpc-3647	96	24	arthritis	arthritis	NOUN
dpc-3647	96	25	1.09	1.09	NUM
dpc-3647	96	26	(	(	PUNCT
dpc-3647	96	27	0.75	0.75	NUM
dpc-3647	96	28	)	)	PUNCT
dpc-3647	96	29	without	without	ADP
dpc-3647	96	30	arthritis	arthritis	NOUN
dpc-3647	96	31	1.21	1.21	NUM
dpc-3647	96	32	(	(	PUNCT
dpc-3647	96	33	0.99	0.99	NUM
dpc-3647	96	34	)	)	PUNCT
dpc-3647	96	35	0.07	0.07	NUM
dpc-3647	96	36	psoriasis	psoriasis	NOUN
dpc-3647	96	37	vulgaris	vulgaris	NOUN
dpc-3647	96	38	1.18	1.18	NUM
dpc-3647	96	39	(	(	PUNCT
dpc-3647	96	40	0.90	0.90	NUM
dpc-3647	96	41	)	)	PUNCT
dpc-3647	96	42	other	other	ADJ
dpc-3647	96	43	types	type	NOUN
dpc-3647	96	44	1.19	1.19	NUM
dpc-3647	96	45	(	(	PUNCT
dpc-3647	96	46	1.06	1.06	NUM
dpc-3647	96	47	)	)	PUNCT
dpc-3647	96	48	0.956	0.956	NUM
dpc-3647	96	49	nail	nail	NOUN
dpc-3647	96	50	involvement	involvement	NOUN
dpc-3647	96	51	1.20	1.20	NUM
dpc-3647	96	52	(	(	PUNCT
dpc-3647	96	53	0.87	0.87	NUM
dpc-3647	96	54	)	)	PUNCT
dpc-3647	96	55	without	without	ADP
dpc-3647	96	56	nail	nail	NOUN
dpc-3647	96	57	involvement	involvement	NOUN
dpc-3647	96	58	1.16	1.16	NUM
dpc-3647	96	59	(	(	PUNCT
dpc-3647	96	60	0.91	0.91	NUM
dpc-3647	96	61	)	)	PUNCT
dpc-3647	96	62	0.904	0.904	NUM
dpc-3647	96	63	psoriasis	psoriasis	NOUN
dpc-3647	96	64	duration	duration	NOUN
dpc-3647	96	65	(	(	PUNCT
dpc-3647	96	66	≤20	≤20	PROPN
dpc-3647	96	67	years	year	NOUN
dpc-3647	96	68	)	)	PUNCT
dpc-3647	96	69	1.13	1.13	NUM
dpc-3647	96	70	(	(	PUNCT
dpc-3647	96	71	0.91	0.91	NUM
dpc-3647	96	72	)	)	PUNCT
dpc-3647	96	73	psoriasis	psoriasis	NOUN
dpc-3647	96	74	duration	duration	NOUN
dpc-3647	96	75	(	(	PUNCT
dpc-3647	96	76	>	>	SYM
dpc-3647	96	77	20	20	NUM
dpc-3647	96	78	years	year	NOUN
dpc-3647	96	79	)	)	PUNCT
dpc-3647	96	80	1.25	1.25	NUM
dpc-3647	96	81	(	(	PUNCT
dpc-3647	96	82	0.99	0.99	NUM
dpc-3647	96	83	)	)	PUNCT
dpc-3647	96	84	0.381	0.381	NUM
dpc-3647	96	85	mild/	mild/	NUM
dpc-3647	96	86	moderate	moderate	ADJ
dpc-3647	96	87	psoriasis	psoriasis	NOUN
dpc-3647	96	88	1.13	1.13	NUM
dpc-3647	96	89	(	(	PUNCT
dpc-3647	96	90	0.75	0.75	NUM
dpc-3647	96	91	)	)	PUNCT
dpc-3647	96	92	severe	severe	ADJ
dpc-3647	96	93	psoriasis	psoriasis	NOUN
dpc-3647	96	94	1.19	1.19	NUM
dpc-3647	96	95	(	(	PUNCT
dpc-3647	96	96	1.07	1.07	NUM
dpc-3647	96	97	)	)	PUNCT
dpc-3647	96	98	0.295	0.295	NUM
dpc-3647	96	99	non	non	ADJ
dpc-3647	96	100	-	-	ADJ
dpc-3647	96	101	obese	obese	ADJ
dpc-3647	96	102	1.05	1.05	NUM
dpc-3647	96	103	(	(	PUNCT
dpc-3647	96	104	0.74	0.74	NUM
dpc-3647	96	105	)	)	PUNCT
dpc-3647	96	106	obese	obese	ADV
dpc-3647	96	107	1.30	1.30	NUM
dpc-3647	96	108	(	(	PUNCT
dpc-3647	96	109	1.08	1.08	NUM
dpc-3647	96	110	)	)	PUNCT
dpc-3647	96	111	0.185	0.185	NUM
dpc-3647	96	112	previous	previous	ADJ
dpc-3647	96	113	biological	biological	ADJ
dpc-3647	96	114	treatment	treatment	NOUN
dpc-3647	96	115	1.25	1.25	NUM
dpc-3647	96	116	(	(	PUNCT
dpc-3647	96	117	1.19	1.19	NUM
dpc-3647	96	118	)	)	PUNCT
dpc-3647	96	119	biologic	biologic	NOUN
dpc-3647	96	120	-	-	PUNCT
dpc-3647	96	121	naïve	naïve	ADJ
dpc-3647	96	122	1.16	1.16	NUM
dpc-3647	96	123	(	(	PUNCT
dpc-3647	96	124	0.76	0.76	NUM
dpc-3647	96	125	)	)	PUNCT
dpc-3647	96	126	0.921	0.921	NUM
dpc-3647	96	127	unremarkable	unremarkable	ADJ
dpc-3647	96	128	medical	medical	ADJ
dpc-3647	96	129	history	history	NOUN
dpc-3647	96	130	1.16	1.16	NUM
dpc-3647	96	131	(	(	PUNCT
dpc-3647	96	132	1.01	1.01	NUM
dpc-3647	96	133	)	)	PUNCT
dpc-3647	96	134	with	with	ADP
dpc-3647	96	135	a	a	DET
dpc-3647	96	136	chronic	chronic	ADJ
dpc-3647	96	137	disease	disease	NOUN
dpc-3647	96	138	1.19	1.19	NUM
dpc-3647	96	139	(	(	PUNCT
dpc-3647	96	140	0.79	0.79	NUM
dpc-3647	96	141	)	)	PUNCT
dpc-3647	96	142	0.753	0.753	NUM
dpc-3647	96	143	with	with	ADP
dpc-3647	96	144	hypertension	hypertension	NOUN
dpc-3647	96	145	1.16	1.16	NUM
dpc-3647	96	146	(	(	PUNCT
dpc-3647	96	147	1.00	1.00	NUM
dpc-3647	96	148	)	)	PUNCT
dpc-3647	96	149	without	without	ADP
dpc-3647	96	150	hypertension	hypertension	NOUN
dpc-3647	96	151	1.19	1.19	NUM
dpc-3647	96	152	(	(	PUNCT
dpc-3647	96	153	0.87	0.87	NUM
dpc-3647	96	154	)	)	PUNCT
dpc-3647	96	155	0.607	0.607	NUM
dpc-3647	96	156	with	with	ADP
dpc-3647	96	157	hyperlipidemia	hyperlipidemia	NOUN
dpc-3647	96	158	1.18	1.18	NUM
dpc-3647	96	159	(	(	PUNCT
dpc-3647	96	160	0.67	0.67	NUM
dpc-3647	96	161	)	)	PUNCT
dpc-3647	96	162	without	without	ADP
dpc-3647	96	163	hyperlipidemia	hyperlipidemia	NOUN
dpc-3647	96	164	1.20	1.20	NUM
dpc-3647	96	165	(	(	PUNCT
dpc-3647	96	166	1.01	1.01	NUM
dpc-3647	96	167	)	)	PUNCT
dpc-3647	96	168	0.806	0.806	NUM
dpc-3647	96	169	with	with	ADP
dpc-3647	96	170	diabetes	diabetes	NOUN
dpc-3647	96	171	mellitus	mellitus	NOUN
dpc-3647	96	172	1.23	1.23	NUM
dpc-3647	96	173	(	(	PUNCT
dpc-3647	96	174	1.11	1.11	NUM
dpc-3647	96	175	)	)	PUNCT
dpc-3647	96	176	without	without	ADP
dpc-3647	96	177	diabetes	diabetes	NOUN
dpc-3647	96	178	mellitus	mellitus	NOUN
dpc-3647	96	179	1.16	1.16	NUM
dpc-3647	96	180	(	(	PUNCT
dpc-3647	96	181	0.89	0.89	NUM
dpc-3647	96	182	)	)	PUNCT
dpc-3647	96	183	0.263	0.263	NUM
dpc-3647	96	184	with	with	ADP
dpc-3647	96	185	hepatic	hepatic	ADJ
dpc-3647	96	186	steatosis	steatosis	NOUN
dpc-3647	96	187	1.13	1.13	NUM
dpc-3647	96	188	(	(	PUNCT
dpc-3647	96	189	0.98	0.98	NUM
dpc-3647	96	190	)	)	PUNCT
dpc-3647	96	191	without	without	ADP
dpc-3647	96	192	hepatic	hepatic	ADJ
dpc-3647	96	193	steatosis	steatosis	NOUN
dpc-3647	96	194	1.19	1.19	NUM
dpc-3647	96	195	(	(	PUNCT
dpc-3647	96	196	0.90	0.90	NUM
dpc-3647	96	197	)	)	PUNCT
dpc-3647	96	198	0.472	0.472	NUM
dpc-3647	96	199	with	with	ADP
dpc-3647	96	200	hepatitis	hepatitis	PROPN
dpc-3647	96	201	b	b	PROPN
dpc-3647	96	202	virus	virus	NOUN
dpc-3647	96	203	carriage	carriage	NOUN
dpc-3647	96	204	1.13	1.13	NUM
dpc-3647	96	205	(	(	PUNCT
dpc-3647	96	206	0.98	0.98	NUM
dpc-3647	96	207	)	)	PUNCT
dpc-3647	96	208	without	without	ADP
dpc-3647	96	209	hepatitis	hepatitis	PROPN
dpc-3647	96	210	b	b	PROPN
dpc-3647	96	211	virus	virus	NOUN
dpc-3647	96	212	carriage	carriage	VERB
dpc-3647	96	213	1.19	1.19	NUM
dpc-3647	96	214	(	(	PUNCT
dpc-3647	96	215	0.90	0.90	NUM
dpc-3647	96	216	)	)	PUNCT
dpc-3647	96	217	0.424	0.424	NUM
dpc-3647	96	218	with	with	ADP
dpc-3647	96	219	depression	depression	NOUN
dpc-3647	96	220	1.39	1.39	NUM
dpc-3647	96	221	(	(	PUNCT
dpc-3647	96	222	1.22	1.22	NUM
dpc-3647	96	223	)	)	PUNCT
dpc-3647	96	224	without	without	ADP
dpc-3647	96	225	depression	depression	NOUN
dpc-3647	96	226	1.18	1.18	NUM
dpc-3647	96	227	(	(	PUNCT
dpc-3647	96	228	0.89	0.89	NUM
dpc-3647	96	229	)	)	PUNCT
dpc-3647	96	230	0.777	0.777	NUM
dpc-3647	96	231	with	with	ADP
dpc-3647	96	232	coronary	coronary	ADJ
dpc-3647	96	233	artery	artery	NOUN
dpc-3647	96	234	disease	disease	NOUN
dpc-3647	96	235	1.01	1.01	NUM
dpc-3647	96	236	(	(	PUNCT
dpc-3647	96	237	0.85	0.85	NUM
dpc-3647	96	238	)	)	PUNCT
dpc-3647	96	239	without	without	ADP
dpc-3647	96	240	coronary	coronary	ADJ
dpc-3647	96	241	artery	artery	NOUN
dpc-3647	96	242	disease	disease	NOUN
dpc-3647	96	243	1.20	1.20	NUM
dpc-3647	96	244	(	(	PUNCT
dpc-3647	96	245	0.90	0.90	NUM
dpc-3647	96	246	)	)	PUNCT
dpc-3647	96	247	0.185	0.185	NUM
dpc-3647	96	248	iqr	iqr	X
dpc-3647	97	1	=	=	NOUN
dpc-3647	97	2	interquartile	interquartile	ADJ
dpc-3647	97	3	range	range	NOUN
dpc-3647	97	4	.	.	PUNCT
dpc-3647	98	1	siri	siri	NOUN
dpc-3647	98	2	was	be	AUX
dpc-3647	98	3	statistically	statistically	ADV
dpc-3647	98	4	significantly	significantly	ADV
dpc-3647	98	5	higher	high	ADJ
dpc-3647	98	6	in	in	ADP
dpc-3647	98	7	male	male	ADJ
dpc-3647	98	8	patients	patient	NOUN
dpc-3647	98	9	compared	compare	VERB
dpc-3647	98	10	to	to	ADP
dpc-3647	98	11	females	female	NOUN
dpc-3647	98	12	.	.	PUNCT
dpc-3647	99	1	this	this	DET
dpc-3647	99	2	result	result	NOUN
dpc-3647	99	3	may	may	AUX
dpc-3647	99	4	be	be	AUX
dpc-3647	99	5	related	relate	VERB
dpc-3647	99	6	to	to	PART
dpc-3647	99	7	longer	long	ADV
dpc-3647	99	8	psoriasis	psoriasis	VERB
dpc-3647	99	9	duration	duration	NOUN
dpc-3647	99	10	in	in	ADP
dpc-3647	99	11	male	male	ADJ
dpc-3647	99	12	patients	patient	NOUN
dpc-3647	99	13	than	than	ADP
dpc-3647	99	14	in	in	ADP
dpc-3647	99	15	females	female	NOUN
dpc-3647	99	16	.	.	PUNCT
dpc-3647	100	1	types	type	NOUN
dpc-3647	100	2	of	of	ADP
dpc-3647	100	3	psoriasis	psoriasis	NOUN
dpc-3647	100	4	[	[	X
dpc-3647	100	5	16	16	NUM
dpc-3647	100	6	]	]	PUNCT
dpc-3647	100	7	.	.	PUNCT
dpc-3647	101	1	however	however	ADV
dpc-3647	101	2	,	,	PUNCT
dpc-3647	101	3	ibrahim	ibrahim	PROPN
dpc-3647	101	4	et	et	PROPN
dpc-3647	101	5	al	al	PROPN
dpc-3647	101	6	reported	report	VERB
dpc-3647	101	7	that	that	SCONJ
dpc-3647	101	8	patients	patient	NOUN
dpc-3647	101	9	with	with	ADP
dpc-3647	101	10	pustular	pustular	ADJ
dpc-3647	101	11	psoriasis	psoriasis	NOUN
dpc-3647	101	12	had	have	VERB
dpc-3647	101	13	higher	high	ADJ
dpc-3647	101	14	sii	sii	ADJ
dpc-3647	101	15	levels	level	NOUN
dpc-3647	101	16	compared	compare	VERB
dpc-3647	101	17	to	to	ADP
dpc-3647	101	18	those	those	PRON
dpc-3647	101	19	with	with	ADP
dpc-3647	101	20	psoriasis	psoriasis	NOUN
dpc-3647	101	21	vulgaris	vulgaris	NOUN
dpc-3647	101	22	and	and	CCONJ
dpc-3647	101	23	erythrodermic	erythrodermic	ADJ
dpc-3647	101	24	psoriasis	psoriasis	NOUN
dpc-3647	101	25	[	[	X
dpc-3647	101	26	17	17	NUM
dpc-3647	101	27	]	]	PUNCT
dpc-3647	101	28	.	.	PUNCT
dpc-3647	102	1	dincer	dincer	PROPN
dpc-3647	102	2	rota	rota	PROPN
dpc-3647	102	3	et	et	PROPN
dpc-3647	102	4	al	al	PROPN
dpc-3647	102	5	reported	report	VERB
dpc-3647	102	6	higher	high	ADJ
dpc-3647	102	7	sii	sii	PROPN
dpc-3647	102	8	levels	level	NOUN
dpc-3647	102	9	in	in	ADP
dpc-3647	102	10	patients	patient	NOUN
dpc-3647	102	11	with	with	ADP
dpc-3647	102	12	psoriasis	psoriasis	NOUN
dpc-3647	102	13	compared	compare	VERB
dpc-3647	102	14	to	to	ADP
dpc-3647	102	15	patients	patient	NOUN
dpc-3647	102	16	with	with	ADP
dpc-3647	102	17	dermatological	dermatological	ADJ
dpc-3647	102	18	disorders	disorder	NOUN
dpc-3647	102	19	other	other	ADJ
dpc-3647	102	20	than	than	ADP
dpc-3647	102	21	psoriasis	psoriasis	NOUN
dpc-3647	102	22	.	.	PUNCT
dpc-3647	103	1	sii	sii	PROPN
dpc-3647	103	2	was	be	AUX
dpc-3647	103	3	also	also	ADV
dpc-3647	103	4	associated	associate	VERB
dpc-3647	103	5	with	with	ADP
dpc-3647	103	6	nail	nail	NOUN
dpc-3647	103	7	changes	change	NOUN
dpc-3647	103	8	due	due	ADJ
dpc-3647	103	9	to	to	ADP
dpc-3647	103	10	psoriasis	psoriasis	NOUN
dpc-3647	103	11	[	[	X
dpc-3647	103	12	11	11	NUM
dpc-3647	103	13	]	]	PUNCT
dpc-3647	103	14	.	.	PUNCT
dpc-3647	104	1	kelesoglu	kelesoglu	PROPN
dpc-3647	104	2	dincer	dincer	PROPN
dpc-3647	104	3	et	et	PROPN
dpc-3647	104	4	al	al	PROPN
dpc-3647	104	5	reported	report	VERB
dpc-3647	104	6	higher	high	ADJ
dpc-3647	104	7	sii	sii	PROPN
dpc-3647	104	8	levels	level	NOUN
dpc-3647	104	9	in	in	ADP
dpc-3647	104	10	patients	patient	NOUN
dpc-3647	104	11	with	with	ADP
dpc-3647	104	12	psoriatic	psoriatic	ADJ
dpc-3647	104	13	arthritis	arthritis	NOUN
dpc-3647	104	14	original	original	ADJ
dpc-3647	104	15	article	article	NOUN
dpc-3647	104	16	|	|	ADV
dpc-3647	104	17	dermatol	dermatol	ADJ
dpc-3647	104	18	pract	pract	NOUN
dpc-3647	104	19	concept	concept	NOUN
dpc-3647	104	20	.	.	PUNCT
dpc-3647	105	1	2024;14(1):e2024065	2024;14(1):e2024065	NUM
dpc-3647	105	2	5	5	NUM
dpc-3647	105	3	table	table	NOUN
dpc-3647	105	4	4	4	NUM
dpc-3647	105	5	.	.	PUNCT
dpc-3647	106	1	the	the	DET
dpc-3647	106	2	effect	effect	NOUN
dpc-3647	106	3	of	of	ADP
dpc-3647	106	4	biological	biological	ADJ
dpc-3647	106	5	agent	agent	NOUN
dpc-3647	106	6	treatment	treatment	NOUN
dpc-3647	106	7	of	of	ADP
dpc-3647	106	8	psoriasis	psoriasis	NOUN
dpc-3647	106	9	on	on	ADP
dpc-3647	106	10	systemic	systemic	ADJ
dpc-3647	106	11	immune	immune	ADJ
dpc-3647	106	12	inflammation	inflammation	NOUN
dpc-3647	106	13	index	index	NOUN
dpc-3647	106	14	.	.	PUNCT
dpc-3647	107	1	systemic	systemic	ADJ
dpc-3647	107	2	immune	immune	ADJ
dpc-3647	107	3	inflammation	inflammation	NOUN
dpc-3647	107	4	index	index	NOUN
dpc-3647	107	5	median	median	NOUN
dpc-3647	107	6	(	(	PUNCT
dpc-3647	107	7	iqr	iqr	NOUN
dpc-3647	107	8	)	)	PUNCT
dpc-3647	107	9	p	p	NOUN
dpc-3647	107	10	value	value	NOUN
dpc-3647	107	11	before	before	ADP
dpc-3647	107	12	treatment	treatment	NOUN
dpc-3647	107	13	after	after	ADP
dpc-3647	107	14	treatment	treatment	NOUN
dpc-3647	107	15	all	all	DET
dpc-3647	107	16	patients	patient	NOUN
dpc-3647	107	17	646	646	NUM
dpc-3647	107	18	(	(	PUNCT
dpc-3647	107	19	420	420	NUM
dpc-3647	107	20	)	)	PUNCT
dpc-3647	107	21	492	492	NUM
dpc-3647	107	22	(	(	PUNCT
dpc-3647	107	23	324	324	NUM
dpc-3647	107	24	)	)	PUNCT
dpc-3647	107	25	<	<	X
dpc-3647	107	26	0.001	0.001	NUM
dpc-3647	107	27	tnf	tnf	PROPN
dpc-3647	107	28	-	-	PUNCT
dpc-3647	107	29	α	α	PROPN
dpc-3647	107	30	inhibitors	inhibitor	NOUN
dpc-3647	107	31	607	607	NUM
dpc-3647	107	32	(	(	PUNCT
dpc-3647	107	33	384	384	NUM
dpc-3647	107	34	)	)	PUNCT
dpc-3647	107	35	408	408	NUM
dpc-3647	107	36	(	(	PUNCT
dpc-3647	107	37	341	341	NUM
dpc-3647	107	38	)	)	PUNCT
dpc-3647	107	39	<	<	X
dpc-3647	107	40	0.001	0.001	NUM
dpc-3647	107	41	il-17	il-17	ADP
dpc-3647	107	42	inhibitors	inhibitor	NOUN
dpc-3647	107	43	703	703	NUM
dpc-3647	107	44	(	(	PUNCT
dpc-3647	107	45	485	485	NUM
dpc-3647	107	46	)	)	PUNCT
dpc-3647	107	47	528	528	NUM
dpc-3647	107	48	(	(	PUNCT
dpc-3647	107	49	298	298	NUM
dpc-3647	107	50	)	)	PUNCT
dpc-3647	107	51	<	<	X
dpc-3647	107	52	0.001	0.001	NUM
dpc-3647	107	53	il-12/23	il-12/23	ADJ
dpc-3647	107	54	inhibitor	inhibitor	NOUN
dpc-3647	107	55	603	603	NUM
dpc-3647	107	56	(	(	PUNCT
dpc-3647	107	57	468	468	NUM
dpc-3647	107	58	)	)	PUNCT
dpc-3647	107	59	512	512	NUM
dpc-3647	107	60	(	(	PUNCT
dpc-3647	107	61	344	344	NUM
dpc-3647	107	62	)	)	PUNCT
dpc-3647	107	63	<	<	X
dpc-3647	107	64	0.001	0.001	NUM
dpc-3647	107	65	il-23	il-23	NOUN
dpc-3647	107	66	inhibitor	inhibitor	NOUN
dpc-3647	107	67	689	689	NUM
dpc-3647	107	68	(	(	PUNCT
dpc-3647	107	69	390	390	NUM
dpc-3647	107	70	)	)	PUNCT
dpc-3647	107	71	467	467	NUM
dpc-3647	107	72	(	(	PUNCT
dpc-3647	107	73	182	182	NUM
dpc-3647	107	74	)	)	PUNCT
dpc-3647	107	75	0.056	0.056	NUM
dpc-3647	107	76	adalimumab	adalimumab	NOUN
dpc-3647	107	77	532	532	NUM
dpc-3647	107	78	(	(	PUNCT
dpc-3647	107	79	278	278	NUM
dpc-3647	107	80	)	)	PUNCT
dpc-3647	107	81	374	374	NUM
dpc-3647	107	82	(	(	PUNCT
dpc-3647	107	83	327	327	NUM
dpc-3647	107	84	)	)	PUNCT
dpc-3647	107	85	<	<	X
dpc-3647	107	86	0.001	0.001	NUM
dpc-3647	107	87	infliximab	infliximab	NOUN
dpc-3647	107	88	867	867	NUM
dpc-3647	107	89	(	(	PUNCT
dpc-3647	107	90	356	356	NUM
dpc-3647	107	91	)	)	PUNCT
dpc-3647	107	92	487	487	NUM
dpc-3647	107	93	(	(	PUNCT
dpc-3647	107	94	469	469	NUM
dpc-3647	107	95	)	)	PUNCT
dpc-3647	107	96	0.002	0.002	NUM
dpc-3647	107	97	ixekizumab	ixekizumab	NOUN
dpc-3647	107	98	682	682	NUM
dpc-3647	107	99	(	(	PUNCT
dpc-3647	107	100	432	432	NUM
dpc-3647	107	101	)	)	PUNCT
dpc-3647	107	102	539	539	NUM
dpc-3647	107	103	(	(	PUNCT
dpc-3647	107	104	314	314	NUM
dpc-3647	107	105	)	)	PUNCT
dpc-3647	107	106	<	<	X
dpc-3647	107	107	0.001	0.001	NUM
dpc-3647	107	108	secukinumab	secukinumab	NOUN
dpc-3647	107	109	744	744	NUM
dpc-3647	107	110	(	(	PUNCT
dpc-3647	107	111	624	624	NUM
dpc-3647	107	112	)	)	SYM
dpc-3647	107	113	454	454	NUM
dpc-3647	107	114	(	(	PUNCT
dpc-3647	107	115	276	276	NUM
dpc-3647	107	116	)	)	PUNCT
dpc-3647	107	117	0.004	0.004	NUM
dpc-3647	107	118	ustekinumab	ustekinumab	NOUN
dpc-3647	107	119	603	603	NUM
dpc-3647	107	120	(	(	PUNCT
dpc-3647	107	121	468	468	NUM
dpc-3647	107	122	)	)	PUNCT
dpc-3647	107	123	512	512	NUM
dpc-3647	107	124	(	(	PUNCT
dpc-3647	107	125	344	344	NUM
dpc-3647	107	126	)	)	PUNCT
dpc-3647	107	127	<	<	X
dpc-3647	107	128	0.001	0.001	NUM
dpc-3647	107	129	risankizumab	risankizumab	NOUN
dpc-3647	107	130	559	559	NUM
dpc-3647	107	131	(	(	PUNCT
dpc-3647	107	132	392	392	NUM
dpc-3647	107	133	)	)	PUNCT
dpc-3647	107	134	443	443	NUM
dpc-3647	107	135	(	(	PUNCT
dpc-3647	107	136	145	145	NUM
dpc-3647	107	137	)	)	PUNCT
dpc-3647	107	138	0.013	0.013	NUM
dpc-3647	107	139	guselkumab	guselkumab	NOUN
dpc-3647	107	140	859	859	NUM
dpc-3647	107	141	(	(	PUNCT
dpc-3647	107	142	468	468	NUM
dpc-3647	107	143	)	)	PUNCT
dpc-3647	107	144	501	501	NUM
dpc-3647	107	145	(	(	PUNCT
dpc-3647	107	146	1147	1147	NUM
dpc-3647	107	147	)	)	PUNCT
dpc-3647	107	148	0.893	0.893	NUM
dpc-3647	107	149	il	il	X
dpc-3647	107	150	=	=	SYM
dpc-3647	107	151	interleukin	interleukin	NOUN
dpc-3647	107	152	;	;	PUNCT
dpc-3647	107	153	iqr	iqr	PROPN
dpc-3647	107	154	=	=	PROPN
dpc-3647	107	155	interquartile	interquartile	PROPN
dpc-3647	107	156	range;tnf	range;tnf	PROPN
dpc-3647	107	157	-	-	PUNCT
dpc-3647	107	158	α	α	PROPN
dpc-3647	107	159	=	=	PUNCT
dpc-3647	107	160	tumor	tumor	NOUN
dpc-3647	107	161	necrosis	necrosis	NOUN
dpc-3647	107	162	factor	factor	NOUN
dpc-3647	107	163	-	-	PUNCT
dpc-3647	107	164	α	α	NOUN
dpc-3647	107	165	.	.	PUNCT
dpc-3647	108	1	systemic	systemic	ADJ
dpc-3647	108	2	immune	immune	ADJ
dpc-3647	108	3	inflammation	inflammation	NOUN
dpc-3647	108	4	index	index	NOUN
dpc-3647	108	5	decreased	decrease	VERB
dpc-3647	108	6	in	in	ADP
dpc-3647	108	7	patients	patient	NOUN
dpc-3647	108	8	treated	treat	VERB
dpc-3647	108	9	with	with	ADP
dpc-3647	108	10	adalimumab	adalimumab	NOUN
dpc-3647	108	11	,	,	PUNCT
dpc-3647	108	12	infliximab	infliximab	NOUN
dpc-3647	108	13	,	,	PUNCT
dpc-3647	108	14	ixekizumab	ixekizumab	NOUN
dpc-3647	108	15	,	,	PUNCT
dpc-3647	108	16	secukinumab	secukinumab	NOUN
dpc-3647	108	17	,	,	PUNCT
dpc-3647	108	18	ustekinumab	ustekinumab	NOUN
dpc-3647	108	19	and	and	CCONJ
dpc-3647	108	20	risankizumab	risankizumab	NOUN
dpc-3647	108	21	.	.	PUNCT
dpc-3647	109	1	systemic	systemic	ADJ
dpc-3647	109	2	immune	immune	ADJ
dpc-3647	109	3	inflammation	inflammation	NOUN
dpc-3647	109	4	index	index	NOUN
dpc-3647	109	5	may	may	AUX
dpc-3647	109	6	be	be	AUX
dpc-3647	109	7	useful	useful	ADJ
dpc-3647	109	8	in	in	ADP
dpc-3647	109	9	the	the	DET
dpc-3647	109	10	follow	follow	NOUN
dpc-3647	109	11	-	-	PUNCT
dpc-3647	109	12	up	up	NOUN
dpc-3647	109	13	of	of	ADP
dpc-3647	109	14	patients	patient	NOUN
dpc-3647	109	15	treated	treat	VERB
dpc-3647	109	16	with	with	ADP
dpc-3647	109	17	biological	biological	ADJ
dpc-3647	109	18	agents	agent	NOUN
dpc-3647	109	19	.	.	PUNCT
dpc-3647	110	1	figure	figure	NOUN
dpc-3647	110	2	1	1	NUM
dpc-3647	110	3	.	.	PUNCT
dpc-3647	111	1	the	the	DET
dpc-3647	111	2	effect	effect	NOUN
dpc-3647	111	3	of	of	ADP
dpc-3647	111	4	biological	biological	ADJ
dpc-3647	111	5	agents	agent	NOUN
dpc-3647	111	6	on	on	ADP
dpc-3647	111	7	systemic	systemic	ADJ
dpc-3647	111	8	immune	immune	ADJ
dpc-3647	111	9	inflammation	inflammation	NOUN
dpc-3647	111	10	index	index	NOUN
dpc-3647	111	11	.	.	PUNCT
dpc-3647	112	1	systemic	systemic	ADJ
dpc-3647	112	2	immune	immune	ADJ
dpc-3647	112	3	inflammation	inflammation	NOUN
dpc-3647	112	4	index	index	NOUN
dpc-3647	112	5	decreased	decrease	VERB
dpc-3647	112	6	in	in	ADP
dpc-3647	112	7	all	all	DET
dpc-3647	112	8	treatment	treatment	NOUN
dpc-3647	112	9	groups	group	NOUN
dpc-3647	112	10	.	.	PUNCT
dpc-3647	113	1	table	table	NOUN
dpc-3647	113	2	5	5	NUM
dpc-3647	113	3	.	.	PUNCT
dpc-3647	114	1	the	the	DET
dpc-3647	114	2	effect	effect	NOUN
dpc-3647	114	3	of	of	ADP
dpc-3647	114	4	biological	biological	ADJ
dpc-3647	114	5	agent	agent	NOUN
dpc-3647	114	6	treatment	treatment	NOUN
dpc-3647	114	7	of	of	ADP
dpc-3647	114	8	psoriasis	psoriasis	NOUN
dpc-3647	114	9	on	on	ADP
dpc-3647	114	10	systemic	systemic	ADJ
dpc-3647	114	11	inflammation	inflammation	ADJ
dpc-3647	114	12	response	response	NOUN
dpc-3647	114	13	index	index	NOUN
dpc-3647	114	14	.	.	PUNCT
dpc-3647	115	1	systemic	systemic	ADJ
dpc-3647	115	2	inflammation	inflammation	ADJ
dpc-3647	115	3	response	response	NOUN
dpc-3647	115	4	index	index	NOUN
dpc-3647	115	5	median	median	NOUN
dpc-3647	115	6	(	(	PUNCT
dpc-3647	115	7	iqr	iqr	NOUN
dpc-3647	115	8	)	)	PUNCT
dpc-3647	115	9	p	p	NOUN
dpc-3647	115	10	value	value	NOUN
dpc-3647	115	11	before	before	ADP
dpc-3647	115	12	treatment	treatment	NOUN
dpc-3647	115	13	after	after	ADP
dpc-3647	115	14	treatment	treatment	NOUN
dpc-3647	115	15	all	all	DET
dpc-3647	115	16	patients	patient	NOUN
dpc-3647	115	17	1.18	1.18	NUM
dpc-3647	115	18	(	(	PUNCT
dpc-3647	115	19	0.90	0.90	NUM
dpc-3647	115	20	)	)	PUNCT
dpc-3647	115	21	0.95	0.95	NUM
dpc-3647	115	22	(	(	PUNCT
dpc-3647	115	23	0.74	0.74	NUM
dpc-3647	115	24	)	)	PUNCT
dpc-3647	115	25	<	<	X
dpc-3647	115	26	0.001	0.001	NUM
dpc-3647	115	27	tnf	tnf	PROPN
dpc-3647	115	28	-	-	PUNCT
dpc-3647	115	29	α	α	PROPN
dpc-3647	115	30	inhibitors	inhibitor	NOUN
dpc-3647	115	31	1.15	1.15	NUM
dpc-3647	115	32	(	(	PUNCT
dpc-3647	115	33	0.73	0.73	NUM
dpc-3647	115	34	)	)	PUNCT
dpc-3647	115	35	0.8	0.8	NUM
dpc-3647	115	36	(	(	PUNCT
dpc-3647	115	37	0.58	0.58	NUM
dpc-3647	115	38	)	)	PUNCT
dpc-3647	115	39	<	<	X
dpc-3647	115	40	0.001	0.001	NUM
dpc-3647	115	41	il-17	il-17	ADP
dpc-3647	115	42	inhibitors	inhibitor	NOUN
dpc-3647	115	43	1.16	1.16	NUM
dpc-3647	115	44	(	(	PUNCT
dpc-3647	115	45	1.08	1.08	NUM
dpc-3647	115	46	)	)	PUNCT
dpc-3647	115	47	1.00	1.00	NUM
dpc-3647	115	48	(	(	PUNCT
dpc-3647	115	49	0.88	0.88	NUM
dpc-3647	115	50	)	)	PUNCT
dpc-3647	115	51	<	<	X
dpc-3647	115	52	0.001	0.001	NUM
dpc-3647	115	53	il-12/23	il-12/23	ADJ
dpc-3647	115	54	inhibitor	inhibitor	NOUN
dpc-3647	115	55	1.17	1.17	NUM
dpc-3647	115	56	(	(	PUNCT
dpc-3647	115	57	0.79	0.79	NUM
dpc-3647	115	58	)	)	PUNCT
dpc-3647	115	59	0.95	0.95	NUM
dpc-3647	115	60	(	(	PUNCT
dpc-3647	115	61	0.68	0.68	NUM
dpc-3647	115	62	)	)	PUNCT
dpc-3647	115	63	<	<	X
dpc-3647	115	64	0.001	0.001	NUM
dpc-3647	115	65	il-23	il-23	NOUN
dpc-3647	115	66	inhibitor	inhibitor	NOUN
dpc-3647	115	67	1.52	1.52	NUM
dpc-3647	115	68	(	(	PUNCT
dpc-3647	115	69	1.42	1.42	NUM
dpc-3647	115	70	)	)	PUNCT
dpc-3647	115	71	0.97	0.97	NUM
dpc-3647	115	72	(	(	PUNCT
dpc-3647	115	73	0.78	0.78	NUM
dpc-3647	115	74	)	)	PUNCT
dpc-3647	115	75	0.056	0.056	NUM
dpc-3647	115	76	adalimumab	adalimumab	NOUN
dpc-3647	115	77	1.05	1.05	NUM
dpc-3647	115	78	(	(	PUNCT
dpc-3647	115	79	0.68	0.68	NUM
dpc-3647	115	80	)	)	PUNCT
dpc-3647	115	81	0.78	0.78	NUM
dpc-3647	115	82	(	(	PUNCT
dpc-3647	115	83	0.58	0.58	NUM
dpc-3647	115	84	)	)	PUNCT
dpc-3647	115	85	<	<	X
dpc-3647	115	86	0.001	0.001	NUM
dpc-3647	115	87	infliximab	infliximab	NOUN
dpc-3647	115	88	1.73	1.73	NUM
dpc-3647	115	89	(	(	PUNCT
dpc-3647	115	90	1.14	1.14	NUM
dpc-3647	115	91	)	)	PUNCT
dpc-3647	115	92	0.88	0.88	NUM
dpc-3647	115	93	(	(	PUNCT
dpc-3647	115	94	1.04	1.04	NUM
dpc-3647	115	95	)	)	PUNCT
dpc-3647	115	96	0.001	0.001	NUM
dpc-3647	115	97	ixekizumab	ixekizumab	NOUN
dpc-3647	115	98	1.17	1.17	NUM
dpc-3647	115	99	(	(	PUNCT
dpc-3647	115	100	1.14	1.14	NUM
dpc-3647	115	101	)	)	PUNCT
dpc-3647	115	102	1.00	1.00	NUM
dpc-3647	115	103	(	(	PUNCT
dpc-3647	115	104	0.93	0.93	NUM
dpc-3647	115	105	)	)	PUNCT
dpc-3647	115	106	0.002	0.002	NUM
dpc-3647	115	107	secukinumab	secukinumab	NOUN
dpc-3647	115	108	1.07	1.07	NUM
dpc-3647	115	109	(	(	PUNCT
dpc-3647	115	110	1.27	1.27	NUM
dpc-3647	115	111	)	)	PUNCT
dpc-3647	115	112	1.01	1.01	NUM
dpc-3647	115	113	(	(	PUNCT
dpc-3647	115	114	0.94	0.94	NUM
dpc-3647	115	115	)	)	PUNCT
dpc-3647	115	116	0.018	0.018	NUM
dpc-3647	115	117	ustekinumab	ustekinumab	NOUN
dpc-3647	115	118	1.17	1.17	NUM
dpc-3647	115	119	(	(	PUNCT
dpc-3647	115	120	0.79	0.79	NUM
dpc-3647	115	121	)	)	PUNCT
dpc-3647	115	122	0.95	0.95	NUM
dpc-3647	115	123	(	(	PUNCT
dpc-3647	115	124	0.68	0.68	NUM
dpc-3647	115	125	)	)	PUNCT
dpc-3647	116	1	<	<	X
dpc-3647	116	2	0.001	0.001	NUM
dpc-3647	116	3	risankizumab	risankizumab	NOUN
dpc-3647	116	4	1.75	1.75	NUM
dpc-3647	116	5	(	(	PUNCT
dpc-3647	116	6	1.69	1.69	NUM
dpc-3647	116	7	)	)	PUNCT
dpc-3647	116	8	0.88	0.88	NUM
dpc-3647	116	9	(	(	PUNCT
dpc-3647	116	10	1.08	1.08	NUM
dpc-3647	116	11	)	)	PUNCT
dpc-3647	116	12	0.041	0.041	NUM
dpc-3647	116	13	guselkumab	guselkumab	NOUN
dpc-3647	116	14	1.28	1.28	NUM
dpc-3647	116	15	(	(	PUNCT
dpc-3647	116	16	0.79	0.79	NUM
dpc-3647	116	17	)	)	PUNCT
dpc-3647	116	18	0.98	0.98	NUM
dpc-3647	116	19	(	(	PUNCT
dpc-3647	116	20	3.03	3.03	NUM
dpc-3647	116	21	)	)	PUNCT
dpc-3647	116	22	0.686	0.686	NUM
dpc-3647	116	23	il	il	PROPN
dpc-3647	116	24	=	=	SYM
dpc-3647	116	25	interleukin	interleukin	NOUN
dpc-3647	116	26	;	;	PUNCT
dpc-3647	116	27	iqr	iqr	PROPN
dpc-3647	116	28	=	=	NOUN
dpc-3647	116	29	interquartile	interquartile	NOUN
dpc-3647	116	30	range	range	NOUN
dpc-3647	116	31	;	;	PUNCT
dpc-3647	116	32	tnf	tnf	PROPN
dpc-3647	116	33	-	-	PUNCT
dpc-3647	116	34	α	α	PROPN
dpc-3647	116	35	=	=	PUNCT
dpc-3647	116	36	tumor	tumor	NOUN
dpc-3647	116	37	necrosis	necrosis	NOUN
dpc-3647	116	38	factor	factor	NOUN
dpc-3647	116	39	-	-	PUNCT
dpc-3647	116	40	α	α	NOUN
dpc-3647	116	41	.	.	PUNCT
dpc-3647	117	1	systemic	systemic	ADJ
dpc-3647	117	2	inflammation	inflammation	ADJ
dpc-3647	117	3	response	response	NOUN
dpc-3647	117	4	index	index	NOUN
dpc-3647	117	5	decreased	decrease	VERB
dpc-3647	117	6	in	in	ADP
dpc-3647	117	7	treatment	treatment	NOUN
dpc-3647	117	8	groups	group	NOUN
dpc-3647	117	9	such	such	ADJ
dpc-3647	117	10	as	as	ADP
dpc-3647	117	11	tnf	tnf	PROPN
dpc-3647	117	12	-	-	PUNCT
dpc-3647	117	13	α	α	PROPN
dpc-3647	117	14	inhibitors	inhibitor	NOUN
dpc-3647	117	15	,	,	PUNCT
dpc-3647	117	16	il-17	il-17	ADV
dpc-3647	117	17	inhibitors	inhibitor	NOUN
dpc-3647	117	18	and	and	CCONJ
dpc-3647	117	19	il-12/23	il-12/23	ADJ
dpc-3647	117	20	inhibitor	inhibitor	NOUN
dpc-3647	117	21	.	.	PUNCT
dpc-3647	118	1	systemic	systemic	ADJ
dpc-3647	118	2	inflammation	inflammation	ADJ
dpc-3647	118	3	response	response	NOUN
dpc-3647	118	4	index	index	NOUN
dpc-3647	118	5	may	may	AUX
dpc-3647	118	6	be	be	AUX
dpc-3647	118	7	useful	useful	ADJ
dpc-3647	118	8	in	in	ADP
dpc-3647	118	9	the	the	DET
dpc-3647	118	10	follow	follow	NOUN
dpc-3647	118	11	-	-	PUNCT
dpc-3647	118	12	up	up	NOUN
dpc-3647	118	13	of	of	ADP
dpc-3647	118	14	patients	patient	NOUN
dpc-3647	118	15	treated	treat	VERB
dpc-3647	118	16	with	with	ADP
dpc-3647	118	17	biological	biological	ADJ
dpc-3647	118	18	agents	agent	NOUN
dpc-3647	118	19	.	.	PUNCT
dpc-3647	119	1	than	than	ADP
dpc-3647	119	2	in	in	ADP
dpc-3647	119	3	healthy	healthy	ADJ
dpc-3647	119	4	controls	control	NOUN
dpc-3647	119	5	as	as	ADV
dpc-3647	119	6	well	well	ADV
dpc-3647	119	7	as	as	ADP
dpc-3647	119	8	positive	positive	ADJ
dpc-3647	119	9	correlation	correlation	NOUN
dpc-3647	119	10	between	between	ADP
dpc-3647	119	11	sii	sii	PROPN
dpc-3647	119	12	and	and	CCONJ
dpc-3647	119	13	severity	severity	NOUN
dpc-3647	119	14	of	of	ADP
dpc-3647	119	15	psoriatic	psoriatic	ADJ
dpc-3647	119	16	arthritis	arthritis	NOUN
dpc-3647	119	17	[	[	X
dpc-3647	119	18	18	18	NUM
dpc-3647	119	19	]	]	PUNCT
dpc-3647	119	20	.	.	PUNCT
dpc-3647	120	1	sugimoto	sugimoto	PROPN
dpc-3647	120	2	et	et	PROPN
dpc-3647	120	3	al	al	PROPN
dpc-3647	120	4	reported	report	VERB
dpc-3647	120	5	no	no	DET
dpc-3647	120	6	significant	significant	ADJ
dpc-3647	120	7	difference	difference	NOUN
dpc-3647	120	8	in	in	ADP
dpc-3647	120	9	sii	sii	ADJ
dpc-3647	120	10	and	and	CCONJ
dpc-3647	120	11	siri	siri	NOUN
dpc-3647	120	12	levels	level	NOUN
dpc-3647	120	13	in	in	ADP
dpc-3647	120	14	patients	patient	NOUN
dpc-3647	120	15	with	with	ADP
dpc-3647	120	16	psoriasis	psoriasis	NOUN
dpc-3647	120	17	vulgaris	vulgaris	NOUN
dpc-3647	120	18	and	and	CCONJ
dpc-3647	120	19	psoriatic	psoriatic	ADJ
dpc-3647	120	20	arthritis	arthritis	NOUN
dpc-3647	120	21	and	and	CCONJ
dpc-3647	120	22	in	in	ADP
dpc-3647	120	23	healthy	healthy	ADJ
dpc-3647	120	24	individuals	individual	NOUN
dpc-3647	120	25	.	.	PUNCT
dpc-3647	121	1	on	on	ADP
dpc-3647	121	2	the	the	DET
dpc-3647	121	3	other	other	ADJ
dpc-3647	121	4	hand	hand	NOUN
dpc-3647	121	5	,	,	PUNCT
dpc-3647	121	6	a	a	DET
dpc-3647	121	7	positive	positive	ADJ
dpc-3647	121	8	relationship	relationship	NOUN
dpc-3647	121	9	was	be	AUX
dpc-3647	121	10	detected	detect	VERB
dpc-3647	121	11	between	between	ADP
dpc-3647	121	12	pasi	pasi	NOUN
dpc-3647	121	13	and	and	CCONJ
dpc-3647	121	14	both	both	DET
dpc-3647	121	15	sii	sii	ADJ
dpc-3647	121	16	and	and	CCONJ
dpc-3647	121	17	siri	siri	NOUN
dpc-3647	121	18	.	.	PUNCT
dpc-3647	122	1	sugimoto	sugimoto	PROPN
dpc-3647	122	2	et	et	PROPN
dpc-3647	122	3	al	al	PROPN
dpc-3647	122	4	also	also	ADV
dpc-3647	122	5	revealed	reveal	VERB
dpc-3647	122	6	that	that	SCONJ
dpc-3647	122	7	siri	siri	NOUN
dpc-3647	122	8	might	might	AUX
dpc-3647	122	9	indicate	indicate	VERB
dpc-3647	122	10	higher	high	ADJ
dpc-3647	122	11	possibility	possibility	NOUN
dpc-3647	122	12	of	of	ADP
dpc-3647	122	13	the	the	DET
dpc-3647	122	14	diagnosis	diagnosis	NOUN
dpc-3647	122	15	of	of	ADP
dpc-3647	122	16	psoriatic	psoriatic	ADJ
dpc-3647	122	17	arthritis	arthritis	NOUN
dpc-3647	122	18	.	.	PUNCT
dpc-3647	123	1	in	in	ADP
dpc-3647	123	2	addition	addition	NOUN
dpc-3647	123	3	,	,	PUNCT
dpc-3647	123	4	6	6	NUM
dpc-3647	123	5	original	original	ADJ
dpc-3647	123	6	article	article	NOUN
dpc-3647	123	7	|	|	ADV
dpc-3647	123	8	dermatol	dermatol	ADJ
dpc-3647	123	9	pract	pract	NOUN
dpc-3647	123	10	concept	concept	NOUN
dpc-3647	123	11	.	.	PUNCT
dpc-3647	124	1	2024;14(1):e2024065	2024;14(1):e2024065	NUM
dpc-3647	124	2	with	with	ADP
dpc-3647	124	3	adalimumab	adalimumab	NOUN
dpc-3647	124	4	,	,	PUNCT
dpc-3647	124	5	infliximab	infliximab	NOUN
dpc-3647	124	6	,	,	PUNCT
dpc-3647	124	7	ixekizumab	ixekizumab	NOUN
dpc-3647	124	8	,	,	PUNCT
dpc-3647	124	9	secukinumab	secukinumab	NOUN
dpc-3647	124	10	,	,	PUNCT
dpc-3647	124	11	ustekinumab	ustekinumab	NOUN
dpc-3647	124	12	and	and	CCONJ
dpc-3647	124	13	risankizumab	risankizumab	NOUN
dpc-3647	124	14	significantly	significantly	ADV
dpc-3647	124	15	reduced	reduce	VERB
dpc-3647	124	16	sii	sii	ADJ
dpc-3647	124	17	and	and	CCONJ
dpc-3647	124	18	siri	siri	NOUN
dpc-3647	124	19	levels	level	NOUN
dpc-3647	124	20	in	in	ADP
dpc-3647	124	21	patients	patient	NOUN
dpc-3647	124	22	with	with	ADP
dpc-3647	124	23	psoriasis	psoriasis	NOUN
dpc-3647	124	24	.	.	PUNCT
dpc-3647	125	1	herein	herein	NOUN
dpc-3647	125	2	,	,	PUNCT
dpc-3647	125	3	we	we	PRON
dpc-3647	125	4	presented	present	VERB
dpc-3647	125	5	a	a	DET
dpc-3647	125	6	unique	unique	ADJ
dpc-3647	125	7	and	and	CCONJ
dpc-3647	125	8	comprehensive	comprehensive	ADJ
dpc-3647	125	9	study	study	NOUN
dpc-3647	125	10	on	on	ADP
dpc-3647	125	11	sii	sii	PROPN
dpc-3647	125	12	and	and	CCONJ
dpc-3647	125	13	siri	siri	NOUN
dpc-3647	125	14	in	in	ADP
dpc-3647	125	15	patients	patient	NOUN
dpc-3647	125	16	with	with	ADP
dpc-3647	125	17	psoriasis	psoriasis	NOUN
dpc-3647	125	18	treated	treat	VERB
dpc-3647	125	19	with	with	ADP
dpc-3647	125	20	biological	biological	ADJ
dpc-3647	125	21	agents	agent	NOUN
dpc-3647	125	22	.	.	PUNCT
dpc-3647	126	1	although	although	SCONJ
dpc-3647	126	2	a	a	DET
dpc-3647	126	3	variety	variety	NOUN
dpc-3647	126	4	of	of	ADP
dpc-3647	126	5	biological	biological	ADJ
dpc-3647	126	6	agents	agent	NOUN
dpc-3647	126	7	have	have	AUX
dpc-3647	126	8	been	be	AUX
dpc-3647	126	9	developed	develop	VERB
dpc-3647	126	10	to	to	PART
dpc-3647	126	11	be	be	AUX
dpc-3647	126	12	used	use	VERB
dpc-3647	126	13	in	in	ADP
dpc-3647	126	14	the	the	DET
dpc-3647	126	15	treatment	treatment	NOUN
dpc-3647	126	16	of	of	ADP
dpc-3647	126	17	psoriasis	psoriasis	NOUN
dpc-3647	126	18	,	,	PUNCT
dpc-3647	126	19	there	there	PRON
dpc-3647	126	20	is	be	VERB
dpc-3647	126	21	lack	lack	NOUN
dpc-3647	126	22	of	of	ADP
dpc-3647	126	23	biomarkers	biomarker	NOUN
dpc-3647	126	24	widely	widely	ADV
dpc-3647	126	25	preferred	preferred	ADJ
dpc-3647	126	26	to	to	PART
dpc-3647	126	27	asses	ass	NOUN
dpc-3647	126	28	disease	disease	NOUN
dpc-3647	126	29	severity	severity	NOUN
dpc-3647	126	30	,	,	PUNCT
dpc-3647	126	31	psoriatic	psoriatic	ADJ
dpc-3647	126	32	arthritis	arthritis	NOUN
dpc-3647	126	33	and	and	CCONJ
dpc-3647	126	34	comorbidities	comorbiditie	NOUN
dpc-3647	126	35	and	and	CCONJ
dpc-3647	126	36	to	to	PART
dpc-3647	126	37	be	be	AUX
dpc-3647	126	38	used	use	VERB
dpc-3647	126	39	during	during	ADP
dpc-3647	126	40	the	the	DET
dpc-3647	126	41	course	course	NOUN
dpc-3647	126	42	of	of	ADP
dpc-3647	126	43	treatment	treatment	NOUN
dpc-3647	126	44	of	of	ADP
dpc-3647	126	45	psoriasis	psoriasis	NOUN
dpc-3647	126	46	with	with	ADP
dpc-3647	126	47	biological	biological	ADJ
dpc-3647	126	48	agents	agent	NOUN
dpc-3647	127	1	[	[	X
dpc-3647	127	2	5,19	5,19	NUM
dpc-3647	127	3	-	-	SYM
dpc-3647	127	4	21	21	NUM
dpc-3647	127	5	]	]	PUNCT
dpc-3647	127	6	.	.	PUNCT
dpc-3647	128	1	our	our	PRON
dpc-3647	128	2	results	result	NOUN
dpc-3647	128	3	will	will	AUX
dpc-3647	128	4	contribute	contribute	VERB
dpc-3647	128	5	to	to	ADP
dpc-3647	128	6	the	the	DET
dpc-3647	128	7	literature	literature	NOUN
dpc-3647	128	8	on	on	ADP
dpc-3647	128	9	the	the	DET
dpc-3647	128	10	use	use	NOUN
dpc-3647	128	11	of	of	ADP
dpc-3647	128	12	sii	sii	ADJ
dpc-3647	128	13	and	and	CCONJ
dpc-3647	128	14	siri	siri	NOUN
dpc-3647	128	15	in	in	ADP
dpc-3647	128	16	the	the	DET
dpc-3647	128	17	management	management	NOUN
dpc-3647	128	18	of	of	ADP
dpc-3647	128	19	psoriasis	psoriasis	NOUN
dpc-3647	128	20	patients	patient	NOUN
dpc-3647	128	21	with	with	ADP
dpc-3647	128	22	biological	biological	ADJ
dpc-3647	128	23	agents	agent	NOUN
dpc-3647	128	24	.	.	PUNCT
dpc-3647	129	1	since	since	SCONJ
dpc-3647	129	2	sii	sii	PROPN
dpc-3647	129	3	and	and	CCONJ
dpc-3647	129	4	siri	siri	NOUN
dpc-3647	129	5	can	can	AUX
dpc-3647	129	6	be	be	AUX
dpc-3647	129	7	easily	easily	ADV
dpc-3647	129	8	performed	perform	VERB
dpc-3647	129	9	,	,	PUNCT
dpc-3647	129	10	in	in	ADP
dpc-3647	129	11	clinical	clinical	ADJ
dpc-3647	129	12	practice	practice	NOUN
dpc-3647	129	13	both	both	DET
dpc-3647	129	14	biomarkers	biomarker	NOUN
dpc-3647	129	15	may	may	AUX
dpc-3647	129	16	be	be	AUX
dpc-3647	129	17	helpful	helpful	ADJ
dpc-3647	129	18	in	in	ADP
dpc-3647	129	19	making	make	VERB
dpc-3647	129	20	treatment	treatment	NOUN
dpc-3647	129	21	choice	choice	NOUN
dpc-3647	129	22	and	and	CCONJ
dpc-3647	129	23	in	in	ADP
dpc-3647	129	24	the	the	DET
dpc-3647	129	25	follow	follow	NOUN
dpc-3647	129	26	-	-	PUNCT
dpc-3647	129	27	up	up	NOUN
dpc-3647	129	28	of	of	ADP
dpc-3647	129	29	patients	patient	NOUN
dpc-3647	129	30	with	with	ADP
dpc-3647	129	31	psoriasis	psoriasis	NOUN
dpc-3647	129	32	treated	treat	VERB
dpc-3647	129	33	with	with	ADP
dpc-3647	129	34	biological	biological	ADJ
dpc-3647	129	35	agents	agent	NOUN
dpc-3647	129	36	.	.	PUNCT
dpc-3647	130	1	references	reference	NOUN
dpc-3647	130	2	1	1	NUM
dpc-3647	130	3	.	.	PUNCT
dpc-3647	131	1	sugimoto	sugimoto	PROPN
dpc-3647	131	2	e	e	PROPN
dpc-3647	131	3	,	,	PUNCT
dpc-3647	131	4	matsuda	matsuda	PROPN
dpc-3647	131	5	h	h	PROPN
dpc-3647	131	6	,	,	PUNCT
dpc-3647	131	7	shibata	shibata	PROPN
dpc-3647	131	8	s	s	PROPN
dpc-3647	131	9	,	,	PUNCT
dpc-3647	131	10	et	et	PROPN
dpc-3647	131	11	al	al	PROPN
dpc-3647	131	12	.	.	PROPN
dpc-3647	131	13	impact	impact	NOUN
dpc-3647	131	14	of	of	ADP
dpc-3647	131	15	pretreatment	pretreatment	NOUN
dpc-3647	131	16	systemic	systemic	ADJ
dpc-3647	131	17	inflammatory	inflammatory	ADJ
dpc-3647	131	18	markers	marker	NOUN
dpc-3647	131	19	on	on	ADP
dpc-3647	131	20	treatment	treatment	NOUN
dpc-3647	131	21	persistence	persistence	NOUN
dpc-3647	131	22	with	with	ADP
dpc-3647	131	23	biologics	biologic	NOUN
dpc-3647	131	24	and	and	CCONJ
dpc-3647	131	25	conventional	conventional	ADJ
dpc-3647	131	26	systemic	systemic	ADJ
dpc-3647	131	27	therapy	therapy	NOUN
dpc-3647	131	28	:	:	PUNCT
dpc-3647	131	29	a	a	DET
dpc-3647	131	30	retrospective	retrospective	ADJ
dpc-3647	131	31	study	study	NOUN
dpc-3647	131	32	of	of	ADP
dpc-3647	131	33	patients	patient	NOUN
dpc-3647	131	34	with	with	ADP
dpc-3647	131	35	psoriasis	psoriasis	NOUN
dpc-3647	131	36	vulgaris	vulgaris	NOUN
dpc-3647	131	37	and	and	CCONJ
dpc-3647	131	38	psoriatic	psoriatic	ADJ
dpc-3647	131	39	arthritis	arthritis	NOUN
dpc-3647	131	40	.	.	PUNCT
dpc-3647	132	1	j	j	PROPN
dpc-3647	132	2	clin	clin	PROPN
dpc-3647	132	3	med	med	PROPN
dpc-3647	132	4	.	.	PUNCT
dpc-3647	133	1	2023;12(8):3046	2023;12(8):3046	NUM
dpc-3647	133	2	.	.	PUNCT
dpc-3647	134	1	doi	doi	NOUN
dpc-3647	134	2	:	:	PUNCT
dpc-3647	134	3	10.3390	10.3390	NUM
dpc-3647	134	4	/	/	SYM
dpc-3647	134	5	jcm12083046	jcm12083046	NOUN
dpc-3647	134	6	.	.	PUNCT
dpc-3647	135	1	pmid	pmid	NOUN
dpc-3647	135	2	:	:	PUNCT
dpc-3647	135	3	37109382	37109382	NUM
dpc-3647	135	4	.	.	PUNCT
dpc-3647	136	1	pmcid	pmcid	NOUN
dpc-3647	136	2	:	:	PUNCT
dpc-3647	136	3	pmc10145777	pmc10145777	PROPN
dpc-3647	136	4	.	.	PUNCT
dpc-3647	137	1	2	2	X
dpc-3647	137	2	.	.	X
dpc-3647	137	3	korman	korman	PROPN
dpc-3647	137	4	nj	nj	PROPN
dpc-3647	137	5	.	.	PUNCT
dpc-3647	138	1	management	management	NOUN
dpc-3647	138	2	of	of	ADP
dpc-3647	138	3	psoriasis	psoriasis	NOUN
dpc-3647	138	4	as	as	ADP
dpc-3647	138	5	a	a	DET
dpc-3647	138	6	systemic	systemic	ADJ
dpc-3647	138	7	disease	disease	NOUN
dpc-3647	138	8	:	:	PUNCT
dpc-3647	138	9	what	what	PRON
dpc-3647	138	10	is	be	AUX
dpc-3647	138	11	the	the	DET
dpc-3647	138	12	evidence	evidence	NOUN
dpc-3647	138	13	?	?	PUNCT
dpc-3647	139	1	br	br	PROPN
dpc-3647	139	2	j	j	PROPN
dpc-3647	139	3	dermatol	dermatol	NOUN
dpc-3647	139	4	.	.	PUNCT
dpc-3647	140	1	2020;182(4):840	2020;182(4):840	NUM
dpc-3647	140	2	-	-	SYM
dpc-3647	140	3	848	848	NUM
dpc-3647	140	4	.	.	PUNCT
dpc-3647	141	1	doi	doi	NOUN
dpc-3647	141	2	:	:	PUNCT
dpc-3647	141	3	10.1111	10.1111	NUM
dpc-3647	141	4	/	/	SYM
dpc-3647	141	5	bjd.18245	bjd.18245	PROPN
dpc-3647	141	6	.	.	PUNCT
dpc-3647	142	1	pmid	pmid	NOUN
dpc-3647	142	2	:	:	PUNCT
dpc-3647	142	3	31225638	31225638	NUM
dpc-3647	142	4	.	.	PUNCT
dpc-3647	142	5	 	 	SPACE
dpc-3647	143	1	pmcid	pmcid	ADJ
dpc-3647	143	2	:	:	PUNCT
dpc-3647	143	3	pmc7187293	pmc7187293	NOUN
dpc-3647	143	4	.	.	PUNCT
dpc-3647	144	1	3	3	X
dpc-3647	144	2	.	.	X
dpc-3647	144	3	tashiro	tashiro	PROPN
dpc-3647	144	4	t	t	PROPN
dpc-3647	144	5	,	,	PUNCT
dpc-3647	144	6	sawada	sawada	PROPN
dpc-3647	144	7	y.	y.	PROPN
dpc-3647	144	8	psoriasis	psoriasis	NOUN
dpc-3647	144	9	and	and	CCONJ
dpc-3647	144	10	systemic	systemic	ADJ
dpc-3647	144	11	inflammatory	inflammatory	ADJ
dpc-3647	144	12	disorders	disorder	NOUN
dpc-3647	144	13	.	.	PUNCT
dpc-3647	145	1	int	int	PROPN
dpc-3647	145	2	j	j	PROPN
dpc-3647	145	3	mol	mol	ADP
dpc-3647	145	4	sci	sci	PROPN
dpc-3647	145	5	.	.	PUNCT
dpc-3647	146	1	2022;23(8):4457	2022;23(8):4457	NUM
dpc-3647	146	2	.	.	PUNCT
dpc-3647	147	1	doi	doi	NOUN
dpc-3647	147	2	:	:	PUNCT
dpc-3647	147	3	10.3390	10.3390	NUM
dpc-3647	147	4	/ijms23084457	/ijms23084457	PUNCT
dpc-3647	147	5	.	.	PUNCT
dpc-3647	148	1	pmid	pmid	NOUN
dpc-3647	148	2	:	:	PUNCT
dpc-3647	148	3	35457278	35457278	NUM
dpc-3647	148	4	.	.	PUNCT
dpc-3647	149	1	pmcid	pmcid	NOUN
dpc-3647	149	2	:	:	PUNCT
dpc-3647	149	3	pmc9028262	pmc9028262	NOUN
dpc-3647	149	4	.	.	PUNCT
dpc-3647	150	1	adherence	adherence	NOUN
dpc-3647	150	2	to	to	ADP
dpc-3647	150	3	biological	biological	ADJ
dpc-3647	150	4	agent	agent	NOUN
dpc-3647	150	5	treatment	treatment	NOUN
dpc-3647	150	6	of	of	ADP
dpc-3647	150	7	patients	patient	NOUN
dpc-3647	150	8	with	with	ADP
dpc-3647	150	9	psoriasis	psoriasis	NOUN
dpc-3647	150	10	vulgaris	vulgaris	NOUN
dpc-3647	150	11	and	and	CCONJ
dpc-3647	150	12	psoriatic	psoriatic	ADJ
dpc-3647	150	13	arthritis	arthritis	NOUN
dpc-3647	150	14	was	be	AUX
dpc-3647	150	15	not	not	PART
dpc-3647	150	16	related	relate	VERB
dpc-3647	150	17	to	to	ADP
dpc-3647	150	18	high	high	ADJ
dpc-3647	150	19	sii	sii	ADJ
dpc-3647	150	20	or	or	CCONJ
dpc-3647	150	21	siri	siri	NOUN
dpc-3647	150	22	levels	level	NOUN
dpc-3647	150	23	[	[	X
dpc-3647	150	24	1	1	NUM
dpc-3647	150	25	]	]	PUNCT
dpc-3647	150	26	.	.	PUNCT
dpc-3647	151	1	within	within	ADP
dpc-3647	151	2	this	this	DET
dpc-3647	151	3	study	study	NOUN
dpc-3647	151	4	,	,	PUNCT
dpc-3647	151	5	sii	sii	PROPN
dpc-3647	151	6	was	be	AUX
dpc-3647	151	7	higher	high	ADJ
dpc-3647	151	8	in	in	ADP
dpc-3647	151	9	males	male	NOUN
dpc-3647	151	10	,	,	PUNCT
dpc-3647	151	11	obese	obese	ADJ
dpc-3647	151	12	patients	patient	NOUN
dpc-3647	151	13	,	,	PUNCT
dpc-3647	151	14	patients	patient	NOUN
dpc-3647	151	15	with	with	ADP
dpc-3647	151	16	severe	severe	ADJ
dpc-3647	151	17	psoriasis	psoriasis	NOUN
dpc-3647	151	18	and	and	CCONJ
dpc-3647	151	19	longer	long	ADJ
dpc-3647	151	20	disease	disease	NOUN
dpc-3647	151	21	duration	duration	NOUN
dpc-3647	151	22	,	,	PUNCT
dpc-3647	151	23	patients	patient	NOUN
dpc-3647	151	24	with	with	ADP
dpc-3647	151	25	psoriatic	psoriatic	ADJ
dpc-3647	151	26	arthritis	arthritis	NOUN
dpc-3647	151	27	,	,	PUNCT
dpc-3647	151	28	nail	nail	NOUN
dpc-3647	151	29	findings	finding	NOUN
dpc-3647	151	30	and	and	CCONJ
dpc-3647	151	31	patients	patient	NOUN
dpc-3647	151	32	who	who	PRON
dpc-3647	151	33	received	receive	VERB
dpc-3647	151	34	previous	previous	ADJ
dpc-3647	151	35	biological	biological	ADJ
dpc-3647	151	36	agent	agent	NOUN
dpc-3647	151	37	treatment	treatment	NOUN
dpc-3647	151	38	.	.	PUNCT
dpc-3647	152	1	sii	sii	PROPN
dpc-3647	152	2	was	be	AUX
dpc-3647	152	3	also	also	ADV
dpc-3647	152	4	higher	high	ADJ
dpc-3647	152	5	in	in	ADP
dpc-3647	152	6	patients	patient	NOUN
dpc-3647	152	7	with	with	ADP
dpc-3647	152	8	comorbidities	comorbiditie	NOUN
dpc-3647	152	9	such	such	ADJ
dpc-3647	152	10	as	as	ADP
dpc-3647	152	11	hypertension	hypertension	NOUN
dpc-3647	152	12	,	,	PUNCT
dpc-3647	152	13	diabetes	diabetes	NOUN
dpc-3647	152	14	,	,	PUNCT
dpc-3647	152	15	hepatic	hepatic	ADJ
dpc-3647	152	16	steatosis	steatosis	NOUN
dpc-3647	152	17	,	,	PUNCT
dpc-3647	152	18	depression	depression	NOUN
dpc-3647	152	19	and	and	CCONJ
dpc-3647	152	20	coronary	coronary	ADJ
dpc-3647	152	21	artery	artery	NOUN
dpc-3647	152	22	disease	disease	NOUN
dpc-3647	152	23	.	.	PUNCT
dpc-3647	153	1	on	on	ADP
dpc-3647	153	2	the	the	DET
dpc-3647	153	3	other	other	ADJ
dpc-3647	153	4	hand	hand	NOUN
dpc-3647	153	5	,	,	PUNCT
dpc-3647	153	6	siri	siri	NOUN
dpc-3647	153	7	was	be	AUX
dpc-3647	153	8	statistically	statistically	ADV
dpc-3647	153	9	significantly	significantly	ADV
dpc-3647	153	10	higher	high	ADJ
dpc-3647	153	11	in	in	ADP
dpc-3647	153	12	male	male	ADJ
dpc-3647	153	13	patients	patient	NOUN
dpc-3647	153	14	compared	compare	VERB
dpc-3647	153	15	to	to	ADP
dpc-3647	153	16	females	female	NOUN
dpc-3647	153	17	.	.	PUNCT
dpc-3647	154	1	this	this	DET
dpc-3647	154	2	result	result	NOUN
dpc-3647	154	3	may	may	AUX
dpc-3647	154	4	be	be	AUX
dpc-3647	154	5	related	relate	VERB
dpc-3647	154	6	to	to	PART
dpc-3647	154	7	longer	long	ADV
dpc-3647	154	8	psoriasis	psoriasis	VERB
dpc-3647	154	9	duration	duration	NOUN
dpc-3647	154	10	in	in	ADP
dpc-3647	154	11	male	male	ADJ
dpc-3647	154	12	patients	patient	NOUN
dpc-3647	154	13	than	than	ADP
dpc-3647	154	14	in	in	ADP
dpc-3647	154	15	females	female	NOUN
dpc-3647	154	16	.	.	PUNCT
dpc-3647	155	1	siri	siri	NOUN
dpc-3647	155	2	was	be	AUX
dpc-3647	155	3	also	also	ADV
dpc-3647	155	4	higher	high	ADJ
dpc-3647	155	5	in	in	ADP
dpc-3647	155	6	obese	obese	ADJ
dpc-3647	155	7	patients	patient	NOUN
dpc-3647	155	8	,	,	PUNCT
dpc-3647	155	9	patients	patient	NOUN
dpc-3647	155	10	with	with	ADP
dpc-3647	155	11	severe	severe	ADJ
dpc-3647	155	12	psoriasis	psoriasis	NOUN
dpc-3647	155	13	,	,	PUNCT
dpc-3647	155	14	longer	long	ADV
dpc-3647	155	15	disease	disease	VERB
dpc-3647	155	16	duration	duration	NOUN
dpc-3647	155	17	and	and	CCONJ
dpc-3647	155	18	nail	nail	NOUN
dpc-3647	155	19	involvement	involvement	NOUN
dpc-3647	155	20	and	and	CCONJ
dpc-3647	155	21	patients	patient	NOUN
dpc-3647	155	22	who	who	PRON
dpc-3647	155	23	received	receive	VERB
dpc-3647	155	24	previous	previous	ADJ
dpc-3647	155	25	biological	biological	ADJ
dpc-3647	155	26	agent	agent	NOUN
dpc-3647	155	27	treatment	treatment	NOUN
dpc-3647	155	28	.	.	PUNCT
dpc-3647	156	1	in	in	ADP
dpc-3647	156	2	addition	addition	NOUN
dpc-3647	156	3	,	,	PUNCT
dpc-3647	156	4	siri	siri	NOUN
dpc-3647	156	5	was	be	AUX
dpc-3647	156	6	higher	high	ADJ
dpc-3647	156	7	in	in	ADP
dpc-3647	156	8	patients	patient	NOUN
dpc-3647	156	9	with	with	ADP
dpc-3647	156	10	comorbidities	comorbiditie	NOUN
dpc-3647	156	11	such	such	ADJ
dpc-3647	156	12	as	as	ADP
dpc-3647	156	13	diabetes	diabetes	NOUN
dpc-3647	156	14	and	and	CCONJ
dpc-3647	156	15	depression	depression	NOUN
dpc-3647	156	16	.	.	PUNCT
dpc-3647	157	1	sii	sii	PROPN
dpc-3647	157	2	and	and	CCONJ
dpc-3647	157	3	siri	siri	NOUN
dpc-3647	157	4	were	be	AUX
dpc-3647	157	5	similar	similar	ADJ
dpc-3647	157	6	in	in	ADP
dpc-3647	157	7	patients	patient	NOUN
dpc-3647	157	8	with	with	ADP
dpc-3647	157	9	psoriasis	psoriasis	NOUN
dpc-3647	157	10	vulgaris	vulgaris	NOUN
dpc-3647	157	11	and	and	CCONJ
dpc-3647	157	12	in	in	ADP
dpc-3647	157	13	patients	patient	NOUN
dpc-3647	157	14	with	with	ADP
dpc-3647	157	15	other	other	ADJ
dpc-3647	157	16	types	type	NOUN
dpc-3647	157	17	of	of	ADP
dpc-3647	157	18	psoriasis	psoriasis	NOUN
dpc-3647	157	19	.	.	PUNCT
dpc-3647	158	1	both	both	PRON
dpc-3647	158	2	sii	sii	ADJ
dpc-3647	158	3	and	and	CCONJ
dpc-3647	158	4	siri	siri	NOUN
dpc-3647	158	5	significantly	significantly	ADV
dpc-3647	158	6	decreased	decrease	VERB
dpc-3647	158	7	after	after	ADP
dpc-3647	158	8	treatment	treatment	NOUN
dpc-3647	158	9	with	with	ADP
dpc-3647	158	10	tnf	tnf	PROPN
dpc-3647	158	11	-	-	PUNCT
dpc-3647	158	12	α	α	NOUN
dpc-3647	158	13	inhibitors	inhibitor	NOUN
dpc-3647	158	14	such	such	ADJ
dpc-3647	158	15	as	as	ADP
dpc-3647	158	16	adalimumab	adalimumab	NOUN
dpc-3647	158	17	and	and	CCONJ
dpc-3647	158	18	infliximab	infliximab	NOUN
dpc-3647	158	19	,	,	PUNCT
dpc-3647	158	20	il-17	il-17	ADV
dpc-3647	158	21	inhibitors	inhibitor	NOUN
dpc-3647	158	22	such	such	ADJ
dpc-3647	158	23	as	as	ADP
dpc-3647	158	24	ixekizumab	ixekizumab	NOUN
dpc-3647	158	25	and	and	CCONJ
dpc-3647	158	26	secukinumab	secukinumab	NOUN
dpc-3647	158	27	,	,	PUNCT
dpc-3647	158	28	il-23	il-23	ADJ
dpc-3647	158	29	inhibitor	inhibitor	NOUN
dpc-3647	158	30	such	such	ADJ
dpc-3647	158	31	as	as	ADP
dpc-3647	158	32	risankizumab	risankizumab	NOUN
dpc-3647	158	33	,	,	PUNCT
dpc-3647	158	34	as	as	ADV
dpc-3647	158	35	well	well	ADV
dpc-3647	158	36	as	as	ADP
dpc-3647	158	37	ustekinumab	ustekinumab	NOUN
dpc-3647	158	38	.	.	PUNCT
dpc-3647	159	1	our	our	PRON
dpc-3647	159	2	results	result	NOUN
dpc-3647	159	3	revealed	reveal	VERB
dpc-3647	159	4	that	that	SCONJ
dpc-3647	159	5	both	both	CCONJ
dpc-3647	159	6	sii	sii	ADJ
dpc-3647	159	7	and	and	CCONJ
dpc-3647	159	8	siri	siri	NOUN
dpc-3647	159	9	might	might	AUX
dpc-3647	159	10	indicate	indicate	VERB
dpc-3647	159	11	severity	severity	NOUN
dpc-3647	159	12	of	of	ADP
dpc-3647	159	13	psoriasis	psoriasis	NOUN
dpc-3647	159	14	,	,	PUNCT
dpc-3647	159	15	however	however	ADV
dpc-3647	159	16	,	,	PUNCT
dpc-3647	159	17	sii	sii	PROPN
dpc-3647	159	18	might	might	AUX
dpc-3647	159	19	also	also	ADV
dpc-3647	159	20	be	be	AUX
dpc-3647	159	21	associated	associate	VERB
dpc-3647	159	22	with	with	ADP
dpc-3647	159	23	psoriatic	psoriatic	ADJ
dpc-3647	159	24	arthritis	arthritis	NOUN
dpc-3647	159	25	.	.	PUNCT
dpc-3647	160	1	furthermore	furthermore	ADV
dpc-3647	160	2	,	,	PUNCT
dpc-3647	160	3	sii	sii	PROPN
dpc-3647	160	4	may	may	AUX
dpc-3647	160	5	be	be	AUX
dpc-3647	160	6	associated	associate	VERB
dpc-3647	160	7	with	with	ADP
dpc-3647	160	8	hypertension	hypertension	NOUN
dpc-3647	160	9	,	,	PUNCT
dpc-3647	160	10	diabetes	diabetes	NOUN
dpc-3647	160	11	,	,	PUNCT
dpc-3647	160	12	hepatic	hepatic	ADJ
dpc-3647	160	13	steatosis	steatosis	NOUN
dpc-3647	160	14	,	,	PUNCT
dpc-3647	160	15	depression	depression	NOUN
dpc-3647	160	16	and	and	CCONJ
dpc-3647	160	17	coronary	coronary	ADJ
dpc-3647	160	18	artery	artery	NOUN
dpc-3647	160	19	disease	disease	NOUN
dpc-3647	160	20	in	in	ADP
dpc-3647	160	21	patients	patient	NOUN
dpc-3647	160	22	with	with	ADP
dpc-3647	160	23	psoriasis	psoriasis	NOUN
dpc-3647	160	24	,	,	PUNCT
dpc-3647	160	25	whereas	whereas	SCONJ
dpc-3647	160	26	siri	siri	NOUN
dpc-3647	160	27	with	with	ADP
dpc-3647	160	28	diabetes	diabetes	NOUN
dpc-3647	160	29	and	and	CCONJ
dpc-3647	160	30	depression	depression	NOUN
dpc-3647	160	31	.	.	PUNCT
dpc-3647	161	1	treatment	treatment	NOUN
dpc-3647	161	2	figure	figure	NOUN
dpc-3647	161	3	2	2	NUM
dpc-3647	161	4	.	.	PUNCT
dpc-3647	162	1	the	the	DET
dpc-3647	162	2	effect	effect	NOUN
dpc-3647	162	3	of	of	ADP
dpc-3647	162	4	biological	biological	ADJ
dpc-3647	162	5	agents	agent	NOUN
dpc-3647	162	6	on	on	ADP
dpc-3647	162	7	systemic	systemic	ADJ
dpc-3647	162	8	inflammation	inflammation	ADJ
dpc-3647	162	9	response	response	NOUN
dpc-3647	162	10	index	index	NOUN
dpc-3647	162	11	.	.	PUNCT
dpc-3647	163	1	systemic	systemic	ADJ
dpc-3647	163	2	inflammation	inflammation	ADJ
dpc-3647	163	3	response	response	NOUN
dpc-3647	163	4	index	index	NOUN
dpc-3647	163	5	decreased	decrease	VERB
dpc-3647	163	6	in	in	ADP
dpc-3647	163	7	all	all	DET
dpc-3647	163	8	treatment	treatment	NOUN
dpc-3647	163	9	groups	group	NOUN
dpc-3647	163	10	.	.	PUNCT
dpc-3647	164	1	original	original	ADJ
dpc-3647	164	2	article	article	NOUN
dpc-3647	164	3	|	|	ADV
dpc-3647	164	4	dermatol	dermatol	ADJ
dpc-3647	164	5	pract	pract	NOUN
dpc-3647	164	6	concept	concept	NOUN
dpc-3647	164	7	.	.	PUNCT
dpc-3647	165	1	2024;14(1):e2024065	2024;14(1):e2024065	NUM
dpc-3647	165	2	7	7	NUM
dpc-3647	165	3	higher	high	ADJ
dpc-3647	165	4	cardiovascular	cardiovascular	ADJ
dpc-3647	165	5	risk	risk	NOUN
dpc-3647	165	6	according	accord	VERB
dpc-3647	165	7	to	to	ADP
dpc-3647	165	8	seven	seven	NUM
dpc-3647	165	9	risk	risk	NOUN
dpc-3647	165	10	algorithms	algorithm	NOUN
dpc-3647	165	11	:	:	PUNCT
dpc-3647	165	12	results	result	NOUN
dpc-3647	165	13	of	of	ADP
dpc-3647	165	14	a	a	DET
dpc-3647	165	15	10	10	NUM
dpc-3647	165	16	-	-	PUNCT
dpc-3647	165	17	year	year	NOUN
dpc-3647	165	18	single	single	ADJ
dpc-3647	165	19	-	-	PUNCT
dpc-3647	165	20	center	center	NOUN
dpc-3647	165	21	retrospective	retrospective	ADJ
dpc-3647	165	22	study	study	NOUN
dpc-3647	165	23	and	and	CCONJ
dpc-3647	165	24	clinical	clinical	ADJ
dpc-3647	165	25	management	management	NOUN
dpc-3647	165	26	of	of	ADP
dpc-3647	165	27	psoriatic	psoriatic	ADJ
dpc-3647	165	28	patients	patient	NOUN
dpc-3647	165	29	with	with	ADP
dpc-3647	165	30	cardiovascular	cardiovascular	ADJ
dpc-3647	165	31	risk	risk	NOUN
dpc-3647	165	32	.	.	PUNCT
dpc-3647	166	1	dermatol	dermatol	NOUN
dpc-3647	166	2	ther	ther	ADV
dpc-3647	166	3	.	.	PUNCT
dpc-3647	167	1	2020;33(6):14451	2020;33(6):14451	NUM
dpc-3647	167	2	.	.	PUNCT
dpc-3647	168	1	doi	doi	NOUN
dpc-3647	168	2	:	:	PUNCT
dpc-3647	168	3	10.1111	10.1111	NUM
dpc-3647	168	4	/	/	SYM
dpc-3647	168	5	dth.14451	dth.14451	NOUN
dpc-3647	168	6	.	.	PUNCT
dpc-3647	169	1	pmid	pmid	NOUN
dpc-3647	169	2	:	:	PUNCT
dpc-3647	169	3	33098612	33098612	NUM
dpc-3647	169	4	.	.	PUNCT
dpc-3647	170	1	13	13	NUM
dpc-3647	170	2	.	.	PUNCT
dpc-3647	171	1	liu	liu	PROPN
dpc-3647	171	2	n	n	PROPN
dpc-3647	171	3	,	,	PUNCT
dpc-3647	171	4	birstler	birstler	PROPN
dpc-3647	171	5	j	j	PROPN
dpc-3647	171	6	,	,	PUNCT
dpc-3647	171	7	venkatesh	venkatesh	PROPN
dpc-3647	171	8	m	m	PROPN
dpc-3647	171	9	,	,	PUNCT
dpc-3647	171	10	hanrahan	hanrahan	PROPN
dpc-3647	171	11	l	l	PROPN
dpc-3647	171	12	,	,	PUNCT
dpc-3647	171	13	chen	chen	PROPN
dpc-3647	171	14	g	g	PROPN
dpc-3647	171	15	,	,	PUNCT
dpc-3647	171	16	funk	funk	NOUN
dpc-3647	171	17	l.	l.	NOUN
dpc-3647	171	18	obesity	obesity	NOUN
dpc-3647	171	19	and	and	CCONJ
dpc-3647	171	20	bmi	bmi	PROPN
dpc-3647	171	21	cut	cut	VERB
dpc-3647	171	22	points	point	NOUN
dpc-3647	171	23	for	for	ADP
dpc-3647	171	24	associated	associated	ADJ
dpc-3647	171	25	comorbidities	comorbiditie	NOUN
dpc-3647	171	26	:	:	PUNCT
dpc-3647	171	27	electronic	electronic	ADJ
dpc-3647	171	28	health	health	NOUN
dpc-3647	171	29	record	record	NOUN
dpc-3647	171	30	study	study	NOUN
dpc-3647	171	31	.	.	PUNCT
dpc-3647	172	1	j	j	PROPN
dpc-3647	172	2	med	med	PROPN
dpc-3647	172	3	internet	internet	NOUN
dpc-3647	172	4	res	re	NOUN
dpc-3647	172	5	.	.	PUNCT
dpc-3647	173	1	2021;23(8):24017	2021;23(8):24017	NUM
dpc-3647	173	2	.	.	PUNCT
dpc-3647	174	1	doi	doi	NOUN
dpc-3647	174	2	:	:	PUNCT
dpc-3647	174	3	10.2196/24017	10.2196/24017	NUM
dpc-3647	174	4	.	.	PUNCT
dpc-3647	175	1	pmid	pmid	NOUN
dpc-3647	175	2	:	:	PUNCT
dpc-3647	175	3	34383661	34383661	NUM
dpc-3647	175	4	.	.	PUNCT
dpc-3647	176	1	pmcid	pmcid	NOUN
dpc-3647	176	2	:	:	PUNCT
dpc-3647	176	3	pmc8386370	pmc8386370	NOUN
dpc-3647	176	4	.	.	PUNCT
dpc-3647	177	1	14	14	NUM
dpc-3647	177	2	.	.	PUNCT
dpc-3647	178	1	he	he	PRON
dpc-3647	178	2	l	l	PROPN
dpc-3647	178	3	,	,	PUNCT
dpc-3647	178	4	xie	xie	PROPN
dpc-3647	178	5	x	x	PROPN
dpc-3647	178	6	,	,	PUNCT
dpc-3647	178	7	xue	xue	PROPN
dpc-3647	178	8	j	j	PROPN
dpc-3647	178	9	,	,	PUNCT
dpc-3647	178	10	xie	xie	PROPN
dpc-3647	178	11	h	h	PROPN
dpc-3647	178	12	,	,	PUNCT
dpc-3647	178	13	zhang	zhang	PROPN
dpc-3647	178	14	y.	y.	PROPN
dpc-3647	178	15	association	association	PROPN
dpc-3647	178	16	of	of	ADP
dpc-3647	178	17	the	the	DET
dpc-3647	178	18	systemic	systemic	ADJ
dpc-3647	178	19	immune	immune	ADJ
dpc-3647	178	20	-	-	PUNCT
dpc-3647	178	21	inflammation	inflammation	NOUN
dpc-3647	178	22	index	index	NOUN
dpc-3647	178	23	with	with	ADP
dpc-3647	178	24	all	all	DET
dpc-3647	178	25	-	-	PUNCT
dpc-3647	178	26	cause	cause	NOUN
dpc-3647	178	27	mortality	mortality	NOUN
dpc-3647	178	28	in	in	ADP
dpc-3647	178	29	patients	patient	NOUN
dpc-3647	178	30	with	with	ADP
dpc-3647	178	31	arteriosclerotic	arteriosclerotic	ADJ
dpc-3647	178	32	cardiovascular	cardiovascular	ADJ
dpc-3647	178	33	disease	disease	NOUN
dpc-3647	178	34	.	.	PUNCT
dpc-3647	179	1	front	front	PROPN
dpc-3647	179	2	cardiovasc	cardiovasc	PROPN
dpc-3647	179	3	med	me	VERB
dpc-3647	179	4	.	.	PUNCT
dpc-3647	180	1	2022;9:952953	2022;9:952953	NUM
dpc-3647	180	2	.	.	PUNCT
dpc-3647	181	1	doi	doi	NOUN
dpc-3647	181	2	:	:	PUNCT
dpc-3647	181	3	10.3389	10.3389	NUM
dpc-3647	181	4	/	/	SYM
dpc-3647	181	5	fcvm.2022.952953	fcvm.2022.952953	PROPN
dpc-3647	181	6	.	.	PUNCT
dpc-3647	182	1	pmid	pmid	NOUN
dpc-3647	182	2	:	:	PUNCT
dpc-3647	182	3	36172591	36172591	NUM
dpc-3647	182	4	.	.	PUNCT
dpc-3647	182	5	 	 	SPACE
dpc-3647	183	1	pmcid	pmcid	NOUN
dpc-3647	183	2	:	:	PUNCT
dpc-3647	183	3	pmc9510918	pmc9510918	NOUN
dpc-3647	183	4	.	.	PUNCT
dpc-3647	184	1	15	15	NUM
dpc-3647	184	2	.	.	PUNCT
dpc-3647	184	3	han	han	PROPN
dpc-3647	184	4	k	k	PROPN
dpc-3647	184	5	,	,	PUNCT
dpc-3647	184	6	shi	shi	PROPN
dpc-3647	184	7	d	d	PROPN
dpc-3647	184	8	,	,	PUNCT
dpc-3647	184	9	yang	yang	PROPN
dpc-3647	184	10	l	l	PROPN
dpc-3647	184	11	,	,	PUNCT
dpc-3647	184	12	et	et	PROPN
dpc-3647	184	13	al	al	PROPN
dpc-3647	184	14	.	.	PUNCT
dpc-3647	185	1	prognostic	prognostic	ADJ
dpc-3647	185	2	value	value	NOUN
dpc-3647	185	3	of	of	ADP
dpc-3647	185	4	systemic	systemic	ADJ
dpc-3647	185	5	inflammatory	inflammatory	ADJ
dpc-3647	185	6	response	response	NOUN
dpc-3647	185	7	index	index	NOUN
dpc-3647	185	8	in	in	ADP
dpc-3647	185	9	patients	patient	NOUN
dpc-3647	185	10	with	with	ADP
dpc-3647	185	11	acute	acute	ADJ
dpc-3647	185	12	coronary	coronary	ADJ
dpc-3647	185	13	syndrome	syndrome	NOUN
dpc-3647	185	14	undergoing	undergo	VERB
dpc-3647	185	15	percutaneous	percutaneous	ADJ
dpc-3647	185	16	coronary	coronary	ADJ
dpc-3647	185	17	intervention	intervention	NOUN
dpc-3647	185	18	.	.	PUNCT
dpc-3647	186	1	ann	ann	PROPN
dpc-3647	186	2	med	med	PROPN
dpc-3647	186	3	.	.	PUNCT
dpc-3647	187	1	2022;54(1):1667	2022;54(1):1667	NUM
dpc-3647	187	2	-	-	PUNCT
dpc-3647	187	3	1677	1677	NUM
dpc-3647	187	4	.	.	PUNCT
dpc-3647	188	1	doi	doi	NOUN
dpc-3647	188	2	:	:	PUNCT
dpc-3647	188	3	10.1080/07853890.2022.2083671	10.1080/07853890.2022.2083671	NUM
dpc-3647	188	4	.	.	PUNCT
dpc-3647	189	1	pmid	pmid	NOUN
dpc-3647	189	2	:	:	PUNCT
dpc-3647	189	3	35695557	35695557	NUM
dpc-3647	189	4	.	.	PUNCT
dpc-3647	190	1	pmcid	pmcid	NOUN
dpc-3647	190	2	:	:	PUNCT
dpc-3647	190	3	pmc9225721	pmc9225721	NOUN
dpc-3647	190	4	.	.	PUNCT
dpc-3647	191	1	16	16	NUM
dpc-3647	191	2	.	.	PUNCT
dpc-3647	192	1	melikoglu	melikoglu	PROPN
dpc-3647	192	2	m	m	PROPN
dpc-3647	192	3	,	,	PUNCT
dpc-3647	192	4	pala	pala	PROPN
dpc-3647	192	5	e.	e.	PROPN
dpc-3647	192	6	systemic	systemic	PROPN
dpc-3647	192	7	immune	immune	PROPN
dpc-3647	192	8	-	-	PUNCT
dpc-3647	192	9	inflammation	inflammation	NOUN
dpc-3647	192	10	index	index	NOUN
dpc-3647	192	11	as	as	ADP
dpc-3647	192	12	a	a	DET
dpc-3647	192	13	biomarker	biomarker	NOUN
dpc-3647	192	14	of	of	ADP
dpc-3647	192	15	psoriasis	psoriasis	NOUN
dpc-3647	192	16	severity	severity	NOUN
dpc-3647	192	17	.	.	PUNCT
dpc-3647	193	1	arch	arch	ADJ
dpc-3647	193	2	basic	basic	ADJ
dpc-3647	193	3	clin	clin	PROPN
dpc-3647	193	4	res	re	NOUN
dpc-3647	193	5	.	.	PUNCT
dpc-3647	194	1	2023;5(2):291	2023;5(2):291	NUM
dpc-3647	194	2	-	-	SYM
dpc-3647	194	3	295	295	NUM
dpc-3647	194	4	.	.	PUNCT
dpc-3647	195	1	doi	doi	NOUN
dpc-3647	195	2	:	:	PUNCT
dpc-3647	195	3	10.5152	10.5152	NUM
dpc-3647	195	4	/	/	SYM
dpc-3647	195	5	abcr.2023.22124	abcr.2023.22124	NOUN
dpc-3647	195	6	.	.	PUNCT
dpc-3647	196	1	17	17	NUM
dpc-3647	196	2	.	.	PUNCT
dpc-3647	197	1	ibrahim	ibrahim	PROPN
dpc-3647	197	2	sh	sh	PROPN
dpc-3647	197	3	,	,	PUNCT
dpc-3647	197	4	guan	guan	PROPN
dpc-3647	197	5	m	m	PROPN
dpc-3647	197	6	,	,	PUNCT
dpc-3647	197	7	li	li	PROPN
dpc-3647	197	8	s.	s.	PROPN
dpc-3647	197	9	systemic	systemic	ADJ
dpc-3647	197	10	immune	immune	ADJ
dpc-3647	197	11	inflammatory	inflammatory	ADJ
dpc-3647	197	12	index	index	NOUN
dpc-3647	197	13	is	be	AUX
dpc-3647	197	14	associated	associate	VERB
dpc-3647	197	15	with	with	ADP
dpc-3647	197	16	pustular	pustular	ADJ
dpc-3647	197	17	psoriasis	psoriasis	NOUN
dpc-3647	197	18	:	:	PUNCT
dpc-3647	197	19	a	a	DET
dpc-3647	197	20	single	single	ADJ
dpc-3647	197	21	center	center	NOUN
dpc-3647	197	22	retrospective	retrospective	ADJ
dpc-3647	197	23	study	study	NOUN
dpc-3647	197	24	.	.	PUNCT
dpc-3647	198	1	j	j	PROPN
dpc-3647	198	2	cosmet	cosmet	VERB
dpc-3647	198	3	dermatol	dermatol	NOUN
dpc-3647	198	4	sci	sci	PROPN
dpc-3647	198	5	appl	appl	NOUN
dpc-3647	198	6	.	.	PUNCT
dpc-3647	199	1	2022;12(4):174	2022;12(4):174	NUM
dpc-3647	199	2	-	-	PUNCT
dpc-3647	199	3	186	186	NUM
dpc-3647	199	4	.	.	PUNCT
dpc-3647	200	1	doi	doi	NOUN
dpc-3647	200	2	:	:	PUNCT
dpc-3647	200	3	10.4236	10.4236	NUM
dpc-3647	200	4	/	/	SYM
dpc-3647	200	5	jcdsa.2022.124015	jcdsa.2022.124015	NOUN
dpc-3647	200	6	.	.	PUNCT
dpc-3647	201	1	18	18	NUM
dpc-3647	201	2	.	.	PUNCT
dpc-3647	202	1	kelesoglu	kelesoglu	PROPN
dpc-3647	202	2	dincer	dincer	PROPN
dpc-3647	202	3	ab	ab	PROPN
dpc-3647	202	4	,	,	PUNCT
dpc-3647	202	5	sezer	sezer	PROPN
dpc-3647	202	6	s.	s.	PROPN
dpc-3647	202	7	systemic	systemic	ADJ
dpc-3647	202	8	immune	immune	ADJ
dpc-3647	202	9	inflammation	inflammation	ADJ
dpc-3647	202	10	index	index	NOUN
dpc-3647	202	11	as	as	ADP
dpc-3647	202	12	a	a	DET
dpc-3647	202	13	reliable	reliable	ADJ
dpc-3647	202	14	disease	disease	NOUN
dpc-3647	202	15	activity	activity	NOUN
dpc-3647	202	16	marker	marker	NOUN
dpc-3647	202	17	in	in	ADP
dpc-3647	202	18	psoriatic	psoriatic	ADJ
dpc-3647	202	19	arthritis	arthritis	NOUN
dpc-3647	202	20	.	.	PUNCT
dpc-3647	203	1	j	j	PROPN
dpc-3647	203	2	coll	coll	PROPN
dpc-3647	203	3	physicians	physicians	PROPN
dpc-3647	203	4	surg	surg	PROPN
dpc-3647	203	5	pak	pak	PROPN
dpc-3647	203	6	.	.	PUNCT
dpc-3647	204	1	2022;32(6):773	2022;32(6):773	NUM
dpc-3647	204	2	-	-	PUNCT
dpc-3647	204	3	778	778	PROPN
dpc-3647	204	4	.	.	PUNCT
dpc-3647	205	1	doi	doi	NOUN
dpc-3647	205	2	:	:	PUNCT
dpc-3647	205	3	10.29271	10.29271	NUM
dpc-3647	205	4	/jcpsp.2022.06.773	/jcpsp.2022.06.773	NOUN
dpc-3647	205	5	.	.	PUNCT
dpc-3647	206	1	pmid	pmid	NOUN
dpc-3647	206	2	:	:	PUNCT
dpc-3647	206	3	35686411	35686411	NUM
dpc-3647	206	4	.	.	PUNCT
dpc-3647	207	1	19	19	NUM
dpc-3647	207	2	.	.	PUNCT
dpc-3647	207	3	ramessur	ramessur	PROPN
dpc-3647	207	4	r	r	NOUN
dpc-3647	207	5	,	,	PUNCT
dpc-3647	207	6	corbett	corbett	PROPN
dpc-3647	207	7	m	m	PROPN
dpc-3647	207	8	,	,	PUNCT
dpc-3647	207	9	marshall	marshall	PROPN
dpc-3647	207	10	d	d	PROPN
dpc-3647	207	11	,	,	PUNCT
dpc-3647	207	12	et	et	PROPN
dpc-3647	207	13	al	al	PROPN
dpc-3647	207	14	.	.	PUNCT
dpc-3647	208	1	biomarkers	biomarker	NOUN
dpc-3647	208	2	of	of	ADP
dpc-3647	208	3	disease	disease	NOUN
dpc-3647	208	4	progression	progression	NOUN
dpc-3647	208	5	in	in	ADP
dpc-3647	208	6	people	people	NOUN
dpc-3647	208	7	with	with	ADP
dpc-3647	208	8	psoriasis	psoriasis	NOUN
dpc-3647	208	9	:	:	PUNCT
dpc-3647	208	10	a	a	DET
dpc-3647	208	11	scoping	scope	VERB
dpc-3647	208	12	review	review	NOUN
dpc-3647	208	13	.	.	PUNCT
dpc-3647	209	1	br	br	PROPN
dpc-3647	209	2	j	j	PROPN
dpc-3647	209	3	dermatol	dermatol	NOUN
dpc-3647	209	4	.	.	PUNCT
dpc-3647	210	1	2022;187(4):481	2022;187(4):481	NUM
dpc-3647	210	2	-	-	SYM
dpc-3647	210	3	493	493	NUM
dpc-3647	210	4	.	.	PUNCT
dpc-3647	211	1	doi	doi	NOUN
dpc-3647	211	2	:	:	PUNCT
dpc-3647	211	3	10.1111	10.1111	NUM
dpc-3647	211	4	/	/	SYM
dpc-3647	211	5	bjd.21627.pmid	bjd.21627.pmid	NOUN
dpc-3647	211	6	:	:	PUNCT
dpc-3647	211	7	35482474	35482474	NUM
dpc-3647	211	8	.	.	PUNCT
dpc-3647	212	1	pmcid	pmcid	ADJ
dpc-3647	212	2	:	:	PUNCT
dpc-3647	212	3	pmc9796834	pmc9796834	NOUN
dpc-3647	212	4	.	.	PUNCT
dpc-3647	213	1	20	20	NUM
dpc-3647	213	2	.	.	X
dpc-3647	214	1	molteni	molteni	PROPN
dpc-3647	214	2	re	re	PROPN
dpc-3647	214	3	.	.	PUNCT
dpc-3647	214	4	biomarkers	biomarker	NOUN
dpc-3647	214	5	in	in	ADP
dpc-3647	214	6	the	the	DET
dpc-3647	214	7	pathogenesis	pathogenesis	NOUN
dpc-3647	214	8	,	,	PUNCT
dpc-3647	214	9	diagnosis	diagnosis	NOUN
dpc-3647	214	10	,	,	PUNCT
dpc-3647	214	11	and	and	CCONJ
dpc-3647	214	12	treatment	treatment	NOUN
dpc-3647	214	13	of	of	ADP
dpc-3647	214	14	psoriasis	psoriasis	NOUN
dpc-3647	214	15	.	.	PUNCT
dpc-3647	215	1	psoriasis	psoriasis	NOUN
dpc-3647	215	2	(	(	PUNCT
dpc-3647	215	3	auckl	auckl	NOUN
dpc-3647	215	4	)	)	PUNCT
dpc-3647	215	5	.	.	PUNCT
dpc-3647	216	1	2012;2:55	2012;2:55	NOUN
dpc-3647	216	2	-	-	PUNCT
dpc-3647	216	3	66	66	NUM
dpc-3647	216	4	.	.	PUNCT
dpc-3647	217	1	doi	doi	NOUN
dpc-3647	217	2	:	:	PUNCT
dpc-3647	217	3	10.2147	10.2147	NUM
dpc-3647	217	4	/	/	SYM
dpc-3647	217	5	ptt.s24995	ptt.s24995	NOUN
dpc-3647	217	6	.	.	PUNCT
dpc-3647	218	1	21	21	NUM
dpc-3647	218	2	.	.	PUNCT
dpc-3647	219	1	jiménez	jiménez	PROPN
dpc-3647	219	2	c	c	PROPN
dpc-3647	219	3	,	,	PUNCT
dpc-3647	219	4	bordagaray	bordagaray	PROPN
dpc-3647	219	5	mj	mj	PROPN
dpc-3647	219	6	,	,	PUNCT
dpc-3647	219	7	villarroel	villarroel	PROPN
dpc-3647	219	8	jl	jl	PROPN
dpc-3647	219	9	,	,	PUNCT
dpc-3647	219	10	et	et	PROPN
dpc-3647	219	11	al	al	PROPN
dpc-3647	219	12	.	.	PUNCT
dpc-3647	219	13	biomarkers	biomarker	NOUN
dpc-3647	219	14	in	in	ADP
dpc-3647	219	15	oral	oral	ADJ
dpc-3647	219	16	fluids	fluid	NOUN
dpc-3647	219	17	as	as	ADP
dpc-3647	219	18	diagnostic	diagnostic	ADJ
dpc-3647	219	19	tool	tool	NOUN
dpc-3647	219	20	for	for	ADP
dpc-3647	219	21	psoriasis	psoriasis	NOUN
dpc-3647	219	22	.	.	PUNCT
dpc-3647	220	1	life	life	NOUN
dpc-3647	220	2	.	.	PUNCT
dpc-3647	221	1	2022;12(4):501	2022;12(4):501	NUM
dpc-3647	221	2	.	.	PUNCT
dpc-3647	222	1	doi	doi	NOUN
dpc-3647	222	2	:	:	PUNCT
dpc-3647	222	3	10.3390	10.3390	NUM
dpc-3647	222	4	/	/	SYM
dpc-3647	222	5	life12040501	life12040501	PROPN
dpc-3647	222	6	.	.	PUNCT
dpc-3647	223	1	pmid	pmid	NOUN
dpc-3647	223	2	:	:	PUNCT
dpc-3647	223	3	35454992	35454992	NUM
dpc-3647	223	4	.	.	PUNCT
dpc-3647	223	5	  	  	SPACE
dpc-3647	224	1	pmcid	pmcid	ADJ
dpc-3647	224	2	:	:	PUNCT
dpc-3647	224	3	pmc9027180	pmc9027180	NOUN
dpc-3647	224	4	.	.	PUNCT
dpc-3647	225	1	4	4	X
dpc-3647	225	2	.	.	X
dpc-3647	225	3	wu	wu	PROPN
dpc-3647	225	4	jj	jj	PROPN
dpc-3647	225	5	,	,	PUNCT
dpc-3647	225	6	kavanaugh	kavanaugh	PROPN
dpc-3647	225	7	a	a	PROPN
dpc-3647	225	8	,	,	PUNCT
dpc-3647	225	9	lebwohl	lebwohl	ADJ
dpc-3647	225	10	mg	mg	PROPN
dpc-3647	225	11	,	,	PUNCT
dpc-3647	225	12	gniadecki	gniadecki	NOUN
dpc-3647	225	13	r	r	NOUN
dpc-3647	225	14	,	,	PUNCT
dpc-3647	225	15	merola	merola	PROPN
dpc-3647	225	16	jf	jf	PROPN
dpc-3647	225	17	.	.	PUNCT
dpc-3647	226	1	psoriasis	psoriasis	NOUN
dpc-3647	226	2	and	and	CCONJ
dpc-3647	226	3	metabolic	metabolic	NOUN
dpc-3647	226	4	syndrome	syndrome	NOUN
dpc-3647	226	5	:	:	PUNCT
dpc-3647	226	6	implications	implication	NOUN
dpc-3647	226	7	for	for	ADP
dpc-3647	226	8	the	the	DET
dpc-3647	226	9	management	management	NOUN
dpc-3647	226	10	and	and	CCONJ
dpc-3647	226	11	treatment	treatment	NOUN
dpc-3647	226	12	of	of	ADP
dpc-3647	226	13	psoriasis	psoriasis	NOUN
dpc-3647	226	14	.	.	PUNCT
dpc-3647	227	1	j	j	PROPN
dpc-3647	227	2	eur	eur	PROPN
dpc-3647	227	3	acad	acad	PROPN
dpc-3647	227	4	dermatol	dermatol	NOUN
dpc-3647	227	5	venereol	venereol	NOUN
dpc-3647	227	6	.	.	PUNCT
dpc-3647	228	1	2022;36(6):797	2022;36(6):797	NUM
dpc-3647	228	2	-	-	PUNCT
dpc-3647	228	3	806	806	NUM
dpc-3647	228	4	.	.	PUNCT
dpc-3647	229	1	doi	doi	NOUN
dpc-3647	229	2	:	:	PUNCT
dpc-3647	229	3	10.1111	10.1111	NUM
dpc-3647	229	4	/	/	SYM
dpc-3647	229	5	jdv.18044	jdv.18044	X
dpc-3647	229	6	.	.	PUNCT
dpc-3647	230	1	pmid	pmid	NOUN
dpc-3647	230	2	:	:	PUNCT
dpc-3647	230	3	35238067	35238067	NUM
dpc-3647	230	4	.	.	PUNCT
dpc-3647	231	1	pmcid	pmcid	NOUN
dpc-3647	231	2	:	:	PUNCT
dpc-3647	231	3	pmc9313585	pmc9313585	NOUN
dpc-3647	231	4	.	.	PUNCT
dpc-3647	232	1	5	5	X
dpc-3647	232	2	.	.	X
dpc-3647	232	3	honma	honma	PROPN
dpc-3647	232	4	m	m	PROPN
dpc-3647	232	5	,	,	PUNCT
dpc-3647	232	6	nozaki	nozaki	PROPN
dpc-3647	232	7	h.	h.	PROPN
dpc-3647	232	8	molecular	molecular	ADJ
dpc-3647	232	9	pathogenesis	pathogenesis	NOUN
dpc-3647	232	10	of	of	ADP
dpc-3647	232	11	psoriasis	psoriasis	NOUN
dpc-3647	232	12	and	and	CCONJ
dpc-3647	232	13	biomarkers	biomarker	NOUN
dpc-3647	232	14	reflecting	reflect	VERB
dpc-3647	232	15	disease	disease	NOUN
dpc-3647	232	16	activity	activity	NOUN
dpc-3647	232	17	.	.	PUNCT
dpc-3647	233	1	j	j	PROPN
dpc-3647	233	2	clin	clin	PROPN
dpc-3647	233	3	med	med	PROPN
dpc-3647	233	4	.	.	PUNCT
dpc-3647	234	1	2021;10(15):3199	2021;10(15):3199	X
dpc-3647	234	2	.	.	PUNCT
dpc-3647	234	3	doi	doi	NOUN
dpc-3647	234	4	:	:	PUNCT
dpc-3647	234	5	10.3390	10.3390	NUM
dpc-3647	234	6	/	/	SYM
dpc-3647	234	7	jcm10153199	jcm10153199	NOUN
dpc-3647	234	8	.	.	PUNCT
dpc-3647	235	1	pmid	pmid	NOUN
dpc-3647	235	2	:	:	PUNCT
dpc-3647	235	3	34361983	34361983	NUM
dpc-3647	235	4	.	.	PUNCT
dpc-3647	235	5	 	 	SPACE
dpc-3647	236	1	pmcid	pmcid	NOUN
dpc-3647	236	2	:	:	PUNCT
dpc-3647	236	3	pmc8346978	pmc8346978	ADJ
dpc-3647	236	4	.	.	PUNCT
dpc-3647	237	1	6	6	NUM
dpc-3647	237	2	.	.	PUNCT
dpc-3647	238	1	xia	xia	PROPN
dpc-3647	238	2	y	y	PROPN
dpc-3647	238	3	,	,	PUNCT
dpc-3647	238	4	xia	xia	PROPN
dpc-3647	238	5	c	c	PROPN
dpc-3647	238	6	,	,	PUNCT
dpc-3647	238	7	wu	wu	PROPN
dpc-3647	238	8	l	l	PROPN
dpc-3647	238	9	,	,	PUNCT
dpc-3647	238	10	li	li	PROPN
dpc-3647	238	11	z	z	PROPN
dpc-3647	238	12	,	,	PUNCT
dpc-3647	238	13	li	li	PROPN
dpc-3647	238	14	h	h	PROPN
dpc-3647	238	15	,	,	PUNCT
dpc-3647	238	16	zhang	zhang	PROPN
dpc-3647	238	17	j.	j.	PROPN
dpc-3647	238	18	systemic	systemic	PROPN
dpc-3647	238	19	immune	immune	ADJ
dpc-3647	238	20	inflammation	inflammation	NOUN
dpc-3647	238	21	index	index	NOUN
dpc-3647	238	22	(	(	PUNCT
dpc-3647	238	23	sii	sii	PROPN
dpc-3647	238	24	)	)	PUNCT
dpc-3647	238	25	,	,	PUNCT
dpc-3647	238	26	system	system	NOUN
dpc-3647	238	27	inflammation	inflammation	ADJ
dpc-3647	238	28	response	response	NOUN
dpc-3647	238	29	index	index	NOUN
dpc-3647	238	30	(	(	PUNCT
dpc-3647	238	31	siri	siri	NOUN
dpc-3647	238	32	)	)	PUNCT
dpc-3647	238	33	and	and	CCONJ
dpc-3647	238	34	risk	risk	NOUN
dpc-3647	238	35	of	of	ADP
dpc-3647	238	36	all	all	DET
dpc-3647	238	37	-	-	PUNCT
dpc-3647	238	38	cause	cause	NOUN
dpc-3647	238	39	mortality	mortality	NOUN
dpc-3647	238	40	and	and	CCONJ
dpc-3647	238	41	cardiovascular	cardiovascular	ADJ
dpc-3647	238	42	mortality	mortality	NOUN
dpc-3647	238	43	:	:	PUNCT
dpc-3647	238	44	a	a	DET
dpc-3647	238	45	20	20	NUM
dpc-3647	238	46	-	-	PUNCT
dpc-3647	238	47	year	year	NOUN
dpc-3647	238	48	follow	follow	NOUN
dpc-3647	238	49	-	-	PUNCT
dpc-3647	238	50	up	up	ADP
dpc-3647	238	51	cohort	cohort	NOUN
dpc-3647	238	52	study	study	NOUN
dpc-3647	238	53	of	of	ADP
dpc-3647	238	54	42,875	42,875	NUM
dpc-3647	238	55	us	us	PROPN
dpc-3647	238	56	adults	adult	NOUN
dpc-3647	238	57	.	.	PUNCT
dpc-3647	239	1	j	j	PROPN
dpc-3647	239	2	clin	clin	PROPN
dpc-3647	239	3	med	med	PROPN
dpc-3647	239	4	.	.	PUNCT
dpc-3647	240	1	2023;12(3):1128	2023;12(3):1128	X
dpc-3647	240	2	.	.	PUNCT
dpc-3647	241	1	doi	doi	NOUN
dpc-3647	241	2	:	:	PUNCT
dpc-3647	241	3	10.3390	10.3390	NUM
dpc-3647	241	4	/	/	SYM
dpc-3647	241	5	jcm12031128	jcm12031128	NOUN
dpc-3647	241	6	.	.	PUNCT
dpc-3647	242	1	pmid	pmid	NOUN
dpc-3647	242	2	:	:	PUNCT
dpc-3647	242	3	36769776	36769776	NUM
dpc-3647	242	4	.	.	PUNCT
dpc-3647	243	1	pmcid	pmcid	NOUN
dpc-3647	243	2	:	:	PUNCT
dpc-3647	243	3	pmc9918056	pmc9918056	PROPN
dpc-3647	243	4	.	.	PUNCT
dpc-3647	244	1	7	7	X
dpc-3647	244	2	.	.	X
dpc-3647	244	3	fest	f	ADJ
dpc-3647	244	4	j	j	NOUN
dpc-3647	244	5	,	,	PUNCT
dpc-3647	244	6	ruiter	ruiter	NOUN
dpc-3647	244	7	r	r	NOUN
dpc-3647	244	8	,	,	PUNCT
dpc-3647	244	9	mulder	mulder	NOUN
dpc-3647	244	10	m	m	PROPN
dpc-3647	244	11	,	,	PUNCT
dpc-3647	244	12	et	et	PROPN
dpc-3647	244	13	al	al	PROPN
dpc-3647	244	14	.	.	PUNCT
dpc-3647	245	1	the	the	DET
dpc-3647	245	2	systemic	systemic	ADJ
dpc-3647	245	3	immune	immune	ADJ
dpc-3647	245	4	inflammation	inflammation	NOUN
dpc-3647	245	5	index	index	NOUN
dpc-3647	245	6	is	be	AUX
dpc-3647	245	7	associated	associate	VERB
dpc-3647	245	8	with	with	ADP
dpc-3647	245	9	an	an	DET
dpc-3647	245	10	increased	increase	VERB
dpc-3647	245	11	risk	risk	NOUN
dpc-3647	245	12	of	of	ADP
dpc-3647	245	13	incident	incident	NOUN
dpc-3647	245	14	cancer	cancer	NOUN
dpc-3647	245	15	-	-	PUNCT
dpc-3647	245	16	a	a	DET
dpc-3647	245	17	population	population	NOUN
dpc-3647	245	18	-	-	PUNCT
dpc-3647	245	19	based	base	VERB
dpc-3647	245	20	cohort	cohort	NOUN
dpc-3647	245	21	study	study	NOUN
dpc-3647	245	22	.	.	PUNCT
dpc-3647	246	1	int	int	NOUN
dpc-3647	246	2	j	j	PROPN
dpc-3647	246	3	cancer	cancer	NOUN
dpc-3647	246	4	.	.	PUNCT
dpc-3647	247	1	2020;146(3):692	2020;146(3):692	NUM
dpc-3647	247	2	-	-	SYM
dpc-3647	247	3	698	698	NUM
dpc-3647	247	4	.	.	PUNCT
dpc-3647	248	1	doi	doi	NOUN
dpc-3647	248	2	:	:	PUNCT
dpc-3647	248	3	10.1002	10.1002	NUM
dpc-3647	248	4	/	/	SYM
dpc-3647	248	5	ijc.32303	ijc.32303	NOUN
dpc-3647	248	6	.	.	NOUN
dpc-3647	249	1	pmid	pmid	NOUN
dpc-3647	249	2	:	:	PUNCT
dpc-3647	249	3	30924141	30924141	NUM
dpc-3647	249	4	.	.	PUNCT
dpc-3647	250	1	pmcid	pmcid	NOUN
dpc-3647	250	2	:	:	PUNCT
dpc-3647	250	3	pmc6916270	pmc6916270	ADJ
dpc-3647	250	4	.	.	PUNCT
dpc-3647	251	1	8	8	X
dpc-3647	251	2	.	.	X
dpc-3647	251	3	song	song	PROPN
dpc-3647	251	4	y	y	PROPN
dpc-3647	251	5	,	,	PUNCT
dpc-3647	251	6	guo	guo	PROPN
dpc-3647	251	7	w	w	PROPN
dpc-3647	251	8	,	,	PUNCT
dpc-3647	251	9	li	li	PROPN
dpc-3647	251	10	z	z	PROPN
dpc-3647	251	11	,	,	PUNCT
dpc-3647	251	12	guo	guo	PROPN
dpc-3647	251	13	d	d	PROPN
dpc-3647	251	14	,	,	PUNCT
dpc-3647	251	15	li	li	PROPN
dpc-3647	251	16	z	z	PROPN
dpc-3647	251	17	,	,	PUNCT
dpc-3647	251	18	li	li	PROPN
dpc-3647	251	19	y.	y.	PROPN
dpc-3647	251	20	systemic	systemic	ADJ
dpc-3647	251	21	immune	immune	NOUN
dpc-3647	251	22	-	-	PUNCT
dpc-3647	251	23	inflammation	inflammation	NOUN
dpc-3647	251	24	index	index	NOUN
dpc-3647	251	25	is	be	AUX
dpc-3647	251	26	associated	associate	VERB
dpc-3647	251	27	with	with	ADP
dpc-3647	251	28	hepatic	hepatic	ADJ
dpc-3647	251	29	steatosis	steatosis	NOUN
dpc-3647	251	30	:	:	PUNCT
dpc-3647	251	31	evidence	evidence	NOUN
dpc-3647	251	32	from	from	ADP
dpc-3647	251	33	nhanes	nhane	NOUN
dpc-3647	251	34	2015	2015	NUM
dpc-3647	251	35	-	-	SYM
dpc-3647	251	36	2018	2018	NUM
dpc-3647	251	37	.	.	PUNCT
dpc-3647	252	1	front	front	ADJ
dpc-3647	252	2	immunol	immunol	NOUN
dpc-3647	252	3	.	.	PUNCT
dpc-3647	253	1	2022;13:1058779	2022;13:1058779	NUM
dpc-3647	253	2	.	.	PUNCT
dpc-3647	253	3	doi	doi	NOUN
dpc-3647	253	4	:	:	PUNCT
dpc-3647	253	5	10.3389	10.3389	NUM
dpc-3647	253	6	/	/	SYM
dpc-3647	253	7	fimmu.2022.1058779	fimmu.2022.1058779	NOUN
dpc-3647	253	8	.	.	PUNCT
dpc-3647	254	1	pmid	pmid	NOUN
dpc-3647	254	2	:	:	PUNCT
dpc-3647	254	3	36466832	36466832	NUM
dpc-3647	254	4	.	.	PUNCT
dpc-3647	255	1	pmcid	pmcid	ADJ
dpc-3647	255	2	:	:	PUNCT
dpc-3647	255	3	pmc9718528	pmc9718528	NOUN
dpc-3647	255	4	.	.	PUNCT
dpc-3647	256	1	9	9	X
dpc-3647	256	2	.	.	X
dpc-3647	256	3	li	li	PROPN
dpc-3647	256	4	x	x	PROPN
dpc-3647	256	5	,	,	PUNCT
dpc-3647	256	6	huan	huan	PROPN
dpc-3647	256	7	j	j	PROPN
dpc-3647	256	8	,	,	PUNCT
dpc-3647	256	9	lin	lin	PROPN
dpc-3647	256	10	l	l	PROPN
dpc-3647	256	11	,	,	PUNCT
dpc-3647	256	12	hu	hu	PROPN
dpc-3647	256	13	y.	y.	PROPN
dpc-3647	256	14	association	association	PROPN
dpc-3647	256	15	of	of	ADP
dpc-3647	256	16	systemic	systemic	ADJ
dpc-3647	256	17	inflammatory	inflammatory	ADJ
dpc-3647	256	18	biomarkers	biomarker	NOUN
dpc-3647	256	19	with	with	ADP
dpc-3647	256	20	depression	depression	NOUN
dpc-3647	256	21	risk	risk	NOUN
dpc-3647	256	22	:	:	PUNCT
dpc-3647	256	23	results	result	NOUN
dpc-3647	256	24	from	from	ADP
dpc-3647	256	25	national	national	ADJ
dpc-3647	256	26	health	health	NOUN
dpc-3647	256	27	and	and	CCONJ
dpc-3647	256	28	nutrition	nutrition	NOUN
dpc-3647	256	29	examination	examination	NOUN
dpc-3647	256	30	survey	survey	NOUN
dpc-3647	256	31	2005	2005	NUM
dpc-3647	256	32	-	-	SYM
dpc-3647	256	33	2018	2018	NUM
dpc-3647	256	34	analyses	analysis	NOUN
dpc-3647	256	35	.	.	PUNCT
dpc-3647	257	1	front	front	ADJ
dpc-3647	257	2	psychiatry	psychiatry	NOUN
dpc-3647	257	3	.	.	PUNCT
dpc-3647	258	1	2023;14:1097196	2023;14:1097196	NUM
dpc-3647	258	2	.	.	PUNCT
dpc-3647	259	1	doi	doi	NOUN
dpc-3647	259	2	:	:	PUNCT
dpc-3647	259	3	10.3389	10.3389	NUM
dpc-3647	259	4	/	/	SYM
dpc-3647	259	5	fpsyt.2023.1097196	fpsyt.2023.1097196	NUM
dpc-3647	259	6	.	.	PUNCT
dpc-3647	260	1	pmid	pmid	NOUN
dpc-3647	260	2	:	:	PUNCT
dpc-3647	260	3	36846218	36846218	NUM
dpc-3647	260	4	.	.	PUNCT
dpc-3647	261	1	pmcid	pmcid	NOUN
dpc-3647	261	2	:	:	PUNCT
dpc-3647	261	3	pmc9945233	pmc9945233	NOUN
dpc-3647	261	4	.	.	PUNCT
dpc-3647	262	1	10	10	NUM
dpc-3647	262	2	.	.	PUNCT
dpc-3647	263	1	yorulmaz	yorulmaz	INTJ
dpc-3647	263	2	a	a	PRON
dpc-3647	263	3	,	,	PUNCT
dpc-3647	263	4	hayran	hayran	NOUN
dpc-3647	263	5	y	y	PROPN
dpc-3647	263	6	,	,	PUNCT
dpc-3647	263	7	akpinar	akpinar	NOUN
dpc-3647	263	8	u	u	PROPN
dpc-3647	263	9	,	,	PUNCT
dpc-3647	263	10	yalcin	yalcin	PROPN
dpc-3647	263	11	b.	b.	PROPN
dpc-3647	263	12	systemic	systemic	ADJ
dpc-3647	263	13	immune	immune	ADJ
dpc-3647	263	14	inflammation	inflammation	NOUN
dpc-3647	263	15	index	index	NOUN
dpc-3647	263	16	(	(	PUNCT
dpc-3647	263	17	sii	sii	PROPN
dpc-3647	263	18	)	)	PUNCT
dpc-3647	263	19	predicts	predict	NOUN
dpc-3647	263	20	increased	increase	VERB
dpc-3647	263	21	severity	severity	NOUN
dpc-3647	263	22	in	in	ADP
dpc-3647	263	23	psoriasis	psoriasis	NOUN
dpc-3647	263	24	and	and	CCONJ
dpc-3647	263	25	psoriatic	psoriatic	ADJ
dpc-3647	263	26	arthritis	arthritis	NOUN
dpc-3647	263	27	.	.	PUNCT
dpc-3647	264	1	curr	curr	PROPN
dpc-3647	264	2	health	health	PROPN
dpc-3647	264	3	sci	sci	PROPN
dpc-3647	264	4	j.	j.	PROPN
dpc-3647	264	5	2020;46(4):352	2020;46(4):352	PROPN
dpc-3647	264	6	-	-	PUNCT
dpc-3647	264	7	357	357	NUM
dpc-3647	264	8	.	.	PUNCT
dpc-3647	265	1	doi	doi	NOUN
dpc-3647	265	2	:	:	PUNCT
dpc-3647	265	3	10.12865	10.12865	NUM
dpc-3647	265	4	/	/	SYM
dpc-3647	265	5	chsj.46.04.05	chsj.46.04.05	NOUN
dpc-3647	265	6	.	.	PUNCT
dpc-3647	266	1	pmid	pmid	NOUN
dpc-3647	266	2	:	:	PUNCT
dpc-3647	266	3	33717509	33717509	NUM
dpc-3647	266	4	.	.	PUNCT
dpc-3647	267	1	pmcid	pmcid	NOUN
dpc-3647	267	2	:	:	PUNCT
dpc-3647	267	3	pmc7948012	pmc7948012	NOUN
dpc-3647	267	4	.	.	PUNCT
dpc-3647	268	1	11	11	NUM
dpc-3647	268	2	.	.	PUNCT
dpc-3647	268	3	dincer	dincer	PROPN
dpc-3647	268	4	rota	rota	PROPN
dpc-3647	268	5	d	d	PROPN
dpc-3647	268	6	,	,	PUNCT
dpc-3647	268	7	tanacan	tanacan	PROPN
dpc-3647	268	8	e.	e.	PROPN
dpc-3647	268	9	the	the	DET
dpc-3647	268	10	utility	utility	NOUN
dpc-3647	268	11	of	of	ADP
dpc-3647	268	12	systemic	systemic	ADJ
dpc-3647	268	13	-	-	PUNCT
dpc-3647	268	14	immune	immune	ADJ
dpc-3647	268	15	inflammation	inflammation	NOUN
dpc-3647	268	16	index	index	NOUN
dpc-3647	268	17	for	for	ADP
dpc-3647	268	18	predicting	predict	VERB
dpc-3647	268	19	the	the	DET
dpc-3647	268	20	disease	disease	NOUN
dpc-3647	268	21	activation	activation	NOUN
dpc-3647	268	22	in	in	ADP
dpc-3647	268	23	patients	patient	NOUN
dpc-3647	268	24	with	with	ADP
dpc-3647	268	25	psoriasis	psoriasis	NOUN
dpc-3647	268	26	.	.	PUNCT
dpc-3647	269	1	int	int	PROPN
dpc-3647	270	1	j	j	PROPN
dpc-3647	270	2	clin	clin	PROPN
dpc-3647	270	3	pract	pract	PROPN
dpc-3647	270	4	.	.	PUNCT
dpc-3647	271	1	2021;75(6):e14101	2021;75(6):e14101	NUM
dpc-3647	271	2	.	.	PUNCT
dpc-3647	272	1	doi	doi	NOUN
dpc-3647	272	2	:	:	PUNCT
dpc-3647	272	3	10.1111	10.1111	NUM
dpc-3647	272	4	/	/	SYM
dpc-3647	272	5	ijcp.14101	ijcp.14101	PROPN
dpc-3647	272	6	.	.	PUNCT
dpc-3647	273	1	pmid	pmid	NOUN
dpc-3647	273	2	:	:	PUNCT
dpc-3647	273	3	33619821	33619821	NUM
dpc-3647	273	4	.	.	PUNCT
dpc-3647	274	1	12	12	NUM
dpc-3647	274	2	.	.	PUNCT
dpc-3647	274	3	conforti	conforti	PROPN
dpc-3647	274	4	c	c	PROPN
dpc-3647	274	5	,	,	PUNCT
dpc-3647	274	6	currado	currado	X
dpc-3647	274	7	d	d	NOUN
dpc-3647	274	8	,	,	PUNCT
dpc-3647	274	9	navarini	navarini	ADJ
dpc-3647	274	10	l	l	NOUN
dpc-3647	274	11	,	,	PUNCT
dpc-3647	274	12	et	et	PROPN
dpc-3647	274	13	al	al	PROPN
dpc-3647	274	14	.	.	PROPN
dpc-3647	274	15	moderate	moderate	PROPN
dpc-3647	274	16	-	-	PUNCT
dpc-3647	274	17	to	to	ADP
dpc-3647	274	18	-	-	PUNCT
dpc-3647	274	19	severe	severe	ADJ
dpc-3647	274	20	plaque	plaque	NOUN
dpc-3647	274	21	psoriasis	psoriasis	NOUN
dpc-3647	274	22	,	,	PUNCT
dpc-3647	274	23	described	describe	VERB
dpc-3647	274	24	by	by	ADP
dpc-3647	274	25	pasi	pasi	NOUN
dpc-3647	274	26	≥10	≥10	ADP
dpc-3647	274	27	%	%	NOUN
dpc-3647	274	28	,	,	PUNCT
dpc-3647	274	29	can	can	AUX
dpc-3647	274	30	be	be	AUX
dpc-3647	274	31	associated	associate	VERB
dpc-3647	274	32	with	with	ADP